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Introduction 
An inflammatory reaction by the host innate immune system can arise following 
infection, ischemia, trauma, tissue damage or a combination of such insults1. Toll-like 
receptors are an integral part of the innate immune system and these receptors 
recognize conserved pathogen-associated molecular patterns (PAMPs). In addition, 
TLR are considered to be implicated in the response to ligands, released by damaged 
or dead host cells, the so called damage-associated molecular patterns (DAMPs)2. 
Engagement of TLR with their ligands initiates a signaling cascade which ultimately 
results in an inflammatory response, aimed at elimination of the infecting microbe 
and recovery of the tissue. However, excessive or continuous activation of the 
immune system driven by TLR is considered to be involved in acute and chronic 
inflammatory syndromes including septic shock, ischemia reperfusion injury, 
necrotizing enterocolitis and inflammatory bowel disease. Understanding the biology 
of TLR will provide further insight into processes responsible for initiation and 
maintenance of inappropriate immune activation. Increased insight in the role of TLR 
in health and disease, might help to develop therapeutic strategies aimed at 
manipulating TLR signaling pathways to treat organ injury accompanying uncontrolled 
inflammation. 
Innate immunity 
The innate immune system is a universal and evolutionary ancient form of host 
defence against infectious organisms. The central function of this system is the 
recognition of microbial invasion and the initiation of responses that limit the spread 
of pathogenic microorganisms in host tissues3. The innate immune system comprises 
of passive and active components. The passive arm of the innate immune system 
includes anatomical barriers that prevent physical access of microorganisms4. 
Examples of anatomical barriers are the intestinal epithelium and the dry skin with 
their secretions, ciliated epithelial cells in the respiratory tract, and mucous 
membrane secretions. Secretory molecules include mucus, fatty acids, interferons, 
lactoferrin, trefoil factors and antimicrobial substances. Members of the latter group 
such as alpha-defensins and beta-defensins, lysozyme and cathelicidins can directly 
destroy microorganisms5-7. 
When microorganisms breech the anatomical barrier, the active innate immune 
system comes into play. This part of the immune system relies on evolutionarily 
ancient germline-encoded receptors, the pattern-recognition receptors (PRR) and 
circulating pattern recognition molecules (e.g. complement system), which both 
recognize highly conserved microbial structures, known as PAMPs. These microbial 
patterns are not unique to pathogenic organisms, but also occur in nonpathogenic 
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commensal microorganisms. Therefore, these immuno stimulating molecules are also 
referred to as micro-organism associated molecular patterns (MAMPs).  
Circulating pattern recognition molecules such as mannose binding lectin (MBL), 
Ficolin, and C1q function as initiators of the complement system. The complement 
system can be activated by three different pathways: i.e. the lectin pathway, the 
classical complement pathway and the alternative complement pathway. All pathways 
converge at the level of C3, which ultimately leads to the activation of C5 and the lytic 
pathway. The lectin pathway is activated after the recognition and binding of PAMPs 
by lectin proteins (MBL, ficolin H and ficolin L16). The classical complement pathway is 
activated by antigen-antibody complexes, resulting in activation of the complement 
factor C1q. Alternatively, C-reactive protein may activate the classical pathway of 
complement by binding C1q. 
The alternative complement pathway is activated upon binding of C3b to microbial 
surfaces or antibody molecules. The alternative pathway is continuously activated at a 
low level8,9. This spontaneous “C3 tick-over” leads to the deposition of C3b on 
biological particles in plasma or on cell surfaces10. In addition, the alternative pathway 
can act as an amplification loop to the other two pathways once C3b has been 
generated11. 
Gram-negative bacteria are prone to direct lysis by the complement system through 
the C5-C9 membrane attack complex (MAC)12,13. Gram-positive organisms are not 
susceptible to this extracellular killing13. Alternatively, they are opsonized by C3b, 
which allows phagocytosis and subsequent release of the pro-inflammatory 
anaphylatoxins (C5a and C3a) that attract white blood cells and finally formation of 
the MAC complex, which forms a pore in the target membrane11. 
Besides circulating pattern recognition molecules, cell associated PRR such as the 
Nod-like receptors (NLR) are an important component of the active innate immune 
system functional in recognition and activation of host defense responses against 
PAMPs14. NLRs are confined to the cytosol where they detect their ligands15. This 
localization enables NLRs to recognize and sense bacteria or their toxins that have 
evaded detection by PRR through invasion of cells or escaped from endosomal 
compartments. In addition, NLRs have been shown to detect ligands that are 
delivered intracellularly by non invasive pathogens. For instance, Helicobacter pylori 
induces immune activation via NOD1 by peptidoglycan that is delivered into the cell 
via the so called bacterial type IV secretion system16. 
More than 20 human and 30 murine NLR proteins have been identified. They do not 
appear to have known homologs in nonvertebrates15,17. To date, the functions of 
Nod-1 and -2, NALP3, Ipaf and Naip have been studied most15,17. Downstream signals 
include activation of the NF-κB pathway, caspase-1-dependent inflammasome (a high-
molecular-weight complex composed of multiple NLRs with the ability to cleave and 
activate pro-caspase-1, IL-1β and pro-IL-18)18,19, and ERK, JNK and p38 pathways20. 
Certain NLR mutations are associated with genetic risk factors for chronic 
inflammatory disorders21,22 such as Crohn's disease. This is likely related to abnormal 
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intestinal microbe recognition, leading to an inflammatory response instigated by 
commensal and pathogenic bacteria.  
Toll like receptors (TLRs) 
In addition to the NLRs, the most studied PRR are the Toll-like receptors, which are 
able to detect danger elements both inside and outside the cell. TLR are type I integral 
membrane glycoproteins characterized by extracellular domains that contain varying 
numbers of leucine-rich-repeat (LRR) motifs, and a cytoplasmic Toll/interleukin-1 
(IL-1) receptor (TIR) signaling domain. To date, at least 13 mammalian TLR have been 
identified23,24. From these TLR, TLR10 is present in man but not in mice25. In contrast, 
TLR 11, 12, and 13 are expressed in mice but absent in man24,26. TLR expressed at the 
cellular surface including TLR 1, 2, 4, 5, 6 and 11 sense lipids, lipoproteins or 
peptidoglycans from bacteria and fungi (summarized in Table 1.1)23,24. The other TLR 
(3, 7, 8 and 9) detect bacterial and viral nucleic acids (Table 1.1) and these nucleic-acid 
receptors are found almost exclusively in intracellular compartments such as 
endosomes23,24. The ligands for TLR 10, 12 and 13 remain unidentified.  
 
Table 1.1 TLR and their microbial ligands.  
TLR Microbial ligands Microorganism 
TLR1 Tri-acyl peptides Mycobacteria, Neisseria,Borrelia  
TLR2 Lipoprotein, PGN, Lipoteichoic acid 
(LTA), phenol-soluble modulin, 
Lipoarabinomannan Zymosan 
Gram-postive bacteria e.g. S.epidermidis, Neisseria and 
Yeast  
TLR3 dsRNA  Viruses 
TLR4 LPS Gram-negative bacteria 
TLR5 Flagellin Flagellated Gram-positive and -negative bacteria 
TLR6 Lipoteichoic acid, Zymosan, Diacyl 
lipopeptides 
Gram-positive bacteria, Mycoplasma and Yeast 
TLR7 ssRNA Viruses (e.g. influenza, VSV, HIV)  
TLR8 ssRNA Viruses  
TLR9 Unmethylated CpG-containing DNA Gram-positive and -negative bacteria and viral DNA (e.g. 
HSV 1 and 2; murine CMV)  
TLR10 Unknown Unknown 
TLR11 Unknown Uropathogenic E. coli  
TLR12 Unknown Unknown 
TLR13 Unknown Unknown 
 
Different adaptor proteins are implicated in TLR signaling including MyD88, Mal 
(MyD88 adaptor-like) also termed TIRAP (TIR-domain-containing adaptor protein), 
TRIF (TIR-domain-containing adapter-inducing IFN-β) and TRAM (TRIF related adaptor 
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molecule) (Figure 1.1)27. MyD88 is the universal adapter protein for signal 
transduction of the interleukin (IL)-1 receptor family and most TLR, with the exception 
of TLR327. TRIF has been demonstrated to be the crucial adaptor protein for TLR3. TRIF 
is also involved in a TLR4-mediated MyD88-independent pathway28-30. TRIF activation 
ultimately results in activation of IFN regulatory factor-3 (IRF-3) and induction of 
IFN-ß31-34.  
Signaling via the MyD88 dependent pathway, induces activation of the mitogen-
activated protein kinases JNK, p38 and ERK and nuclear factor-kappa B (NF-κB). The 
transcription factor NF-κB plays a critical role in the coordination of both innate and 
adaptive immune responses by regulating gene expression of many cellular immune 
mediators35.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 1.1 TLR signaling pathways. 
Upon engagement with their ligands, all TLR with the exception of TLR3, recruit MyD88 to 
their TIR domain. For the extracellular TLR, TIRAP and TRAM act as bridging adapters, 
involved in recruitment of MyD88. MyD88 recruits IRAK1 and IRAK4 and then TRAF6, finally 
resulting in activation of inflammatory transcription factors. Ligation of the intracellular TLR 
7, 8 and 9 induces recruitment of IRAK1 and IRAK4, finally leading to dimerization and 
subsequent translocation of IRF7 to the nucleus, where it binds to the promoter of 
IFN-alpha genes. A TLR4-mediated MyD88-independent pathway and TLR3 dependent 
activation are both mediated by TRIF, ultimately resulting in translocation of IRF-3 or 7 to 
the nucleus. Control of TLR activation is mediated by negative regulators including IRAK-M, 
TOLLIP, SIGIRR and A20. 
MyD88 MyD88
Viral
ssRNA
Viral
dsRNA
Bacterial
CpG DNA
Endosome
TLR7 TLR8 TLR9
TRIF
TRAF3
IKK
TBK1
IRAK4
IRAK1
IRF7 IRF3
IRF7 IRF3
Antiviral
immune response T cell stimulation
TLR3
Inammation
AP-1
AP-1
NF-kB
NF-kBJNK p38 ERK
IkBa
IKK
TAB1TAK1
TRAF6
TIRAP
TRAM
IRAKM
IRAK4
IRAK1
MyD88MyD88
TIRAP
MyD88
TIRAP
MyD88
TLR4 TLR4 TLR5 TLR6 TLR2 TLR2 TLR1
CD14
MD-2
Bacteria - Bacteria -/+
Flagellin
Bacteria -/+
LAM BLP PGNZymosan
Yeast
LPS
IKK
TRIF
SIGIRR SIGIRRSIGIRR
A20
TOLLIP
MyD88
 Introduction⏐15 
TLR activation is essential for the ability of the immune system to combat invading 
pathogens. A strict regulation is of major importance, since a lack of control leads to 
detrimental and inappropriate inflammatory responses that might result in allergic 
diseases and autoimmune/inflammatory diseases such as lupus, atherosclerosis, type I 
diabetes, arthritis, inflammatory bowel disease, psoriasis and dermatomyositis24,36. 
Therefore, negative immune regulators of the TLR signaling pathway such as IRAK-M, 
TOLLIP, SIGIRR and A20 protect the host against excessive immune activation37. 
Besides an important corner stone of the innate immune system, TLR play a crucial 
role in bridging innate and adaptive immunity by modulating dendritic cell (DC) 
maturation and their migration to lymph nodes where they instruct the antigen 
specific T-lymphocytes38. Additionally, it has been shown that generation of T-cell 
dependent antigen-specific antibody responses also requires activation of TLR in 
B cells39. However, later studies suggest that TLR signaling in B cells amplifies, but is 
not required for antibody production or maintenance of memory40. Microorganisms, 
via their PAMPs, may also contribute directly to the perpetuation and activation of 
long term T-cell memory as T-cells also express TLR41. Taken together, a large body of 
evidence emphasizes the importance of TLR in the generation of an optimal and 
orchestrated response to bacterial stimuli.  
Crosstalk between PRR systems 
Infectious agents contain multiple immunostimulatory molecules, capable to activate 
the innate immune system via different PRR. Evidence is increasing that the strongest 
response against different types of microbes, is achieved by different PRR 
combinations. In addition, multiple TLR and even different PRR systems become 
simultaneously or consecutively activated. The resulting PRR signaling proceeds 
synergistically or antagonistically as a result of crosstalk between different PRR 
systems42,43. For example, several studies have reported a synergistic outcome on 
cytokine expression in different cells stimulated with a mixture of NLR and TLR 
agonists, whereas a single TLR or NLR activator showed little activity44,45. In contrast, 
Nod2 activation appeared to inhibit TLR-2 mediated cytokine release in murine 
splenocytes46. In addition, C5a was shown to negatively impact TLR4-induced 
synthesis of IL-12, IL-23 and IL-27 in murine macrophages47. These recent findings 
highlight the importance of considering TLR activation in the context of other signaling 
pathways, as occurs in vivo during infection and inflammation. 
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Lipopolysaccharide recognition 
Host mechanisms that recognize Gram-negative bacterial LPS are among the most 
sensitive and best studied. Endotoxin (lipopolysaccharide, LPS) constitutes the outer 
leaflet of the outer membrane of Gram-negative bacteria (Figure 1.2). LPS consists of 
three covalently linked regions; lipid A, core oligosaccharide, and an O side chain 
(Figure 1.2).  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 1.2 Schematic structure of lipopolysaccharide (LPS) in the bacterial cell wall. 
 LPS has three domains: the lipid A moiety, the core oligosaccharide and the O-antigen or O-
side chain. The lipid-A component anchors the LPS molecule in the outer membrane of the 
bacterial cell wall. Lipid A is composed of a phosphorylated diglucosamine carrying acyl 
residues. The core oligosaccharide is composed of short series of different sugars. It is 
connected with the O-antigen, a polymer of repeating sugar units.  
 
Lipid A is responsible for the toxicity of LPS, and is composed of fatty acyl chains linked 
to two N-acetylglucosamine residues. Both glucosamine backbones of lipid A are 
frequently phosphorylated. This phosphorylation process is important for the 
biological activity of LPS. More precisely, diphosphorylated lipid A is 1000-times more 
active than monophosphorylated lipid A48. In addition, the immunostimulatory 
potency of LPS is influenced to a large extent by the number and length of the fatty 
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acyl chains49,50. The most immunologically active form of lipid A contains six fatty acyl 
groups (hexa-acyl) of 12–16 carbons in length and it is found in pathogenic bacteria 
such as Escherichia coli and Salmonella species51,52. Lipid A structures containing four 
or five fatty acids, can inhibit the strong endotoxic response triggered by hexa-
acylated LPS53,54. This phenomenon is used in the search for pharmacological tools for 
treatment of endotoxin-mediated indications such as sepsis. Likewise, a synthetic 
tetra-acylated lipid A compound, designated Eritoran is a strong antagonist of hexa-
acyl LPS, with therapeutic potential55.  
TLR4 is the central signaling receptor for LPS in mammals. TLR4-deficient and 
knockout mice are hyporesponsive to LPS56,57 and therefore highly susceptible to 
certain Gram-negative bacterial infections. TLR4 requires MD-2, a secreted 
glycoprotein of 160 amino acids, to interact functionally with LPS58. The efficiency of 
LPS-MD-2 interactions is markedly increased by pretreatment of LPS with LBP and 
CD14 to produce a LPS:CD14 monomeric complex59-62. MD-2 associates with the 
ectodomain of TLR4 and the TLR4–MD-2 heterodimer is considered to form the entire 
recognition complex for LPS. Recent studies have revealed the crystal structure of 
MD-2, bound to two different tetra-acylated lipid A antagonists, namely Eritoran and 
lipid IVa55,63. These studies showed that human MD-2 contains a deep hydrophobic 
cavity, situated between two β sheets. Interestingly, both studies showed that the 
four lipid chains of Eritoran and lipid IVa occupy almost all of the available space in 
this hydrophobic pocket of MD-2. This suggests that the agonistic hexa-acyl LPS 
molecule attaches to MD-2 in a different manner than the antagonistic molecules. Kim 
et al. hypothesized that structural changes of the hydrophobic pocket are required to 
allow binding of agonistic hexa-acyl LPS. They speculated that such changes may 
induce an otherwise hidden binding site which favors interaction of MD-2 with the 
central or C-terminal domain of a second TLR4 protein55. As a consequence, TLR4 
homodimerizes and recruits two sets of adaptor molecules required for signaling. 
Future research is warranted to verify the described hypothesis. 
Soluble MD-2 (sMD-2) 
Interestingly, only a small portion of MD-2 binds TLR4 while the majority is released 
by the cell as soluble MD-2 (sMD-2)64,65. The MD-2 protein contains seven conserved 
cysteine residues that enable formation of large disulfide-linked oligomers. 
Interestingly, only monomeric sMD-2 associates with TLR460,66,67. This finding was 
further extended by a report showing that only monomeric sMD-2 is able to bind 
LPS68. Moreover, Kim et al. showed that one MD-2 molecule binds to one TLR4 
molecule, confirming that only monomeric MD-2 interacts with TLR4 and mediates 
LPS signaling55.  
On the search for the function of sMD-2, studies suggested that sMD-2 modulates LPS 
signaling during Gram-negative infections by supplementing cells that express TLR4 
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but lack MD-2 such as pulmonary and intestinal epithelial cells69,70. This suggestion 
was extended by Ohnishi et al. who showed that LPS induces formation of CD14-TLR4 
complexes on the cell surface in the absence of mMD-2 while subsequent binding of 
sMD-2 is essential for activation71. Moreover, sMD-2 mediates opsonization of Gram-
negative bacteria by TLR4-dependent phagocytosis72,73. Although a direct bacteriocidal 
effect was not proven by these studies, opsonization by MD-2 was shown to enhance 
intracellular killing. Finally, sMD-2 has been found in biological fluids such as plasma, 
milk, tears and urine.  
Taken together, both TLR4-bound MD-2 and sMD-2 play an important role in the host 
defense against Gram-negative infections, making MD-2 a potential pharmacological 
target for drug development in LPS-related conditions such as sepsis.  
Innate immunity of the gut  
Immediately after birth, organs connected with the external environment like the skin 
and intestine are colonized by microbiota. The most diverse and abundant bacterial 
load is found in the gastrointestinal tract. Intestinal microbiota provide important 
functions to the host, including the synthesis of essential nutrients, in part by 
metabolism of indigestible compounds74. In addition, gut microbiota prevent 
colonization of many pathogenic bacteria, a process referred to as colonization 
resistance75. Finally, the gut microbiota contribute to the development of the 
intestinal architecture and the mammalian immune system74,76,77. 
The enormous and diverse number of intestinal bacteria and their proximity to host 
tissues raises the question how the symbiotic relationship between microbiota and 
the host is maintained without inducing potentially injurious immune responses.  
An undesirable inflammatory response towards intestinal residents is thought to be 
avoided by a well organized and complex interplay between microbiota, the intestinal 
barrier and the innate immune system. The intestinal barrier separates the lumen that 
contains the intestinal microbiota from the lamina propria thereby confining the 
microbiota to the lumen. The intestinal barrier is formed by a single layer of 
enterocytes that is renewed every 4-5 days (Figure 1.3). The epithelial cells are 
connected by intercellular tight junctions, in order to prevent paracellular transport of 
macromolecules from the lumen to the underlying lamina propria78-80. In the small 
and large intestines goblet cells (Figure 1.3) secrete large quantities of mucin, which is 
composed of highly glycosylated proteins that form a thick protective layer of mucus 
over the surface epithelium. Besides preventing bacterial translocation, this mucus 
layer neutralizes stomach acid and protects against shear stress and chemical 
damage81. 
Segregation of microbiota in the intestinal lumen is also accomplished by 
immunoglobulin A (IgA) which is secreted by subepithelial plasma cells and 
transcytosed across the epithelium into the lumen. Luminal IgA provides a barrier by 
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binding bacteria and other antigens. Consistently, IgA deficiency leads to increased 
penetration of symbiotic bacteria into host tissues82,83. 
In addition, antimicrobial factors prevent translocation of microbiota through the 
epithelial barrier. These natural antibiotics are released by different intestinal 
epithelial cells. Enterocytes play an active role in defending epithelial surfaces by 
secreting ß-defensins and cathelicidins84,85. Members of both families display a broad-
spectrum killing activity against a wide range of bacteria, fungi, and viruses86. In the 
small bowel at the base of the crypts of Lieberkühn, specialized epithelial cells called 
Paneth cells (Figure 1.3) are equipped with secretory granules that contain several 
proteins involved in host defence, including α-defensins, lysozyme, and phospholipase 
A2
87. Paneth cells secrete antimicrobial peptides constitutively in order to keep 
intestinal crypts sterile. Moreover, exposure of Paneth cells to bacterial products such 
as LPS and muramyl dipepeptide induces increased levels of these antimicrobial 
peptides88-91. Recently, Paneth cell intrinsic MyD88 signaling was shown to limit 
penetration of luminal bacteria to tissues, disclosing a role for epithelial MyD88 in 
maintaining intestinal homeostasis92. In addition, using a Paneth cell ablation model, 
the same group revealed that Paneth cells are essential for controlling intestinal 
barrier penetration by commensal and pathogenic bacteria92. 
Next, strategic localization of different TLR might contribute to intestinal immune 
tolerance to commensal bacteria. First, apical epithelial cells are virtually 
unresponsive to LPS due to reduced or absent expression of TLR4 on their cell 
surface93,94. In line, Ortega-Cava et al. confirmed the absence of TLR4 expression on 
apical epithelial cells facing the gut lumen and showed that TLR4 is exclusively 
expressed by epithelial cells in intestinal crypts95. Second, expression of TLR5 has been 
shown to be limited to the basolateral surface of enterocytes, indicating that innate 
immune activation can only be accomplished by invaded bacteria96. These findings 
suggest that under physiological conditions, epithelial PRR are not exposed to luminal 
symbiotic bacteria and their products. Hence, these receptors are strategically 
positioned to respond to bacteria, once they have breached the epithelial barrier. 
Finally, active suppression of molecules responsible for intracellular PRR, is considered 
to be involved in the intestinal immune tolerance to commensal microbiota. In 
particular, expression of Toll-interacting protein (Tollip), an intracellular protein which 
inhibits IRAK activation97 correlates directly with the luminal load of microbiota in 
vivo98. Consistently, the highest Tollip expression in the gastrointestinal tract is seen in 
healthy colonic mucosa, which contains the highest numbers of commensal bacteria98. 
Also decreased IL-1R-associated kinase (IRAK) expression is considered to limit 
hyperreactivity of the healthy intestine to luminal microbiota98. However, it can also 
be argued that suppression of proinflammatory responses towards the microbiota 
creates a problem for the host, as it renders the innate immune system incapable to 
elicit an adequate response when challenged by pathogens. Additional research is 
warranted to unravel how the intestinal immune system can respond adequately to 
pathogens while remaining tolerant against commensals.  
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Figure 1.3 Cellular composition of the small bowel. Stem cells are located at the base of the crypts 
where they divide, migrate and differentiate into goblet cells, enterocytes, and 
enteroendocrine cells (not shown) or Paneth cells. Paneth cells secrete their antimicrobial 
peptides in the crypt lumen to keep it sterile.  
 
 
Although intestinal microbiota have beneficial roles in health as discussed above, 
these commensals are considered to be key players in the pathophysiology of 
systemic and local inflammatory disorders such as sepsis, IBD and NEC, when they 
breech the intestinal barrier.  
Penetration of the gut barrier by luminal bacteria can occur under several non 
physiological conditions. For instance, splanchnic hypoperfusion such as encountered 
during major surgery or trauma, has been postulated as a cause of disruption of the 
barrier integrity99. Another non physiological condition which is associated with a 
compromised barrier is prematurity. In premature infants the intestine is 
underdeveloped resulting in a diminished barrier function100,101. Moreover, many 
pathogens possess virulence factors that favour adherence to and penetration of the 
epithelial barrier102,103. During invasion of the epithelial cells lining the gut lumen, 
certain pathogens can cause disruption of the intestinal barrier. Translocation of 
bacteria or their toxins from the gut lumen into underlying intestinal layers provoke 
activation of inflammatory cells located in the lamina propria, in order to eliminate 
intruders104. Proinflammatory cytokines produced by these inflammatory cells such as 
TNF-alpha and IFN-gamma induce degradation of intestinal integrity by breakdown of 
intestinal tight junction proteins, such as zonula occludens proteins105-107, resulting in 
increased leakage of luminal material and ensuing greater immune activation. 
Regardless of the cause, disruption of the intestinal barrier predisposes to 
translocation of microbiota and/or their products108-110. Translocation of luminal 
bacterial sometimes results in excessive activation of the immune system. Such an 
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inappropriate response directed against translocated commensal microbiota is often 
considered to be central to the development of IBD. 
Several lines of evidence indicate a fundamental role for commensal bacteria in the 
onset and or progression of these diseases111-115. In particular, spontaneous colitis 
does not occur in IL-2, IL-10 or T-cell receptor (TCR)α/ß knockout mice when 
maintained in a germ-free environment, but colitis develops rapidly when these mice 
are colonized by commensal bacteria116-119. Moreover, rodents with chemically 
induced disruption of the intestinal barrier develop inflammation of the gut in a 
pathogen-free or conventional environment, but not in a germ-free environment120. In 
line, treatment with antibiotics has been shown to reduce intestinal inflammation and 
inflammatory responses, not only in experimental models of colitis but also in a subset 
of patients with IBD121,122.  
Supporting evidence for a role of bacteria in the pathogenesis of NEC is found in the 
fact that the onset of the disease occurs at a time when the intestinal lumen is 
colonized by the gut microbiota123,124, which usually occurs at 8–10 days after birth. In 
concordance with observations in IBD patients, administration of broad-spectrum 
antibiotic therapy reduces inflammatory responses in patients suffering NEC125,126. 
Taken together, these data indicate that intestinal inflammatory disorders such as IBD 
and NEC result from a dysregulated intestinal immune response to the host 
microbiota, once these commensals pass the compromised gut barrier. Considering 
the crucial role of microbiota in the pathogenesis of IBD and NEC, it is tempting to 
speculate that the onset or exacerbation of exaggerated immune activation, that 
characterizes these diseases may be at least in part, mediated by uncontrolled TLR 
signaling.  
Therefore, data concerning the regulation and cellular distribution of TLR family 
members in the healthy and inflamed gut are of interest. Different groups 
investigated TLR localization and regulation in patients with IBD and healthy controls. 
Constitutive TLR3 expression was significantly down-regulated in active Crohn’s 
disease but not in ulcerative colitis127,128. In contrast TLR2 and TLR4 which are barely 
or even undetectable in non-diseased mucosa are upregulated in both Crohn’s disease 
(CD) and ulcerative colitis (UC)127,128. In addition, IBD patients showed an inflammation 
dependent increase of TLR2 expression on lamina propria monocytes127,128. 
Reports on TLR4 localisation in the inflamed human gut are controversial. In UC and 
CD patients, increased TLR4 protein expression as assessed by immunohistochemistry 
was predominantly observed at epithelial cells lining the lumen and at some lamina 
propria-located inflammatory cells127. Hausmann et al. confirmed the presence of 
TLR4-expressing macrophages in the lamina propria but failed to detect TLR4 
expression by primary epithelial cells128. Thus, the debate regarding TLR expression by 
epithelial cells during health and disease is still open. 
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Collectively, more insight into the complex interplay between the gut microbiota, the 
intestinal barrier and the innate immune system is warranted. Such insight might help 
to develop therapeutic interventions to dampen excessive immune activation while 
maintaining immunoprotection.  
TLR and endogenous ligands 
Besides their crucial role in recognition and sensing of microbial molecular 
structures129, TLR are also considered to be involved in the response to ligands, 
released by dying or damaged cells130,131. Although direct binding between TLR and 
these so called damage-associated molecular patterns (DAMPs) remains to be proven, 
there is accumulating evidence that TLR play a role in sensing of endogenous ligands. 
Examples of such host molecules associated with TLR mediated immune activation 
include heat-shock proteins (engaging with TLR2 and -4), the nonhistone chromatin-
binding protein high-mobility group box 1 (HMGB1) (binding with TLR2 and -4), and 
extracellular matrix breakdown components such as hyaluronan (ligand for TLR2 and 
-4), fibronectin (engaging with TLR4) and heparan sulfate (engaging with 
TLR4)130,132-135. Release of DAMPs is for example seen following hypoxia and ischemia. 
Consistently, an important role for TLR2 and TLR4 in the induction of a sterile 
inflammatory immune response in ischemic organs has been frequently 
reported136-140. The absence or inhibition of TLR2 or TLR4 has been shown to decrease 
tissue injury and improve organ function in response to ischemia in the liver, brain, 
heart, lung and kidney137,141-151.  
The demise of cells can occur by autophagy, necrosis, apoptosis or intermediate forms 
of the latter types. Cells undergoing death associated with autophagy are 
characterized by the presence of double membrane autophagic vacuoles. Numerous 
studies have described autophagy as a survival mechanism under poor nutritional or 
growth factor conditions. When cellular stress continues, cell death may proceed by 
autophagy alone. In addition, it often becomes associated with features of apoptotic 
or necrotic cell death152.  
Necrotic cell death is accompanied by cell swelling and loss of plasma membrane 
integrity which results in the passive release of intracellular inflammatory 
mediators153. Until recently, necrosis was considered as an unintended and 
unprogrammed form of cell death lacking underlying signaling events. This might be 
true for cell death resulting from severe physical damage or after exposure to high 
concentrations of detergents, oxidants or ionophores. However, increasing evidence 
support the existence of tightly regulated caspase-independent forms of cell death, 
leading to rupture of plasma membranes154,155. 
Apoptosis is an active process, executed by a family of cysteine proteases, called 
caspases156. Two major pathways of caspase activation have been described, namely 
the extrinsic and intrinsic pathway157. The extrinsic pathway activates caspase-8, while 
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the intrinsic pathway activates caspase-9. Each of these proteases can activate 
caspase-3, which is primarily responsible for cell disassembly by cleaving proteins that 
are needed for normal cell maintenance. Activation of the extrinsic pathway is 
mediated by binding of extracellular ligands to cell surface death receptors158. The 
intrinsic pathway converges at the mitochondrial level159,160, and this pathway is 
controlled by proteins of the B-cell lymphoma protein 2 (Bcl-2) family, that include 
pro-apoptotic members such as Bax and anti-apoptotic members including Bcl-2 and 
Bcl-XL161,162.  
Cells dying apoptotically are characterized by plasma membrane blebbing, nuclear 
and cytoplasmic condensation and formation of so called membrane-bound apoptotic 
bodies163,164. In apoptotic cells, the membrane and cytoplasmic organelles remain 
intact, and cells are rapidly phagocytosed by macrophages or surrounding cells before 
lysis165 in order to prevent leakage of cellular contents. In line, multiple studies 
reported that the release of DAMPs is triggered by necrotic but not by apoptotic cell 
death166-171.  
However, it should be noted that a number of recent publications showed that the 
release of intracellular endogenous ligands is not solely a passive process that only 
occurs once the cell membrane of necrotic cells becomes disrupted. In particular, 
work from Keller et al. provided evidence that the release of “danger” proteins can be 
mediated by a caspase-1 dependent, active process172. In line, with this hypothesis, 
stimulation of macrophages with LPS resulted in the secretion of HMGB1, apparently 
in the absence of necrosis173. In addition, it has recently been demonstrated that 
accumulation of apoptotic cells can stimulate macrophages to secrete HMGB1174. The 
latter protein appeared to have a role, downstream of apoptosis, in the development 
of organ damage in severe sepsis174. Collectively, these studies challenge the paradigm 
that only necrosis is accompanied by an inflammatory response, whereas apoptotic 
cell death is immunologically and inflammatorily silent.  
Consistent with these studies, work from our and other laboratories demonstrated 
that tubular cell apoptosis acts as a primary and major contributor to the 
pathophysiology of renal ischemia/reperfusion (I/R) and determines the outcome of 
renal damage175-177.  
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Aim of this thesis 
As discussed above, the innate immune system is involved in infectious and sterile 
inflammation by mediating responses to both bacterial toxins and damaged tissues. 
Inappropriate immune activation has been associated with surgically relevant diseases 
including sepsis, IBD, NEC and ischemia-reperfusion injury. Although evidence is 
increasing that TLR are actively involved in the pathophysiology of these diseases, 
many questions including the regulation and cellular distribution of these TLR in 
health and disease remain unanswered. Therefore, the main purpose of this thesis is 
to provide insight into aspects of TLR biology in surgical patients. In the first part of 
this thesis, studies on sterile inflammation after ischemia reperfusion (I/R) injury are 
described (chapter 2 & 3). Renal I/R injury is seen during major surgery and 
transplantation surgery in particular. I/R plays an important role in acute end stage 
organ failure. As TLR are considered to be involved in mediating sterile inflammation 
in the course of I/R, the distribution and regulation of TLR2 and TLR4 was explored in 
the kidney following ischemia reperfusion (chapter 2). In chapter 3, the degree of 
ischemic injury in human kidneys was assessed by analyzing the regulation and 
processing of apoptotic proteins during normothermic ischemia.  
In the second part of this thesis, studies on bacterial inflammation are presented. 
During surgery, reduced splanchnic blood flow is considered to promote translocation 
of luminal gut microbiota (mainly Gram-negative Enterobacteriacae) across the 
intestinal epithelial barrier, thereby acting as a source of sepsis at distant sites of the 
gut. In this context, the molecular appearance, regulation and TLR4 costimulatory 
activity of native human sMD-2 in control and septic plasma was analyzed (chapter 4). 
In addition, the in vivo distribution of human MD-2 and the potential cellular sources 
of circulating sMD-2 during endotoxemia and sepsis were studied (chapter 4).  
Epidemiological observations and animal studies suggest an important role for Gram-
negative organisms in the development of intestinal inflammatory pathology in 
preterms and adults. In this context, the localization and regulation of MD-2 was 
studied in the human healthy and inflamed adult and premature gut (chapter 5).  
In chapter 6, the functional consequences of luminal endotoxin exposure of the 
premature and mature gut were studied in an experimental animal model.  
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Abstract  
The reported requirement of functional TLR4 for resistance to Gram-negative 
pyelonephritis prompted us to localize the expression of TLR2 and TLR4 mRNA in the 
kidney at the cellular level by in situ hybridization. The majority of the constitutive 
TLR2 and TLR4 mRNA expression was found to be strategically located in the renal 
epithelial cells.  
Assuming that the TLR mRNA expression is representative of apical protein expression, 
this suggests that these cells are able to detect and react with bacteria present in the 
lumen of the tubules. 
To gain insight in the regulation of TLR expression during inflammation, we employed 
a model for renal inflammation. Renal inflammation evoked by ischemia markedly 
enhanced synthesis of TLR2 and TLR4 mRNA in the distal tubular epithelium, the thin 
limb of Henle’s loop and collecting ducts. The increased renal TLR4 mRNA expression 
was associated with significant elevation of renal TLR4 protein expression as 
evaluated by Western blotting. Using RT-PCR, the enhanced TLR2 and TLR4 mRNA 
expression was shown to be completely dependent on the action of IFN-γ and TNF-α.  
These results indicate a potential mechanism of increased immunosurveillance during 
inflammation at the site in which ascending bacteria enter the kidney tissue, i.e. the 
collecting ducts and the distal part of the nephron. 
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Introduction 
At least two members of the Toll-like receptor (TLR) family are involved in the innate 
defense mechanism against bacterial infections1,2. TLR4 recognizes Gram-negative 
bacteria via the lipopolysaccharide moiety that is present in the surface of these 
microorganisms3-5. Another member of this receptor family, TLR2, induces 
responsiveness to bacterial lipoproteins and components of Gram-positive bacteria 
such as peptidoglycan, indicating the involvement of TLR2 in the resolution of 
infections6-9. After stimulation by bacterial products both receptors trigger the cell to 
produce inflammatory mediators. This process is mediated via a MyD88 dependent 
intracellular signaling pathway that causes translocation of NF-κB. The latter induces 
the transcription of the genes encoding for cytokines, chemokines and adhesion 
molecules crucial to the inflammatory process aimed at clearance of invading 
bacteria1,10. 
Both TLR2 and TLR4 are predominantly expressed by monocytes/macrophages and 
neutrophils11. Lower expression of TLR is observed in vitro by several other leukocytes, 
endothelial cells, epithelial cells and fibroblasts12-16. In vitro experiments indicate that 
TLR expression is modulated by bacterial products and cytokines11. Accordingly, an 
IFN-γ responsive element is found in the promoter region of the gene encoding for 
TLR417. Although the above indicates putative pathways that regulate TLR expression, 
the factors which mediate TLR expression in vivo remain to be elucidated. 
Functional TLR4 expression is required for the resistance to experimental 
pyelonephritis induced by a bladder inoculum with Gram-negative bacteria. This is 
evidenced by the persistence of Gram-negative bacteria in the kidney after 
pyelonephritis induction in C3H/HeJ mice18 that carry a malfunctioning TLR4 3, while 
mice bearing intact TLR4 rapidly clear bacteria from the urinary tract. The cellular 
origin of TLR expression in the kidney responsible for resistance to bacteria is 
unknown. Considering that the kidney is an important port of entry for bacteria, we 
set out to localize TLR expression in the kidney and to study the role of cytokines in 
the regulation of TLR expression in vivo. We used a renal ischemia/reperfusion (I/R) 
model that leads to transient tissue damage that is associated with an inflammatory 
process that develops rapidly during reperfusion19. The enhanced expression of MIP-2, 
KC, TNF-α, IFN-γ, and MHC class I and II molecules in this renal sterile inflammation 
model20,21,22 resembles the pattern of production of immunological mediators after 
bacterial infections to a large extent. This model enabled us to study the modulation 
of the expression of TLR2 and TLR4 mRNA by cytokines in vivo during inflammation. 
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Materials and methods 
Antibodies and reagents 
The following antibodies were used: anti-murine IFN-γ mAb F3 and anti-murine TNF-α 
mAb TN3 were kindly provided by HBT (Uden, The Netherlands) and Celltech (Slough, 
United Kingdom) respectively; polyclonal rabbit anti-murine TLR4 serum was kindly 
provided by Dr. B. Beutler (The Scripps Research Institute, La Jolla, CA); peroxidase-
conjugated goat anti-rat IgG and peroxidase conjugated goat anti-rabbit IgG were 
from Jackson ImmunoResearch Laboratories (West Grove, PA); anti-Tamm Horsfall 
protein was from (Cappel, Durham, NC, sheep-anti-dig/alkaline phosphatase was from 
Roche (Basel, Switserland) and biotinylated rabbit anti-goat IgG was from Dako 
(Glostrup, Denmark). Other reagents were proteinase K (Life technologies, Paisley, 
United Kingdom), dextran sulfate (Pharmacia, Uppsala, Sweden), streptABComplex/AP 
(Dako), polyvinylalcohol (PVA), formamide and β-mercaptoethanol (Merck, 
Darmstadt, Germany), dithiothreitol (DTT) and salmon sperm DNA (Sigma, St. Louis, 
MO), T7 and SP6 RNA polymerase, tRNA, Nitro Blue Tetrazolium (NBT) and 
bicholylindolyl phosphate (BCIP) (Boehringer, Mannheim, Germany).  
Animal model and protocol 
All experiments were approved by the Institutional Animal Care Committee of the 
University of Maastricht (Maastricht, The Netherlands). Renal ischemia was induced 
as described20,21. In brief, male Swiss mice (Charles River Breeding Laboratories, 
Heidelberg, Germany) were anesthetized and body temperature was maintained at 
39°C. After laparotomy ischemia was induced by clamping the left renal pedicle for 45 
minutes during which the wound was covered. Subsequent to removal of the clamp, 
the contralateral kidney was removed and stored. After closing the abdomen, mice 
were supplemented with prewarmed PBS to maintain fluid balance. The animals were 
sacrificed at one and six hours as well as 1, 3 and 5 days after ischemia. The 
experimental left kidney was harvested immediately and divided into specimens for 
assays described below. Mice subjected to ischemia were treated 10 minutes before 
reperfusion with 0.5 ml of PBS i.p. containing either 300 μg of anti-IFN-γ mAb F3, or 
1 mg of anti-TNF-α mAb TN3 or PBS only. Previously we have shown that mice 
receiving an isotype-matched control Ab did not differ in inflammatory parameters or 
renal injury when compared with the ischemia/PBS control group20,21, indicating the 
specific effects of the respective antibodies. 
In situ hybridization 
Oligonucleotide primers were designed for the specific PCR amplification of a 
fragment of murine TLR2 and TLR4. The TLR2 primers were 5’-TCT GGG CAG TCT TGA 
ACA TTT-3’, (sense primer) and 5’-AGA GTC AGG TGA TGG ATG TCG-3’ (antisense 
primer), yielding a 321-bp fragment. The TLR4 primers were 5’-GCA ATG TCT CTG GCA 
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GGT GTA-3’ (sense primer) and 5’-CAA GGG ATA AGA ACG CTG AGA-3’ (antisense 
primer), yielding a product of 406-bp (all primers were synthesized by Eurogentec, 
Seraing, Belgium).  
TLR2 and TLR4 cDNA fragments were amplified from murine kidney cDNA prepared 
from total RNA by reverse transcription (RT) as described below. The fragments were 
both TA-cloned into pGEM-Teasy (Promega, Madison, WI). All clones obtained, 
contained the correct TLR sequences that were evaluated using the Big Dye 
termination cycle sequencing kit (Perkin Elmer/Cetus, Emeryville, CA), according to 
the manufacturer’s instructions. DH5-α competent cells were transformed by heat-
shock procedures. Subsequently, clones containing plasmids with the TLR insert were 
selected, isolated and purified using the Qiafilter Plasmid midi kit (Qiagen, Hilden, 
Germany). Sense probes were prepared after linearization of the plasmid with NcoI 
and transcription with SP6 polymerase, antisense probes were prepared from the 
plasmid after linearisation with SpeI by transcription with T7 polymerase. cRNA 
probes were labeled by incorporation of digoxigen-labeled UTP following the 
manufacturers protocol (Boehringer). In situ hybridization was performed as 
described by de Boer et al.23 using 3 µm paraffin sections placed on coated slides 
(SuperFrost Plus, Menzel-Gläser, Braunschweig, Germany). Briefly, after prewarming 
the sections and subsequent rehydration with an decreasing xylene and ethanol 
gradient, the sections were hybridized with 30 ng probe in 300 μl for 16 hours. The 
hybridization was performed at 50°C for TLR2 and at 55°C for TLR4 using a solution 
containing 50% formamide, 1 mg/ml tRNA, 10% dextran sulfate, 10 mM DTT, 
0.25 mg/ml salmon sperm DNA and 4x standard saline citrate (SSC). Subsequently, 
sections were first washed in 2x SSC with 50% formamide at 37°C, secondly in 0.1x SSC 
with 20 mM β-mercaptoethanol at 42°C and finally, sections were treated with 
100 U/ml RNase T1 in 2x SSC with 1 mM EDTA at 37°C. Digoxigen-labeled hybrids were 
detected with alkaline phosphatase conjugated sheep-anti-digoxigenin using NBT as 
chromogen and BCIP as coupling agent. Polyvinylalcohol was used to enhance the 
signal.  
Evaluation of mRNA levels by RT-PCR 
For RT-PCR total RNA was extracted from kidneys using the SV Total RNA isolation 
system (Promega) and treated with RQ1 RNase-Free DNase (Promega). Total RNA was 
reverse transcribed using oligo (dT) primer and Moloney murine leukemia virus 
reverse transcriptase (Life technologies) according to the supplier’s recommendations. 
cDNA samples were standardized based on the content of β-actin cDNA as house-
keeping gene. β-actin cDNA was evaluated by performance of a β-actin PCR on 
multiple dilutions of each cDNA sample. The amount of amplified product was 
estimated by densitometry of ethidiumbromide stained 1.2% agarose gels using a CCD 
camera and Imagemaster VDS software (Pharmacia). The TLR primers used for the 
generation of the cRNA probes were also used for PCR amplification. Primers for 
murine β-actin were: 5’-TAA AAC GCA GCT CAG TAA CAG TCG G-3’ (sense primer) and 
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5’-TGC AAT CCT GTG GCA TCC ATG AAA C–3’ (antisense primer); primers used for the 
amplification of murine TNF-α mRNA: 5’-GGC AGG TCT ACT TTG GAG TCA TTG C-3’ 
and 5’-ACA TTC GAG GCT CCA GTG AAT TCG G-3’ (antisense primer); primers designed 
for amplification of murine IFN-γ mRNA: 5’-AGC GGC TGA CTG AAC TCA GAT TGT AG-3’ 
(sense primer) and 5’-GTC ACA GTT TTC AGC TGT ATA GGG-3’ (antisense primer). All 
primers were used for PCR amplification of murine cDNA kidney samples from mice 
exposed to the interventions. PCR reactions with TLR2, TLR4, β-actin, IFN-γ or TNF-α 
specific primers were performed using appropriate dilutions of the cDNA. PCR 
reactions were performed in a total volume of 25 µl in PCR buffer (Perkin Elmer), in 
the presence of 0.2 mM dNTP (Pharmacia), 1.0 µM of each primer, 0.3 mM MgCl2 and 
0.5 U Taq polymerase (Perkin Elmer). PCR conditions for each primer couple were as 
follows: β-actin: 95°C for 30 sec, 60°C for 45 sec and 72°C for 30 sec during 21 cycles; 
TLR2: 95°C for 30 sec, 57°C for 30 sec and 72°C for 45 sec during 33 cycles; TLR4 : 95°C 
for 45 sec, 61°C for 45 sec and 72°C for 45 sec during 36 cycles; IFN-γ: 95°C for 30 sec, 
63°C for 30 sec and 72°C for 30 sec during 40 cycles; TNF-α: 95°C for 30 sec, 63°C for 
45 sec and 72°C for 30 sec during 38 cycles. Levels of TLR2, TLR4, TNF-α and IFN-γ RNA 
expression were evaluated by densitometric image analysis as described above. 
Relative TLR mRNA levels were calculated by comparison of band intensities of the 
TLR RT-PCR products with standard curves prepared by PCR amplifications on dilution 
series of a highly concentrated murine kidney cDNA.  
Immunohistochemistry 
Staining with the anti-Tamm Horsfall protein on paraffin sections was conducted to 
discriminate between distal tubules, proximal tubular epithelium, the loop of Henle 
and collecting ducts. Immunohistochemistry was carried out on sections adjacent to 
those used for in situ hybridization. Paraffin sections treated as described above, were 
incubated with appropriate dilutions of primary antibody, washed and developed 
using biotinylated rabbit-anti-goat IgG, and alkaline phosphatase labeled strep-
ABComplex and visualized as described above. 
TLR4 Western blotting  
Renal tissue samples for evaluation of TLR4 protein expression were obtained from 
mice of which the renal blood vessels were flushed, immediately after the mice were 
sacrificed, with ice-cold PBS containing nitroprusside and heparin by canulation of the 
left ventricle and opening of the vena cava. This was done to remove TLR4 expressing 
blood leukocytes. Western blotting on renal tissue was performed using 8% 
polyacrylamide SDS gels. Aliquots (50 µl) of kidney homogenates (50 mg/ml) in 2% 
SDS sample buffer were subjected to SDS-PAGE and transferred to polyvinylidene 
fluoride membranes (Immobilon P, Millipore, Bedford, MA). After transfer of the 
proteins membranes were blocked with 5% non-fat dry milk in 50 mM Tris, 150 mM 
NaCl, 0.1% Tween-20, pH 7.4 (TBS-T). Membranes were than incubated with 
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polyclonal rabbit anti-murine TLR4 serum24, kindly provided by Dr. B. Beutler (Scripps 
Research Institute, La Jolla, CA), at a 1:2500 dilution in TBS-T with 0.5% non-fat dry 
milk. Positive bands were visualized by chemiluminescence technology (Supersignal, 
Pierce, Rockford, IL) using peroxidase conjugated goat anti-rabbit IgG at a 1:5000 
dilution. 
Results 
Basal expression of TLR2 and TLR4 in the kidney 
To gain insight into renal expression of TLR, we evaluated mRNA expression of both 
TLR2 and TLR4 by RT-PCR in cDNA samples of healthy kidneys. Constitutive expression 
of both renal TLR2 and TLR4 mRNA was observed (Figure 2.1). To determine the 
cellular origin of this constitutive expression TLR mRNA was localized by in situ 
hybridization. As depicted in Figure 2.2A, 2.2B and 2.3A, 2.3B basal expression of TLR2 
and TLR4 mRNA was observed predominantly in the epithelial cells of the distal and 
proximal tubules and in Bowman’s capsular epithelium. Expression in glomeruli and 
endothelial cells was minor. While macrophages are reported to express relatively 
abundant levels of TLR2 and TLR4 mRNA, it appeared that epithelial cells express the 
majority of the TLR mRNA in the kidney. Only few resident macrophage like cell types 
were observed in the renal tissue and these cells stained to a similar extent as tubular 
epithelium. Proximal epithelial cells in these healthy kidneys stained slightly more 
intensely for TLR4 mRNA compared with the distal epithelium. Control incubations 
using sense riboprobes were negative for healthy and experimental kidneys (Figure 
2.3G).  
 
 
 
 
 
 
 
 
 
 
Figure 2.1 Constitutive and post-ischemic renal TLR2 and TLR4 mRNA expression. Renal TLR 2 and TLR4 
mRNA was evaluated by specific RT-PCR amplification of renal cDNA samples of healthy 
control mice and mice subjected to renal I/R. TLR2 and TLR4 mRNA was constitutively present 
in healthy renal tissue. Ischemia followed by one or six hours reperfusion resulted in 
abrogation of TLR expression. At 24 hours after ischemia, mRNA expression of both TLR 
returned to detectable levels. TLR2 and TLR4 expression was markedly enhanced at days 3 
and 5 post ischemia. Results shown are representative for 3 independent RT-PCR reactions on 
renal cDNA samples of two mice in each treatment group or more. cDNAs were standardized 
for β-actin content. 
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Figure 2.2 Localization of constitutive and inflammation induced renal TLR2 mRNA by in situ hybridization. 
Renal TLR2 localization is shown in medulla (A) and cortex (B) of healthy kidneys, and in mice 
subjected to renal ischemia followed by one day (C,D) and five days (E,F) of reperfusion 
respectively. Constitutive expression for TLR2 was moderate and diffuse in cortex (B) and 
relatively low in the medulla (A). One day post-ischemia staining for TLR2 mRNA was reduced 
(C,D). Five days post-ischemia TLR2 expression is strongly enhanced (E,F) and predominantly 
located in collecting ducts, distal tubular epithelium and Henle’s loop. The arrow indicates a 
macrophage like cell. See page 157 for colour figure. 
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Figure 2.3 Localization of constitutive and inflammation induced renal TLR4 mRNA by in situ hybridization. 
TLR4 localization is shown by incubation with the anti-sense riboprobe in medulla (A) and 
cortex (B) in healthy kidneys, and in mice subjected to renal ischemia followed by one day (C,D) 
and five days (E,F) of reperfusion respectively. Control incubations using TLR4 sense riboprobe 
were negative (G). Constitutive expression for TLR4 was moderate and diffuse in cortex, mainly 
by the tubular epithelial cells (B), and relatively low in the medulla (A). One day after ischemia 
TLR4 expression was primarily observed in collecting ducts, distal tubules and the thin limb of 
Henle’s loop (C,D). Five days after ischemia TLR4 mRNA staining was strongly enhanced in 
collecting ducts, the distal tubules and the thin limb of the loops of Henle (E,F). A small number 
of macrophage like cells was observed, which stained all positive. Arrows indicate macrophage 
like cells. Distal tubules were identified by Tamm Horsfall protein staining (H). See page 158 for 
colour figure. 
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Effects of renal injury on TLR2 and TLR4 gene expression  
Mice were exposed to unilateral renal I/R, a process that leads to tissue damage and a 
subsequent sterile inflammatory reaction. This inflammatory process is characterized 
by initial tubular apoptosis, followed by KC, MIP-2, and TNF-α expression and 
subsequent neutrophil influx with apoptosis, necrosis and organ dysfunction peaking 
at day 119,20,22. Thereafter a strongly enhanced IFN-γ mediated MHC-I and II expression 
occurs from day 3 onwards21,25. The effect of this sterile inflammatory process on TLR2 
and TLR4 mRNA levels was assessed by RT-PCR analysis. Levels of renal TLR2 mRNA 
decreased to undetectable levels in animals sacrificed at one and six hours after 
ischemia. TLR2 mRNA returned to basal level after one day (Figure 2.1). A similar 
mRNA expression pattern was observed for TLR4 (Figure 2.1): TLR4 mRNA expression 
was undetectable at one hour, from one to six hours the TLR4 synthesis returned to 
detectable levels. After 24 hours of reperfusion TLR4 expression was enhanced when 
compared to controls. TLR2 and TLR4 mRNA expression were similar in healthy and 
sham operated controls, indicating that the surgical procedure did not influence TLR 
expression (data not shown). The results of densitometric quantification of TLR2 and 
TLR4 mRNA levels at 1, 6 and 24 hours after ischemia are depicted in Figure 2.4A and 
2.4B. At days 3 and 5 after renal ischemia, a significant increase of both TLR2 and 
TLR4 mRNA was detected in the kidney (Figure 2.1). A 4-5-fold increase of TLR2 mRNA 
was observed when compared to healthy controls (Figure 2.5A). Similarly a 4 and 5.5 
fold enhancement of TLR4 mRNA was measured at three and five days post-ischemia 
respectively (Figure 2.5B).  
To elucidate the cellular origin of the described enhanced TLR2 and TLR4 expression in 
this renal inflammation model, TLR mRNA was localized by in situ hybridization. 
Histology showed that renal injury was clearly present one day after ischemia, which 
is associated with the influx of neutrophils20,25. In this inflamed tissue, reduced TLR2 
mRNA expression was observed in the cortex compared to healthy controls (Figure 
2.2D). In the medulla TLR2 transcripts appeared upregulated in the thin limb of 
Henle’s loop (Figure 2.2C). Moreover, TLR2 transcription was detected in macrophage 
like cells in the interstitial tissue (Figure 2.2C, 2.2D). One day after ischemia TLR4 
expression was predominantly observed in the epithelial cells of the distal tubules, the 
thin limb of Henle’s loop and collecting ducts, while low expression was observed in 
the proximal tubules, glomeruli and capsular epithelium. A small number of 
macrophage like cells were present and stained positive. In concordance to the 
enhanced TLR mRNA expression as measured by RT-PCR at five days after ischemia, 
intense staining for both TLR2 and TLR4 mRNA was detected by in situ hybridization at 
the same timepoint. The intense staining was predominantly localized in the collecting 
ducts, the thin limb of Henle’s loop and distal tubules (Figure 2.2E, 2.2F, 2.3E, 2.3F). 
Identification of distal tubules in these experiments was performed by Tamm Horsfall 
protein staining (Figure 2.3H). At five days post-ischemia, a small number of 
macrophage like cells were present which stained positive for TLR2 and TLR4. 
However, compared to the staining in collecting ducts, the loop of Henle and distal 
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tubules, this TLR expression by macrophage like cells constituted only a minority of 
the total expression (Figure 2.2E, 2.2F, 2.3E, 2.3F). At day 5 only moderate TLR 
expression was detected in the glomeruli and proximal tubules (Figure 2.2E, 2.2F, 
2.3E, 2.3F). Taken together, renal I/R leads to marked enhancement of both TLR2 and 
TLR4 mRNA levels, which appeared to be predominantly present in epithelial cells of 
the distal tubules, the collecting ducts and Henle’s thin loop.   
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 2.4 I/R-induced changes in both TLR2 and TLR4 mRNA synthesis during the early reperfusion 
phase. Renal TLR 2 (A) and TLR4 (B) mRNA was evaluated by specific RT-PCR amplification of 
renal cDNA samples of healthy control mice and mice subjected to renal I/R. cDNA’s were 
standardized for β-actin content. Quantitative data were obtained by densitometric 
evaluation of RT-PCR products which were compared to a standard curve obtained by 
amplification of a serial dilution of highly concentrated cDNA. TLR2 expression (A) after one 
hour (n=2) and six hours (n=2) following ischemia was not detectable. TLR2 expression 
returned to basal levels (n=4) at 24 hours following ischemia (n=3) (A). A similar expression 
pattern following I/R was observed for TLR4 (B). However, increased renal TLR4 mRNA 
expression was observed at 24 hours. A representative graph is shown for the outcome of 3 
separate PCR experiments on the indicated samples.  
Role of IFN-γ and TNF-α in regulation of renal TLR expression  
Renal I/R results in TNF-α modulated renal inflammation that is followed by IFN-γ 
dependent up-regulation of MHC class I and II molecules, indicating an active cytokine 
mediated immune response in the organ20,21,25. The role of these cytokines in the 
observed upregulation of TLR mRNA expression in our I/R induced renal inflammation 
model was evaluated by blocking TNF-α and IFN-γ with inhibitory antibodies. The 
observed enhancement of renal TLR2 mRNA expression five days after ischemia was 
completely prevented in animals treated with anti IFN-γ or anti TNF-α antibodies 
(Figure 2.6A, 2.6B). Moreover, blocking of either IFN-γ or TNF-α reduced the TLR2 
mRNA expression at day 5 to below the constitutive level (Figure 2.6B). In contrast to 
this major inhibitory effect of anti TNF-α on TLR2 mRNA synthesis in our renal 
inflammation model, blocking of TNF-α resulted only in a partial reduction of TLR4 
mRNA expression (Figure 2.6A, 2.6C). Similar to the effect of anti IFN-γ on TLR2 mRNA 
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expression, blocking of IFN-γ completely prevented the enhancement of TLR4 mRNA 
synthesis at five days after ischemia, resulting in TLR4 mRNA expression below the 
constitutive level. Our findings indicate that TLR2 and TLR4 expression are regulated 
differentially by TNF-α and IFN-γ. Because both IFN-γ and TNF-α are involved in the 
enhanced TLR mRNA expression we determined the effect of cytokine inhibition on 
cytokine mRNA expression. Anti IFN-γ treatment decreased IFN-γ mRNA translation in 
the kidneys five days after the ischemic insult whereas TNF-α mRNA was not 
decreased by inhibition of IFN-γ (Figure 2.7A). Anti TNF-α antibody administration did 
not decrease the renal TNF-α and renal IFN-γ mRNA levels when compared with PBS 
treated animals (Figure 2.7B). These findings show that IFN-γ does not enhance TLR 
mRNA expression in our model by induction of TNF-α and that TNF-α does not 
enhance TLR mRNA expression by induction of IFN-γ.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 2.5 Renal I/R induced inflammation enhances TLR2 and TLR4 mRNA expression. Renal TLR 2 (A) 
and TLR4 (B) mRNA was evaluated by specific RT-PCR amplification of renal cDNA samples of 
healthy control mice and mice subjected to renal I/R. cDNA’s were standardized for β-actin 
content. The means of densitometric evaluations are shown. Strongly enhanced TLR2 (A) 
mRNA levels were detected at three days (n=3) and five days (n=4) after ischemia, compared 
to levels detected one day after ischemia (n=3) and controls (n=4). Similarly, strongly 
enhanced TLR4 (B) expression was observed at three and five days following ischemia. A 
representative graph is shown for the outcome of three separate PCR experiments on the 
indicated samples. 
TLR4 protein expression after renal I/R 
Renal TLR4 expression was evaluated by Western blotting using specific anti-murine 
TLR4 antiserum. Whole renal tissue samples, and liver as positive control, were 
homogenized in SDS and proteins were separated by SDS-PAGE. Subsequent 
immunoblotting with the anti-murine TLR4 antiserum revealed positive bands with an 
apparent molecular weight of ~95 kD and ~120 kD in normal liver and in kidney tissue 
five days after renal I/R (Figure 2.8). The calculated molecular weight of mature TLR4 
based on its amino acid sequence is 93.5 kD and is consistent with the anti-TLR4 
0
5
10
15
20
25
He
alt
hy
co
nt
ro
l
Da
y 1
   
Da
y 3
Da
y 5
 
Days after ischemia
TL
R2
 m
RN
A
le
ve
ls
He
alt
hy
co
nt
ro
l
Da
y 1
  
Da
y 3
  
Da
y 5
  
Days after ischemia
TL
R4
 m
RN
A
le
ve
ls
0
5
10
15
20
25
TL
R2
 m
RN
A
le
ve
ls
TL
R4
 m
RN
A
le
ve
ls
 Renal localization of TLR expression⏐45 
positive bands at ~95 kD in the Western blot. The band at a molecular weight of 
~120 kD in renal tissue after I/R and in normal liver probably represents a glycosylated 
form of the TLR4 protein. The observed molecular weight form of 120 kD of murine 
TLR4 is consistent with the reported apparent molecular weight of human 
recombinant TLR426. Basal TLR4 protein expression was not detectable with the used 
Western blotting technique in healthy murine renal tissue (Figure 2.8). These 
observations show that the upregulation of TLR4 mRNA expression during renal 
inflammation induced by I/R is accompanied by a significant increased TLR4 protein 
expression in the kidney.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 2.6 Inflammation induced renal TLR2 and TLR4 expression is IFN-γ and TNF-α dependent. Renal 
TLR2 (A,B) and TLR4 (A,C) transcripts were detected in mice five days after ischemia by RT-PCR 
and quantitated as described for Figure 1 and 5. Mice were treated with inhibitory anti TNF-α 
or anti IFN-γ antibodies at the time of reperfusion. TLR2 (A,B) upregulation is prevented 
completely by both anti IFN-γ (n=2) and anti TNF-α (n=2) when compared to PBS treated 
animals (n=4). Enhancement of TLR4 (A,C) mRNA expression is only partially blocked by anti 
TNF-α but completely abrogated by anti IFN-γ. Representative graphs are shown for the 
outcome of 3 separate PCR experiments on the indicated samples. 
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Figure 2.7 Effect of cytokine inhibition on I/R induced renal cytokine expression. Renal IFN-γ (A) and TNF-
α (B) mRNA levels were detected at day 5 after renal ischemia by RT-PCR in mice treated with 
anti TNF-α or anti IFN-γ. cDNA was standardized for β-actin content. Shown are the means of 
densitometric values. IFN-γ mRNA (A) expression at five day after ischemia is reduced by anti 
IFN-γ (n=2) but not by anti TNF-α (n=2) when compared with PBS treated animals (n=4). 
Treatment with anti TNF-α or anti IFN-γ did not affect TNF-α (B) mRNA levels. Representative 
graphs are shown for the outcome of 3 separate PCR experiments on the indicated samples. 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 2.8 I/R induced renal TLR4 protein expression. Murine TLR4 protein expression was evaluated by 
Western blotting using polyclonal rabbit anti-murine TLR4 serum. Tissue samples were 
homogenized in SDS-sample buffer and proteins were separated on 8% polyacrylamide 
SDSgels and immunoblotted using PVDF membranes. Lane 1, liver; lane 2, control kidney; 
lane 3, kidney five days after I/R. 
Discussion  
In this work, we describe the mRNA localization for TLR2, the apparent receptor for 
products of Gram-positive bacteria27, and for TLR4, which recognizes LPS present on 
Gram-negative bacteria3, in renal tubular epithelial cells. Our description of TLR2 and 
TLR4 mRNA localization in the kidney is the first to show constitutive TLR2 and TLR4 in 
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vivo expression in the epithelial cells of the proximal and distal tubules. Moreover, we 
observed that a non-microbial inflammation as induced by I/R causes remarkably 
enhanced TLR2 and TLR4 mRNA expression by epithelial cells of the distal tubules, the 
thin limb of the loops of Henle, and collecting ducts. The enhanced TLR mRNA 
expression during renal inflammation was found to be mediated by both IFN-γ and 
TNF-α and is associated with a major increase of renal TLR4 protein expression. While 
in vitro TLR4 mRNA expression and responsiveness had been reported for several cell 
types such as leukocytes, endothelial cells, epithelial cells and fibroblasts, but most 
abundantly for macrophages11-15, the differential expression of TLR4 in vivo remained 
to be elucidated. Our study indicates that murine renal epithelial cells express TLR2 
and TLR4 in vivo. The observation that TLR2 and TLR4 mRNA expression in the kidney 
is predominantly located in renal tubular epithelium appears to have some 
implications for the understanding of the innate immune defense mechanism in the 
kidney against pyelonephritis as a result of ascending urinary tract infections (UTI). 
Gut derived Gram-negative and Gram-positive bacteria are the most prevalent 
microbial pathogens responsible for UTI, with Escherichia coli being the most 
common28. Our data suggest that tubular epithelial cells can monitor the presence of 
both types of bacteria. In this context, Hagberg et al.18 showed already in 1984 that 
C3H/HeJ mice, who lack functional TLR43, are highly susceptible to persistent Gram-
negative pyelonephritis. TLR dependent cellular activation leads to the translocation 
of NF-κB to the nucleus which leads to transcription of genes encoding for cytokines, 
chemokines, adhesion molecules and antimicrobial peptides1,3,10,29. Consistently, TLR4 
signaling, induction of CXC chemokine expression and CXC receptor signaling18,30, and 
subsequent neutrophil recruitment are crucial for the clearance of Gram-negative 
bacteria from the kidney31,32. Our results suggest that the functional role of TLR4 in 
prevention of pyelonephritis as described18 could be the result of functional TLR4 
expression by the renal tubular epithelial cells. To monitor bacteria in the lumen of 
tubules and collecting ducts the TLR receptors should be expressed on the apical 
membrane of the renal epithelial cells. It should be noted that we located renal TLR 
expression at the mRNA level and obviously these results need to be confirmed by 
studies at the protein level by immunohistochemistry and with functional studies. In 
regard of the functionality of TLR4 in the kidney it is noteworthy that the mRNA for 
MD-2, the essential cofactor for TLR4, is abundantly present in the murine kidney3. 
We have confirmed the abundant renal MD-2 mRNA expression by RT-PCR analysis, 
and also observed elevation of MD-2 mRNA after I/R (data not shown).  
We applied a renal I/R model to elucidate the regulation of TLR expression during 
inflammation. This model allowed us to evaluate cytokine mediated TLR mRNA 
expression in an inflammatory process that is not influenced by bacterial products. 
Most interestingly, a shift occurs from the observed diffuse proximal and distal 
staining for TLR2 and TLR4 mRNA in healthy kidneys to a predominant and enhanced 
expression five days after ischemia in the distal epithelial tubular cells, the thin limb of 
the loops of Henle and collecting ducts. Following renal I/R injury monocyte and T-cell 
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influx has been reported from day 3 onwards33. We observed a small number of 
macrophage like cells that stained all positive for both TLR2 and TLR4, however, 
compared to the enhanced expression in collecting ducts, the thin limb of the loops of 
Henle and distal tubules this constituted only a minority of the total TLR expression. 
The increased TLR2 and TLR4 mRNA expression in our renal inflammation model by 
epithelial cells in the distal part of the nephron and the medulla, suggests the 
mobilization of TLR dependent anti-microbial potential during inflammation to the site 
where ascending bacteria may enter the kidney.  
The I/R induced TLR mRNA expression in the later phase of reperfusion (day 3-5) was 
dependent on the action of IFN-γ and TNF-α. Previously we demonstrated that anti 
TNF-α reduces kidney neutrophil influx and deterioration of renal function in our 
murine model of renal I/R20, whereas anti IFN-γ did not affect these parameters21. The 
inhibition of TLR upregulation by anti TNF-α is not caused by a major effect on the 
IFN-γ mRNA synthesis (Figure 2.7). This observation is supported by data showing that 
anti TNF-α does not block the upregulation of MHC molecules in this model, while this 
process is largely IFN-γ dependent20,25. Since blocking of either TNF-α or IFN-γ results 
in inhibition of the majority of TLR2 expression it appears that the observed 
enhancement of TLR2 expression is elicited by a synergistic action of these cytokines. 
TLR4 synthesis is only partially blocked by anti TNF-α and almost completely by anti 
IFN-γ, it appears therefore that the upregulation of TLR4 in our inflammation model is 
primarily mediated by IFN-γ. Thus, the regulation of TLR4 mRNA expression discerns 
with TLR2 in our in vivo model in respect to the dependence on TNF-α. Consistently, 
also in vitro studies indicate that TLR2 and TLR4 expression are regulated via distinct 
pathways11. Our in vivo observation of IFN-γ mediated TLR4 expression is in line with 
the presence of a functional interferon response factor (IRF) motif in the promoter 
region of the human and mouse TLR4 gene17. It should be mentioned that we cannot 
exclude the possibility that TNF-α or IFN-γ act indirectly by stimulation of a putative 
modulator of TLR expression.    
In general IFN-γ is involved in bacterial clearance during the late stages of infection 
with virulent Gram-negative or Gram-positive bacteria34-36. Furthermore, IFN-γ 
deficiency is found to be associated with infection by poorly pathogenic 
mycobacterium strains and Salmonella37. Our observations suggest that IFN-γ 
augments enhanced reactivity to bacteria in vivo by upregulation of TLR2 and TLR4 
mRNA. Indeed, increased expression of TLR4 by IFN-γ may explain the enhanced LPS 
induced lethality of IFN-γ treated rabbits and the enhanced LPS sensitivity of 
monocytes/macrophages induced by IFN-γ38-40. It appears that increased TLR2 and 
TLR4 expression may play a role in the mechanisms involved in IFN-γ mediated 
resistance to virulent bacteria.  
Although an obvious role for IFN-γ in urinary tract infections in humans is not reported 
it must be mentioned that the epithelial cells of the kidney stain strongly positive with 
anti IFN-γ receptor antibodies in immunohistochemistry41, indicating the 
responsiveness of these cells to IFN-γ. IFN-γ deficiency was observed to increase the 
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susceptibility of mice to experimental UTI urinary tract infection with uropathogenic E. 
coli42. The latter is in line with the IFN-γ mediated TLR4 expression (this study) and 
increased susceptibility of TLR4 deficient mice for Gram-negative UTI18. Next to 
behavior and anatomical impairments of the urinary tract, genetic factors also seem 
to be involved in human ascending urinary tract infections27. However, the genetic 
influence in human UTI however needs further investigation (see ref 30).  
In conclusion, TLR2 and TLR4 are constitutively expressed in both proximal and distal 
tubular renal epithelial cells in vivo. During renal inflammation TLR2 and TLR4 mRNA 
synthesis is enhanced by the action of TNF-α and IFN-γ, and this increased expression 
is mainly localized in distal tubules, the thin limb of the loops of Henle and collecting 
ducts. The epithelial localization of TLR mRNA expression suggests a role for epithelial 
derived TLR signaling in the inflammatory response observed during ascending UT 
infections. 
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Abstract  
Ischemic damage plays an important role in post-transplant organ failure. Activation 
of the apoptotic cascade is crucially involved in post-ischemic inflammation resulting 
in tissue damage and organ dysfunction. Here we investigate the initiation of the 
apoptotic cascade during normothermic ischemia in human kidneys using a model for 
normothermic ischemia with kidneys nephrectomized because of renal cell carcinoma. 
Ex vivo, kidneys were stored at 37°C and consecutive biopsies were taken from 
disease free tissue. Pro- and anti-apoptotic proteins were assessed by western 
blotting and immunofluorescence. 
During normothermic ischemia the pro-apoptotic proteins Bax and activated caspase-
9 increased with ischemia time, whereas caspase-8 was not activated. The anti-
apoptotic proteins Bcl-2 and cFLIP decreased in time. Data on Bcl-2 and Bax were 
supported by immunofluorescence for Bcl-2 and activated Bax. However, activation of 
the central effector caspase-3, essential for execution of the apoptotic process, was 
not detected. 
In conclusion, during normothermic ischemia the apoptotic cascade in the human 
kidney is initiated, but not fulfilled. Our data show that the duration of ischemia 
significantly correlates with activation of the apoptotic cascade. These findings 
provide insight in the initiation of apoptotic cell-death during warm ischemia and may 
be useful in the assessment of ischemic injury. 
 Renal Apoptosis During Human Normothermic Ischemia⏐55 
Introduction 
Post-transplant acute renal failure (ARF) is an important determinant of renal 
transplant survival. The occurrence of ARF is substantial in organs derived from 
cadaveric donors and in particular non-heart beating (NHB) category 2 donors1, as 
compared to living donors2. The inevitable ischemia of such NHB donor kidneys 
explains these differences in graft failure to a large extent2. Understanding the 
mechanisms of injury initiated by ischemia-reperfusion (I/R) is therefore of critical 
importance for defining strategies to improve post-transplant organ function. 
In different experimental models it has been established that renal ischemia followed 
by reperfusion leads to apoptotic cell death3,4. Moreover, activation of the apoptotic 
cascade is crucially involved in the induction of post-ischemic inflammation and 
subsequent organ failure3. In line, enhanced apoptotic cell death established by tunel-
staining, was detected in post-transplant biopsies from cadaveric allografts as 
compared to transplants derived from living donors, indicating that ischemic injury 
induces apoptosis in clinical transplantation5. 
Apoptosis is executed by a family of cysteine proteases, called caspases6. Two major 
pathways of caspase activation have been described; i.e. the extrinsic and intrinsic 
pathway7. Activation of the extrinsic pathway, triggered by binding of extracellular 
ligands to cell surface death receptors, results in recruitment of the adaptor molecule 
and Fas-associated death domain (FADD) and activation of caspase-8 upon 
recruitment to the death-inducing signaling complex (DISC). The latter are controlled 
by cFLIP, an intracellular protein that inhibits death receptor signaling by regulating 
both recruitment and processing of pro-caspase-8 within the DISC8.  
The intrinsic pathway is activated by various intracellular stimuli, such as anoxia, 
growth factor deprivation and DNA damage, all affecting the mitochondria, where 
they promote mitochondrial membrane permeabilization and the release of caspase 
activating factors, among others cytochrome c, into the cytosol9,10. Cytosolic 
cytochrome c interacts with apaf-1, leading to its oligomerization and the recruitment 
of pro-caspase-9, which autoactivates within the so called apoptosome11. Members of 
the Bcl-2 family, among others pro-apoptotic Bax and anti-apoptotic Bcl-2, control 
activation of the intrinsic pathway. For any given apoptotic stimulus, the balance 
between death and survival seems to be determined by the ratio of the apoptosis-
stimulating and -suppressing Bcl-2 family members12,13. The activation of either 
extrinsic or intrinsic pathway participates in a cascade that culminates in the 
activation of effector caspases. Activation of primarily effector caspases-3, -6, and -7, 
results in cleavage of a wide range of substrates leading to chromosomal DNA 
fragmentation and cellular morphologic changes characteristic of apoptosis6. 
Although it appears that apoptotic cell death plays a role in the induction of organ 
damage due to renal I/R in humans5,14, it is currently unknown whether the apoptotic 
cascade is already initiated during ischemia or becomes initiated upon reperfusion. In 
this context, we developed a human model for renal normothermic ischemia. This 
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model was used to study proteins involved in the initiation of the apoptotic cascade 
during normothermic ischemia. In particular, we investigated the consumption of 
endogenous caspase inhibitors as well as the activation of initiator and effector 
caspases. Our data indicate that during normothermic ischemia the apoptotic cascade 
is initiated in the human kidney. These data implicate that during normothermic 
ischemia, the circumstances are created that facilitate execution of apoptosis upon 
reperfusion. Therefore our data may be useful in the development of methods to 
assess ischemic injury. Moreover, renewed insight in early ischemic changes provides 
important opportunities to prevent clinical manifestations of reperfusion injury in the 
kidney, and potentially in other organs. 
Materials and methods 
Antibodies 
The following antibodies (ab) were used: anti-murine Bax ab P19 from Santa Cruz 
Biotechnology (Santa Cruz, CA); anti-Bcl-2, anti-human caspase-9 and anti-human 
caspase-3 from Stressgen (Victoria, Canada); monoclonal murine anti-caspase-8 was 
kindly provided by Dr. Klaus Schulze-Osthoff (Institute of Molecular Medicine, 
University of Duesseldorf, Germany); anti human cFLIP (Biocarta; San Diego, CA); Goat 
anti rabbit Texas Red and peroxidase conjugated goat anti-rabbit IgG from Jackson 
Immuno-Research Laboratories (West Grove, PA) and peroxidase conjugated goat 
anti-mouse IgG from Caltag (Burlingame, CA). Anti-Bcl-2 and anti-Bax from Upstate 
biotechnology (Lake Placid, NY) and Lotus Tetragonolobus Lectin from Vector 
(Burlingame, CA) were used for immunohistochemistry. 
Human model for renal normothermic ischemia 
In the present study, kidneys used were nephrectomized because of a renal cell 
carcinoma. These patients did not have a family history of renal cell carcinomas, 
neither did they have other signs of hereditary diseases like von Hippel-Lindau (VHL). 
Taking into consideration the pathology, the age of the patients and the absence of a 
family history/patient anamnesis, the chance that a hereditary effect influences our 
data, is certainly far below 1%. 
Normothermic ischemia started at ligation of the renal artery about 5 min before 
nephrectomy. Thereafter, kidneys (n=5 per group) were immediately stored at 37°C 
and rapidly inspected by the responsible pathologist. Full-thickness biopsies were 
taken from non-diseased tissue. Subsequently, normothermic renal ischemia was 
prolonged up to 85 min. Renal temperature was measured during storage and 
remained between 36 and 37.5°C. Approximately every 15 min full-thickness biopsies 
were taken. Control kidneys (n=4) were cooled at 0°C immediately upon 
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nephrectomy. Biopsies from these control kidneys were taken within 10 min after 
nephrectomy. All biopsies were divided in several parts and either immediately stored 
in liquid nitrogen for western blotting, or embedded in Tissue Tek (EMS; Washington, 
PA) and snap-frozen in isopentane at –80°C for immunohistochemistry. All biopsies 
were stored at -80°C until further processing.  
Western blotting 
Renal tissue samples were homogenized in lysis buffer (200 mM NaCl, 10 mM Tris 
base, 5 mM EDTA, 10% Glycerin, 1 mM PMSF, 0.1 U/ml Aprotinin and 1 µg/ml 
Leupeptin). Homogenates were centrifuged at 300 rpm for 10 min, supernatants were 
collected and centrifuged again at 10.000 rpm for 3 min. Final supernatants were 
harvested and total protein concentrations were determined using the Bradford 
method. To confirm equal protein loading immunoblotting was performed with an 
anti-actin antibody (Sigma, Chicago, IL). Aliquots with equal amounts of protein were 
heated at 100°C for 5 min in SDS sample buffer, separated on 15% SDS-polyacrylamide 
gels and transferred to polyvinylidene fluoride membranes (Immobilon P; Millipore, 
Bedford, MA). After transfer of proteins, blocking, ab incubation steps and washing of 
the membrane were performed in Phosphate buffered saline (PBS) supplemented 
with 3% nonfat dry milk and 0.05% Tween. Except for incubations with ab to cFLIP, 
which were blocked in 50 mM Tris, 150 mM NaCl, 0.1% Tween 20 (TBST) 
supplemented with 5% milk and washed in TBST with 0.5% milk. 
After the incubation with the primary ab and washing, membranes were incubated 
with the appropriate horseradish peroxidase–conjugated secondary ab to rabbit or 
mouse IgG. Positive bands were visualized using chemiluminescence’s (Supersignal; 
Pierce, Rockford, IL). 
Immunoreactive bands for all proteins were evaluated densitometrically using a 
computer-controlled display camera (Imagemaster; Pharmacia, Piscataway, NJ) and 
image analysis Sigma Gel software (SPSS). For each protein, the optical density of each 
ischemic sample was compared with the average value of the four control samples.  
Immunohistochemistry 
Cryostat sections (5 µm) of frozen tissue were cut and stained for Bcl-2 or active Bax. 
Briefly, slides were dried, fixed in acetone for 10 min, and air-dried. Slides were 
rehydrated in PBS for 5 min and subsequently incubated in 10% normal goat serum in 
PBS to block aspecific ab binding. Slides were stained for two hours at RT with either 
anti-Bcl-2 or anti-Bax primary ab in PBS with 1% bovine serum albumin. After three 
washes in PBS for 5 min each, slides were incubated for 30 min with the Texas Red 
labeled secondary ab diluted in the same buffer with the addition of FITC-labeled 
Lotus Lectin for identification of proximal tubular epithelium15. After three washes in 
PBS, the slides were mounted using glycerol-PBS with 1,4-diazabicyclo(2,2,2)octane 
and 4,6-diamidino(2)phenylindole (DAPI) and viewed with an immunofluorescence 
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microscope. No significant staining was detected in slides incubated with control ab 
instead of the primary ab indicating the absence of significant background staining. 
Cryostat sections (5 µm) of frozen tissue were cut and stained for Bcl-2 or active Bax. 
Briefly, slides were dried, fixed in acetone for 10 min, and air-dried. Slides were 
rehydrated in PBS for 5 min and subsequently incubated in 10% normal goat serum in 
PBS to block aspecific ab binding. Slides were stained for two hours at RT with either 
anti-Bcl-2 or anti-Bax primary ab in PBS with 1% bovine serum albumin. After three 
washes in PBS for 5 min each, slides were incubated for 30 min with the Texas Red 
labeled secondary ab diluted in the same buffer with the addition of FITC-labeled 
Lotus Lectin for identification of proximal tubular epithelium15. After three washes in 
PBS, the slides were mounted using glycerol-PBS with 1,4-diazabicyclo(2,2,2)octane 
and 4,6-diamidino(2)phenylindole (DAPI) and viewed with an immunofluorescence 
microscope. No significant staining was detected in slides incubated with control ab 
instead of the primary ab indicating the absence of significant background staining. 
Statistical analysis 
We used the Mann-Whitney test to compare Bax protein expression between the 
control and the “early” ischemia group. The Spearman analysis was used to determine 
correlation between the duration of normothermic ischemia and initiation of 
apoptosis. A P value of less than 0.05 was considered significant. 
Results 
Initiation of the intrinsic pathway during normothermic renal ischemia 
To determine whether apoptogenic processes are initiated during ischemia, we 
evaluated the effect of normothermic ischemia on proteins involved in activation of 
both the intrinsic and extrinsic pathway. Since activation of the intrinsic pathway is 
regulated by members of the Bcl-2 protein family, we first determined the pro-
apoptotic Bax protein content during ischemia by western blotting. As described by 
others, we observed that monomeric Bax (21 kDa) is constitutively expressed in 
human renal tissue16 (Figure 3.1). A short period of renal ischemia (15 until 35 min) led 
to a significant  increase of Bax protein (P<0.02, Mann-Whitney test) (Figure 3.1). Bax 
levels remained clearly elevated up to 60 min. Further prolongation of ischemia 
reduced Bax expression back to basal levels. Next the localisation of active Bax was 
studied using immunohistochemistry. For this purpose, an ab directed to the 
N-terminal region of active Bax that is inaccessible in the inactive conformation was 
applied. The data show that active Bax protein is nearly absent in control tissue 
(Figure 3.2). In concordance with the enhanced Bax protein content, as detected by 
western blotting, cytoplasmic active Bax staining increased in the early ischemic 
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phase. After 30 min of ischemia, activated Bax was predominantly localised in distal 
tubular epithelial cells. At this timepoint, also some focal staining was observed in 
proximal tubules. Proximal tubules were identified using Lotus Lectin staining. 
Similarly, after 80 min of ischemia, the majority of active Bax was detected in distal 
tubules (Figure 3.2).  
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 3.1 Bax protein shows a rapid increase followed by decrease during normothermic ischemia. A) 
Representative immunoblot analysis of Bax. B) Densitometric analysis of Bax immunoblotting 
of ischemic (n=5) and control kidneys (n=4). Data of ischemic kidneys are expressed as the 
fraction of mean of control data. Individual ischemic kidneys are displayed by different 
symbols (■,▲,○,□,Δ) and control kidneys by a filled circle. Constitutive Bax expression 
(21 kDa) was detected in control tissue. After a short period of ischemia renal Bax expression 
levels were significantly increased (P<0.02, Mann-Whitney test). Bax protein levels remained 
elevated up to 60 min. Dotted line represents trendline of all data. 
 
 
Subsequently, we investigated the effect of ischemia on the regulation of the anti-
apoptotic protein Bcl-2. Abundant monomeric Bcl-2 expression (26 kDa) was observed 
in control tissue (Figure 3.3). Bcl-2 western blot analysis revealed that during ischemia 
Bcl-2 levels were reduced. Moreover, this reduction of Bcl-2 significantly correlated 
with the duration of the ischemic insult (r=0.86, P<0.001, Spearman correlation 
analysis) (Figure 3.3). Immunohistology for Bcl-2 resulted in similar data; a decrease of 
Bcl-2 with time. Bcl-2 was primarily detected at the basolateral side of tubular 
epithelial cells. The expression was predominantly observed in proximal tubules while 
a lower expression was detected in distal tubules (Figure 3.4). 
Collectively, enhanced Bax protein levels combined with decreased Bcl-2 levels 
suggests that normothermic ischemia enhances susceptibility for the activation of the 
intrinsic pathway. In this context we determined the activation of initiator caspase-9. 
We observed a significant correlation between activation of caspase-9 (34/37 kDa) 
and the normothermic ischemia time (r=0.79, P<0.001, Spearman correlation analysis) 
(Figure 3.5). Taken together, these data show that already during normothermic 
ischemia, activation of the intrinsic pathway of the apoptotic cascade occurs.  
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Figure 3.2 Activated Bax protein is predominantly expressed by distal tubular epithelial cells. While 
hardly detectable in control kidneys (A), Bax protein was increasingly expressed (red) in distal 
tubules in kidneys exposed to 30 min (B) or 80 min (C) of ischemia. In the ischemic sections 
also some focal staining of proximal tubules was observed (B,C). Proximal tubules were 
identified by FITC Lotus Lectin staining (green). Red staining, active Bax protein (Texas Red); 
blue staining, nuclei (4,6-diamidino(2)phenylindole). Magnification: x200. See page 159 for 
colour figure. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 3.3 Depletion of renal Bcl-2 during normothermic ischemia. A) Representative immunoblot 
analysis of Bcl-2. B) Densitometric analysis of Bcl-2 immunoblotting with ischemic (n=5) and 
control kidneys (n=4). Data of ischemic kidneys are expressed as fraction of the mean of 
control data. Individual ischemic kidneys are displayed by different symbols (■,▲,○,□,Δ) and 
control kidneys by a filled circle. A significant correlation was detected between renal 26 kDa 
Bcl-2 levels and the length of normothermic ischemia (r=0.86, P<0.001, Spearman correlation 
analysis). Dotted line gives trendline of all data. 
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Figure 3.4 Immunofluorescence staining of Bcl-2 during renal normothermic ischemia. Renal Bcl-2 
staining was most abundant (red) in proximal tubules of control tissue (A) and in kidneys 
rendered ischemic for 35 min (B) and 80 min respectively (C). Less staining was detected in 
distal tubules in both control and ischemic tissue. Proximal tubules were identified by FITC 
Lotus Lectin staining (green). Red staining, Bcl-2 protein (Texas Red); green staining, Lotus 
Lectin (fluorescein isothiocyanate); blue staining, nuclei (4,6-diamidino(2)phenylindole). 
Magnification: x200. See page 160 for colour figure. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 3.5 Ischemia induces intrarenal caspase-9 activation. A) Representative immunoblot analysis of 
activated caspase-9. B) Densitometric analysis of caspase-9 immunoblotting with ischemic 
(n=5) and control kidneys (n=4). Data of ischemic kidneys are expressed as fraction of the 
mean of control data. Individual ischemic kidneys are displayed by different symbols 
(■,▲,○,□,Δ) and control kidneys by a filled circle. Activation of caspase-9 (34/37 kDa) is 
significantly correlated with the ischemia time (r=0.79, P<0.001, Spearman correlation 
analysis). Dotted line gives trendline of all data. 
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Initiation of the extrinsic pathway during normothermic renal ischemia 
Next, we examined whether, besides initiation of the intrinsic pathway, also the 
extrinsic pathway was activated during ischemia. Activation of this route is regulated 
by the cytoplasmic protein cFLIP, a competitive inhibitor of caspase-817. We therefore 
measured cFLIP levels during ischemia. Here we show that cFLIP (55 kDa) was 
normally expressed in the human kidney and got depleted during normothermic 
ischemia (Figure 3.6). Interestingly, the reduction of cFLIP levels significantly 
correlated with the duration of ischemia (r=0.78, P<0.001, Spearman correlation 
analysis). Subsequently, we determined whether cFLIP depletion results in activation 
of caspase-8, the initiator caspase of the intrinsic pathway. Similar levels of the pro-
form of caspase-8 (43/44 kDa) were found in control and ischemic tissue (Figure 3.7A). 
In line, activated caspase-8 fragments were not detectable during normothermic 
ischemia (data not shown). Thus, although cFLIP was depleted during ischemia, no 
active caspase-8 was detected. 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 3.6 Depletion of cFLIP during normothermic renal ischemia. A) Representative immunoblot 
analysis of intrarenal cFLIP. B) Densitometric analysis of cFLIP immunoblotting with ischemic 
(n=5) and control kidneys (n=4). Data of ischemic kidneys are expressed as fraction of the 
mean of control data. Individual ischemic kidneys are displayed by different symbols 
(■,▲,○,□,Δ) and control kidneys by a filled circle. cFLIP (55 kDa) expression levels reduces in 
time with induction of the length of ischemia and this correlation is statistically significant 
(r=0.78, P<0.001, Spearman correlation analysis). Dotted line gives trendline of all data. 
 
 
 
 
 
Figure 3.7 Processing of caspase-8 and caspase-3 during renal ischemia. A) The 54/55 kDa inactive 
isoforms of caspase-8 are detected in ischemic and control tissue. The 43/44 kDa fragment 
compromising the intermediate caspase-8 cleavage fragments are not detected (data not 
shown). A representative blot is shown. B) 34 kDa pro-form caspase-3 was present in healthy 
and ischemic tissue. Activation of caspase-3 could not be detected in any samples (data not 
shown). A representative blot is shown.  
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Activation of effector caspases during normothermic renal ischemia 
To evaluate whether the observed activated intrinsic pathway leads to execution of 
the apoptotic process, processing of the central effector caspase, caspase-3 was 
determined. The caspase-3 proform (34 kDa) was detected in control tissue. The basal 
expression levels did not change during ischemia (Figure 3.7B). In line, fragments 
representing active caspase-3 were not observed. Taken together, our data implicate 
that during ischemia the circumstances are created for activation of the apoptotic 
cascade upon reperfusion. 
Discussion  
In the current study, we investigated the initiation of apoptotic cell-death during 
normothermic renal ischemia. In renal transplantation, normothermic warm ischemia 
occurs in NHB donation, especially in category 2 donors. This warm ischemia is 
considered to be the major cause of delayed graft function and or primary non-
function. Also cold ischemia as occurs during preservation of donor organs can lead to 
organ damage. In cadaveric donors, cold ischemia time was associated with the 
numbers of apoptotic cells, present one hour after onset of reperfusion/ 
transplantation5,14. In vitro experiments showed that cold storage of proximal tubular 
cells for 48h resulted in activation of apoptosis, only after rewarming. The apoptotic 
process was not activated during cold storage18. Here we investigate initiation of the 
apoptotic process during normothermic ischemia in an ex vivo model. Initiation of the 
apoptotic cascade occurs either via activation of the extrinsic or the intrinsic pathway. 
Because regulation of the intrinsic pathway is accomplished in part through the 
stoichiometric balance of pro-apoptotic and anti-apoptotic Bcl-2 proteins12,19, we 
studied alterations in levels of anti-apoptotic (Bcl-2) and pro-apoptotic (Bax) members 
of this protein family. Using a human model for renal normothermic ischemia we 
demonstrated that depletion of monomeric Bcl-2, that is able to prevent dimerization 
of the pro-apoptotic Bax, significantly correlated with the extent of ischemia. Our 
findings further extend recent data from Schwarz et al.20. They showed that low 
mRNA levels for Bcl-2 in proximal tubular epithelial cells in pre-transplant cadaveric 
donor kidney biopsies are associated with apoptosis and subsequent ARF and delayed 
allograft function20. These data support our findings that epithelial cells of the 
proximal tubules are the predominant site of renal Bcl-2 protein expression and that 
ischemia leads to reduced Bcl-2 levels. Next, we showed that protein levels of 
monomeric Bax are strongly enhanced by normothermic ischemia, predominantly in 
the early ischemic phase. These data are supported by findings from the group of 
Hébert, who showed in an experimental rat model elevation of renal Bax protein 
expression, 10 min after the induction of cardiac arrest21. Moreover, these western 
blotting data are completed by immunohistochemistry experiments with an ab that 
64⏐Chapter 3 
detects active Bax. Immunohistochemistry data revealed that renal ischemia also 
resulted in activated Bax protein expression. Activated Bax was primarily detected in 
distal tubules. This increased distal active Bax expression and the decreased proximal 
Bcl-2 expression suggests a pro-apoptotic state in both distal and proximal tubular 
epithelium. At this stage there is no explanation for the observed diffuse expression of 
apoptotic proteins. Many mechanisms could be responsible such as differences in 
“stress” in the different parts of the tubule during ischemia. It is generally said that 
the proximal part is more sensitive to ischemia and reperfusion with more necrotic 
cell-death while the distal tubules suffer more from apoptotic cell-death9. However, it 
is not completely elucidated as yet which part of the nephron suffers the most severe 
after an ischemic insult22,23.  
Next, for the first time we showed that a significant correlation exists between 
activation of caspase-9 and the duration of normothermic renal ischemia. The 
observed activation of caspase-9 in the present study did however not result in 
activation of the downstream caspase-3 during normothermic ischemia. Activation of 
this central effector caspase-3 is essential for cleavage of different substrates resulting 
in execution of the apoptotic process. Previous published findings in experimental 
models have been contradictory as to whether caspase-3 is induced during ischemia 
or rather during reperfusion24-27. We do not have an explanation for the observed 
data that activated caspase-9 fails to activate caspase-3 at this stage. However, it is 
known that next to caspases, also XIAP, an inhibitor of caspase-3, is recruited to the 
apoptosome28. How the inhibitory effect of XIAP is overcome and cellular caspase-3 
activation and cell death can take place is at this stage unknown. Possibly reperfusion 
is necessary as major insult to overcome the protective effect of XIAP, resulting in cell 
death. 
Besides activation of the intrinsic pathway, we also demonstrate that the extrinsic 
pathway is already initiated during ischemia. In particular, we show that depletion of 
the competitive caspase-8 inhibitor, cFLIP, significantly correlated with the length of 
normothermic renal ischemia. These findings further extend data from Rasper et al. 
who showed significant cFLIP depletion after ischemia in the reperfused heart17. Since 
cFLIP prevents death-receptor mediated apoptosis by precluding recruitment of 
caspase-8 to the DISC17,29, reductions of the cFLIP content facilitate caspase-8 
activation. However, in our model cFLIP depletion was not accompanied by caspase-8 
activation during ischemia, indicating that low cFLIP levels alone are insufficient to 
activate the intrinsic pathway. Presumably, activation of the extrinsic pathway needs 
conditions that are only met during reperfusion. Indeed, in a rat cardiac I/R model it 
has been demonstrated that caspase-8 activation occurs in the reperfusion phase, but 
is not processed by ischemia alone30.  
Taken together, we show in a human model for renal normothermic ischemia that the 
intrinsic as well as the extrinsic pathway of apoptosis are initiated during ischemia. 
These data indicate that during ischemia the circumstances are created that facilitate 
execution of apoptosis upon reperfusion. This hypothesis is supported by data 
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obtained in our murine model of renal I/R. In this model, we confirmed the 
observation that initiation of the apoptotic process emerges during ischemia. 
Furthermore, the length of the ischemic period corresponds with the extent of 
apoptosis and the concomitant organ function during reperfusion (unpublished 
findings). Potentially, assessment of proteins involved in the early apoptotic process in 
pre-transplant kidney biopsies might be helpful to estimate ischemic damage and 
predict concomitant graft function. Evidence that apoptosis is crucially involved in 
clinical transplantation has been provided by different groups, showing that apoptotic 
cell death is enhanced in post-reperfusion biopsies from cadaveric allografts 
compared with living related renal transplants5,14. However, these studies report 
apoptotic cell death in brain death donors. In these donors, besides ischemia, other 
factors such as periods of diminished organ perfusion, hemodynamic instability and 
activation of the immune-system affect post-transplant organ function31. In contrast, 
our model is restricted to the effect of ischemia itself, thereby reflecting the situation 
in NHB organ donation, in which warm ischemia forms the major determinant of graft 
outcome. Therefore, our novel findings that ischemia alone, already initiates the 
apoptotic process, might explain the increased risk for NHB graft dysfunction. 
In conclusion, in a human model for renal normothermic ischemia we demonstrate 
that the apoptotic cascade is initiated during ischemia. For the first time, the time 
dependent regulation of proteins responsible for the onset of the apoptotic cascade in 
the course of normothermic ischemia is shown. Determination of these processes 
might be beneficial  in assessing the degree of ischemic injury in NHB donor kidneys 
and other organs. Furthermore, these new insights can be explored for the 
development of specific anti-apoptotic treatment to prevent organ damage upon 
transplantation due to ischemic injury. 
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Abstract  
MD-2 is the crucial cofactor of TLR4 in the detection of LPS. Here, we show that 
soluble MD-2 (sMD-2) circulates in plasma of healthy individuals as a polymeric 
protein. The total amount of sMD-2 in septic plasma was strongly elevated and 
contained both sMD-2 polymers and monomers, the latter representing the putative 
biologically active form of MD-2. Moreover, during experimental human 
endotoxemia, the monomeric and total sMD-2 content in plasma increased with the 
kinetics of an acute phase protein. The increase in sMD-2 monomers was paralleled by 
enhanced TLR4 costimulatory activity. The presence of functional sMD-2 during 
endotoxemia and sepsis was confirmed by immunodepletion. Immuno-histochemistry 
revealed that MD-2 expression in septic patients was strongly enhanced on 
endothelium and multiple inflammatory cells in lung and liver. In vitro studies showed 
that sMD-2 release appears to be restricted to endothelial cells and dendritic cells. 
Release of sMD-2 by endothelial cells was strongly enhanced by LPS and TNF-α 
stimulation. Taken together, this study demonstrates the increase of both circulating 
polymeric and functional monomeric sMD-2 during endotoxemia and sepsis, and 
evidence is provided that the endothelium is involved in this process. 
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Introduction 
Recognition of invading microbial pathogens by the innate immune system leads to an 
inflammatory response aimed at elimination of the infecting microbes until the 
adaptive immunity becomes functional. This innate immune reaction towards 
pathogens is predominantly initiated and controlled by Toll-like receptors, a family of 
proteins that specifically recognizes and senses microbial products. LPS, produced by 
Gram-negative bacteria, is a very potent and abundant bacterial product that is 
believed to be one of the central mediators in Gram-negative sepsis. LPS activates the 
host innate immune system via TLR4, thereby initiating a cascade of serine/threonine 
kinases that ultimately results in the transcription of genes involved in inflammation1. 
It has been clearly demonstrated that MD-2 is the crucial cofactor of TLR4 mediated 
LPS signaling, a process that is greatly enhanced by CD14 and the serum component 
LPS-binding protein2-4. Although MD-2 has been reported to be required for TLR4 
membrane expression, a recent study indicates that TLR4 is also transported to the 
cell surface in the absence of MD-25. TLR4/MD-2 transfection experiments have 
shown that MD-2 produced in excess is secreted as a soluble protein (sMD-2)6,7 and 
exists as a heterogeneous collection of disulfide-linked oligomers8.  
Recently, direct evidence for the presence of circulating sMD-2 has been provided9 
and an earlier study suggested that plasma derived sMD-2 could function as 
costimulatory molecule in the response of TLR4 transfected cells to LPS10. 
Furthermore, in vitro studies have shown that sMD-2 can directly bind LPS with high 
affinity and that such LPS/MD-2 complexes form an active ligand capable of activating 
TLR4 positive cells11-13. Interestingly, evidence has been provided that only monomeric 
sMD-2 can associate with TLR414-16. This finding has been confirmed and further 
extended by a report showing that only monomeric sMD-2 is able to bind LPS17.  
The current study was designed to evaluate the biochemical and functional properties 
of sMD-2 in human plasma during systemic inflammation, such as that encountered 
during sepsis and experimental human endotoxemia. To this end, high affinity 
monoclonal antibodies directed to MD-2 were developed that recognize both soluble 
MD-2 and TLR4-bound MD-2.  
Materials and methods 
Healthy controls and patients with severe sepsis and septic shock 
Patients meeting the criteria for severe sepsis and septic shock were prospectively 
enrolled in the study18. Sepsis is as a systemic host response to infection, manifested 
by conditions such as temperature >38°C or <36°C; heart rate >90 beats per minute 
and respiratory rate >20 breaths per minute or PCO2. Severe sepsis is defined as sepsis 
associated with organ failure and septic shock is severe sepsis associated with 
72⏐Chapter 4 
cardiovascular failure necessitating the administration of vasopressor agents19. The 
research protocol was approved by the Ethic Committee of the University Hospital of 
Geneva. An informed consent was provided according to the Declaration of Helsinki. 
In total, 34 subjects were included in the study. The study population comprised 12 
healthy volunteers (six men, six women; mean age ± 1SD, 52 ± 12), 11 patients with 
severe sepsis (five men, six women; 59 ± 12) and 11 patients with septic shock (six 
men, five women; 61 ± 16).  
Blood samples of patients and healthy controls were taken using evacuated blood 
collection tubes containing EDTA. Blood samples were immediately put on melting ice, 
and plasma was prepared by centrifugation at 4000 rpm for 5 min at 4°C. 
Supernatants were stored in aliquots at -20°C. Plasma samples of septic patients were 
obtained within 48 hours after admission to the medical ICU. The ICU mortality in 
patients with severe sepsis and septic shock was 36%. The main infectious source was 
severe community acquired pneumonia (n=7). Other sources were abdominal sepsis 
(n=5), nosocomial pneumonia (n=3), bacterial endocarditis (n=2), primary bacteremia 
(n=2), osteomyelitis (n=1), myositis (n=1) and urosepsis (n=1). Bacterial pathogens 
could be isolated in 7 out of 11 patients with sepsis (2 S.aureus, 2 L.pneumophila, 1 
E.coli, 1 B.fragilis, and 1 S.epidermidis) and in 10 out of 11 patients with septic shock 
(3 S.aureus, 2 H.influenzae, 2 E.coli, 1 S.epidermidis, 1 S.pneumoniae and 1 
P.aeruginosa). 
Endotoxemia in human volunteers 
The study was approved by the institutional scientific and Ethics Committee of the 
Academic Medical Center, University of Amsterdam. Written informed consent was 
obtained from each subject before the start of the study. Eight healthy male 
volunteers (25-35 years) were challenged with an i.v. bolus of 4 ng/kg LPS (E.coli LPS, 
lot G; US Pharmacopeia, Rockville, MD) as described before20. Blood was obtained 
directly before LPS administration (0 hours), and 2, 4, 6, 8, 10, 23 hours thereafter.  
Autopsy tissue from septic patients and controls for 
immunohistochemistry 
Formalin fixed, paraffin embedded lung, liver, kidney, lymph node and spleen tissue 
from four patients that died because of a bronchopneumonia related sepsis was 
obtained from the Maastricht Pathology Tissue Collection (MPTC). Collection, storage 
and use of tissue and patient data were performed in agreement with the “Code for 
Proper Secondary Use of Human Tissue in the Netherlands”. Tissues used in this study 
were collected within 24 hours after death of the patient. Normal tissue was sampled 
from four patients of each group who underwent resection for a carcinoma. Samples 
were taken from healthy parts of the organ, distant from the tumor. 
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Expression of human MD-2 IgGFc and MD-2-Flag fusion proteins 
To avoid multimeric MD-2 formation after transfection, full length human MD-2 was 
amplified from a clone containing MD-2 cDNA with mutated cysteines kindly provided 
by Dr. M. Kennedy and Dr. D. Segal National Institutes of Health, Bethesda, MD). DNA 
encoding the hinge, CH2, and CH3 exons derived from human IgG1 was amplified from 
marathon ready spleen cDNA (Clontech, Palo Alto, CA). Primers used for amplification 
incorporated restriction sites enabling in frame ligation into the expression vector 
pcDNA3.1- (Invitrogen, Carlsbad, CA). In order to increase the mRNA translation 
efficiency, the Kozak consensus translation initiation site was introduced using the 
QuikChange XL site-directed mutagenesis kit according to the manufacturer’s 
instructions (Stratagene, La Jolla, CA). Clones containing the correct DNA sequences 
were identified by sequencing using the Big dye termination cycle sequencing kit 
(Perkin Elmer/Cetus, Emeryville CA), according to the manufacturer’s instructions. 
Next, COS-1 cells were transfected with the expression vector using lipofectamine 
(Roche, Basel, Switzerland) according to the manufacturer's instructions and stable 
lines were established by selection with 700 µg/ml G418 (Life Technologies, Palo Alto, 
CA). Supernatant from stable transfectants was collected and passed over a rat anti-
human IgGFc1 column. Bound protein was eluted with 0.1 M glycine pH 2.6 and 
collected in 1/10 volume 1 M Tris pH 9.0 to neutralize the acidic pH. Purity was 
assessed by SDS PAGE and coomassie staining.  
Recombinant MD-2-Flag fusion protein was produced by COS-1 cells, stably 
transfected with Dr. K. Miyake’s pEFBOS-hMD-2-FLAG (kindly provided via Dr. C. 
Kirschning, Munich, Germany). After centrifugation, supernatant was removed and 
the pellet was washed three times in PBS and lysed in buffer containing 200 mM NaCl, 
10 mM Tris base, 5 mM EDTA, 10% Glycerin, 1mM PMSF, 0.1 U/ml Aprotinin and 
1 µg/ml Leupeptin. The protein concentrations of human MD-2-IgG and MD-2-Flag 
were determined using an anti-human IgG or MD-2 ELISA respectively. Equal 
quantities of MD-2-IgGFc and MD-2-Flag based on standardization of these ELISAs 
with purified MD-2-IgGFc displayed bands of identical intensity on Western blotting. 
Generation of monoclonal antibodies 
Balb/C mice, obtained from Charles River Breeding Laboratories (Heidelberg, 
Germany) were immunized repeatedly with 10 µg human MD-2-IgGFc according to a 
protocol approved by the Institutional Animal Care Committee of the University of 
Maastricht. MAbs for human MD-2 were produced by standard methods using SP2/0 
cells as fusion myeloma. All mAbs (HM30-33) detected specifically MD-2 on 
TLR4/MD-2 transfected HEK cells and sMD-2 in ELISA and western blot and were 
determined as IgG1 isotypes using the IsoStrip mouse mAb isotyping kit (Hycult 
biotechnology, Uden, the Netherlands). HM30 and HM31 were used in ELISA, HM31 in 
western blotting, HM32 in immunohistochemistry and HM33 in flow cytometry. 
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Inhibition studies revealed that two different epitopes are recognized by our mAbs; 
HM30/32 react with the first and HM31/33 with a second epitope. 
sMD-2 ELISA 
A 96-well plate was coated overnight at 4°C with 5 µg of HM30 anti-human MD2 mAb. 
A standard titration curve was obtained by serial dilution of a known quantity of the 
human MD-2-IgGFc recombinant protein. Test samples were diluted at least six fold 
and incubated for 1h at room temperature. Next, the plates were incubated with 
biotin-conjugated anti-human MD2 mAb HM31 (2 µg/ml), followed by washing and 
incubation with streptavidin peroxidase for 1h. After adding 3,3',5,5'-tetramethyl-
benzidine (TMB) substrate, the reaction was stopped with acid and the OD was 
determined at 450 nm. The sandwich ELISA detected the MD-2 protein in cellular 
lysate and cellular supernatant of both MD-2 and TLR4/MD-2 transfected cells. The 
analysis of plasma samples with the ELISA was hampered by lack of consistency when 
compared with western blot. We considered that the formation of large complexes of 
sMD-2 disturbs the correct quantification of sMD-2 in plasma.  
Western blotting 
Plasma aliquots were heated in Laemmli buffer with or without 0.1 M DTT, separated 
on 10% SDS-polyacrylamide gels and transferred to polyvinylidene fluoride 
membranes (Immobilon P; Millipore, Bedford, MA). Membranes were incubated with 
1 µg/ml biotinylated anti-human MD-2 (HM31), followed by streptavidin peroxidase. 
Positive bands were detected using the chemiluminescent substrate Supersignal West 
Pico (Pierce Chemical Co., Rockford, IL) and transferred onto an X-ray film.  
Quantitative sMD-2 analysis 
For this assay, band intensities of the sMD-2 isoforms (17, 20 and 25 kDa), derived 
after reduced western blotting were determined using a FluorS Multi-Imager system 
and Quantity One software (Bio-Rad, Hercules, CA). A protein standard was made by 
lysis of MD-2 Flag transfected HEK cells which was quantified for MD-2 by the above 
described ELISA. For quantitative western blot, the total amount of sMD-2 in each 
plasma sample was calculated in the linear range of a serial dilution of the MD-2 
standard with a range of 0.5 to 10 ng/ml.  
Depletion of native sMD-2 from plasma 
To deplete native sMD-2 from septic plasma in a single step by immunodepletion, the 
murine anti-human MD-2 mAb (HM32) was coupled to CNBr-Sepharose beads 
(750 µg/ml gel; Amersham, Uppsala, Sweden). Human septic plasma was diluted 
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2.5 fold in PBS and incubated at 4°C for 5 hours with the mAb coated beads. Depleted 
plasma was collected by centrifugation.  
MD-2 functional analysis 
TLR4-HEK293 cells were used for stimulation assays as described before10. Briefly, on 
the day of the assay, TLR4-HEK293 cells were collected by trypsin treatment, 
resuspended in DMEM (Gibco) containing 10% FCS and distributed into 96-well plates 
at the concentration of 60,000 cells per well. Plasma from controls, patients and LPS 
volunteers was added at a final concentration of 5%. Ultrapure E.coli K12LCD25 LPS 
(Invivogen) was added to the wells at a final concentration of 30 ng/ml and incubated 
at 37°C for 24 hours. Conditioned supernatants were then collected and assayed for 
human IL-8 protein by ELISA using paired monoclonal antibodies (Endogen, Woburn, 
MA).  
Endothelial cells 
HUVEC or immortalized HUVEC (ECRF-24) were cultured and stimulated in culture 
medium as described previously21. When both HUVEC and ECRF-24 cells were used in 
parallel experiments, similar results were obtained. In line with this, the phenotype of 
both endothelial cell types was previously shown to be similar21. 
Isolation of peripheral blood leukocytes 
Monocytes, lymphocytes and granulocytes were isolated on a discontinuous density 
gradient (Lymphoprep, Nycomed, Oslo, Norway). The interface containing 
mononuclear cells was collected, as well as the pellet containing the granulocytes. The 
latter cells were isolated by lysis of erythrocytes with ammonium chloride and washed 
twice with PBS. Isolated monocytes were differentiated into immature (iDC) and 
mature (DC) dendritic cells respectively as previously described22. 
Flow cytometric analysis 
Flow cytometric analysis was performed on peripheral blood leukocytes and 
endothelial cells.  
Phycoerythrin (PE), and allophycocyanin (APC) conjugated anti-human CD3 (PE), CD19 
(APC) and CD14 (PE) monoclonal antibodies (all from BD Bioscience, Erembodegem, 
Belgium) were used to identify T-cells, B-cells and monocytes, respectively. Immature 
and mature DC populations were double-gated during analysis on forward scatter 
(FSC) vs. side scatter (SSC) and HLA-DR+++ vs. CD11c+++ expression and granulocytes 
were identified and gated on FSC vs. SSC. In each measurement 15.000 events were 
acquired, the live gate containing between 8.000 and 10.000 cells. The lineage vs FSC 
gate contained between 9000 cells (T-cells) and 1000 cells (B-cells). Cultured 
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endothelial cells were harvested by scraping and gated on FSC vs. SSC. For analysis of 
these cells, 15000 events were acquired and the live gate contained between 9000 
and 10.000 cells. Anti-human MD2 18H10 mAb, generated as previously described10 
and FITC labeled HM33 were used to detect the MD-2 protein in the above described 
cells. To demonstrate protein surface expression, cells were washed in FACS buffer 
with the predetermined appropriate antibody dilution or with the corresponding 
isotype controls. Analysis was performed on a FACSsort cytometer (BD).  
Immunohistochemistry 
Paraffin sections of lung and liver tissues were incubated with the anti-human MD-2 
HM31 mAb, followed by incubation with a rabbit anti-mouse biotinylated secondary 
antibody (DAKO, Glostrup, Denmark). Staining was obtained with a streptavidin-biotin 
HRP system (DAKO) and 3-amino-9-ethylcarbazole (AEC) (Sigma, St. Louis, Mo). Nuclei 
were counterstained with haematoxylin. Micro-photographs were made using a Nikon 
Eclipse E800 microscope and a Nikon digital camera DXM1200F.  
Statistical analysis 
Quantitative data are presented as mean ± SEM. The Mann-Whitney U-test was 
used to compare sMD-2 concentrations in plasma from healthy volunteers and septic 
patients. The unpaired Student's t-test was used to compare IL-8 concentrations in 
supernatant from in vitro experiments. The paired Student's t-test was used to 
compare plasma obtained at various timepoints after LPS infusion in healthy 
volunteers. Differences were considered statistically significant at P<0.05. 
Results 
Assessment of sMD-2 in plasma of septic patients 
Recombinant sMD-2 has been reported to multimerize, resulting in the formation of 
large, inactive oligomers6,14, whilst monomeric sMD-2 is supposed to be the active 
form involved in LPS recognition and cell signaling. Figure 4.1A shows the molecular 
appearance of the native sMD-2 protein in plasma. Western blotting under non 
reduced conditions showed that sMD-2 in the circulation of healthy and septic 
individuals consists primarily of multimers. Interestingly, monomeric sMD-2 
(17-25 kDa) was only present in plasma of septic patients (Figure 4.1A). Western blot 
analysis with lower quantities of healthy and septic plasma showed that all multimeric 
forms of sMD-2 in septic plasma are elevated when compared to control plasma, 
indicating that the increased amount of monomeric MD-2 as seen during sepsis is not 
primarily caused by a change from polymeric to monomeric MD-2 (data not shown). 
 Enhanced sMD-2 release during systemic inflammation⏐77 
To demonstrate the specificity of the antibodies, recombinant MD-2 Flag was included 
as a positive control (Figure 4.1A+B). 
Reduction of the disulfide bonds of sMD-2 give rise to monomeric subunits of 
approximately 17, 20 en 25 kDa, corresponding with the calculated mass of 
monomeric MD-2. The 3 isoforms most likely correspond to the unglycosylated 
(17 kDa) and glycosylated (20 and 25 kDa) forms of MD-2. Reduction of sMD-2 
allowed us to quantify the total amount in both control and septic plasma by western 
blotting (Figure 4.1B). Circulating sMD-2 levels were strongly elevated during sepsis 
(mean ± 1SD) 13.1 ± 5.67 ng/ml when compared with healthy controls 2.33 ± 0.52 
ng/ml (P=0.0001) (Figure 4.1C). Next we analyzed, whether the sMD-2 protein 
detected in septic plasma conferred LPS responsiveness to TLR4 transfected HEK cells. 
Plasma of both septic patients and LPS volunteers lacked detectable amounts of LPS 
as previously reported23. In concordance with earlier findings, these experiments 
clearly demonstrate the LPS stimulating capacity of septic plasma10 (P<0.0001, 
unpaired Student’s t-test) (Figure 4.1D). To confirm the sMD-2 dependent TLR4 
costimulatory effect of septic plasma, the protein was depleted using anti-MD-2 
coated sepharose beads (Figure 4.1E). As depicted in Figure 4.1D, the LPS stimulating 
capacity of sMD-2 depleted septic plasma was significantly reduced (P<0.0001, 
unpaired Student’s t-test). Taken together, the data show that plasma of healthy 
individuals contains only sMD-2 polymers while septic plasma also contains detectable 
amounts of sMD-2 monomers, which are most likely responsible for the TLR4 
costimulatory capacity detected with septic plasma. 
Kinetics of the sMD-2 release during experimental human endotoxemia 
In order to examine the kinetics of the release of monomeric and total sMD-2, we 
made use of a human endotoxemia model. This well characterized model is used for 
proof of concept studies involving systemic inflammation triggered by the innate 
immune system in man. Healthy volunteers were administered with an i.v. endotoxin 
bolus of 4 ng/kg, and blood was collected at various time points before and after 
endotoxin administration. Reducing western blot analysis demonstrated in all 
individuals that circulating sMD-2 protein levels started to rise significantly (P<0.001, 
Paired Student's t-test), 6 hours after endotoxin infusion (Figure 4.2A+B). Also plasma 
from endotoxemic volunteers (as septic patients) showed enhanced levels of sMD-2 
monomers (Figure 4.2C; non reducing conditions). Next, we investigated whether the 
rise in active monomeric sMD-2 also leads to increased MD-2 activity, using the above 
described LPS stimulated TLR4 assay. Levels of activation were significantly higher in 
plasma samples obtained from 6 till 23 hours post endotoxin infusion compared with 
plasma’s sampled before LPS administration (P<0.001, Paired Student's t-test) (Figure 
4.2D).  
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Figure 4.1 Detection of soluble MD-2 in plasma from healthy individuals and septic patients. Western 
blot analysis was performed to analyse the molecular appearance of sMD-2 in plasma. A) 
Under non-reduced conditions, sMD-2 in control (lane 1+2) and septic plasma (lane 3+4) is 
mainly present as multimers (≥50kDa). Two representative samples are shown. 
Recombinant MD-2 Flag (P) was used as positive control. Hardly any monomeric (active) 
sMD-2 was ascertained in plasma of healthy individuals under non-reduced conditions 
(lane 1+2). In contrast, during sepsis monomeric sMD-2 was clearly present (lane 3+4). For 
both control (n=7) and septic plasma’s (n=12), representative samples are shown. B) The 
total sMD-2 content in plasma was analysed by immuno-blotting under reduced 
circumstances. Small amounts of sMD-2 were detected in healthy controls (lane 1-3), 
whereas in plasma from septic patients (lane 4-6), sMD-2 protein levels were clearly 
elevated. For both control (n=12) and septic plasma’s (n=22), representative samples are 
shown. Recombinant MD-2 Flag (P) was used as positive control. C) The total sMD-2 
concentration in randomly selected control (n=7) and septic (n=10) plasma was estimated 
by quantitative western blot analysis and results are depicted in a scatter plot. D) 
Activation of TLR4 positive HEK cells by LPS is significantly (*) promoted by plasma of septic 
patients with IL-8 as read out. IL-8 secretion upon LPS activation of TLR4 transfected HEK 
cells is significantly (**) inhibited in the presence of sMD-2 depleted septic plasma when 
compared with untreated plasma of septic patients. E) Reduced western blot analysis 
confirmed a strong decrease of the total sMD-2 content, after sMD-2 depletion of septic 
plasma. Three samples before (1,3,5) and after immuno-depletion of sMD-2 (2,4,6) are 
shown. 
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Figure 4.2 Release of functional sMD-2 in experimental human endotoxemia. Reduced western blot 
analysis demonstrates that i.v. administration of LPS results in the enhanced release of the 
total sMD-2 content in plasma. A) A representative sample (n=8) is shown and time in 
hours in relation to LPS injection is given. B) The total sMD-2 content during endotoxemia 
was analysed by quantitative immuno-blotting under reduced circumstances. Statistical 
significance (*) was reached from 6 hours post LPS infusion. C) Western blotting under non 
reduced circumstances showed enhanced release of MD-2 monomers in plasma, starting 6 
hours post LPS infusion. A representative sample is shown (n=8) and time in hours in 
relation to LPS injection is given. D) Plasma samples of LPS volunteers support LPS 
activation of TLR4 transfected HEK cells. Functional analysis shows that the detected 
increase of sMD-2 in plasma during endotoxemia is mirrored by the LPS supporting activity 
of TLR4 transfected HEK cells. Delta IL-8 is the difference between the IL-8 concentrations 
in supernatants of LPS stimulated versus unstimulated TLR4 positive HEK cells in the 
presence of volunteer plasma for each individual timepoint. Statistical significance (*) was 
reached from 6 hours post LPS infusion. The average for the outcome of six different 
experiments is shown and time in hours in relation to LPS injection is given.  
Cellular source of sMD-2 
To identify the source responsible for the enhanced (active) sMD-2 content during 
human endotoxemia and sepsis, we first examined the cell specific expression of 
MD-2 in the healthy and septic lung and liver, organs critically involved in the 
response to LPS24,25. In lung sections from septic patients, MD-2 expression was 
abundantly expressed by endothelial cells covering small and medium sized arteries 
and arterioles (Figure 4.3A). MD-2 expression was also localized in different subsets of 
inflammatory cells and pericytes. In healthy control tissue, moderate MD-2 expression 
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by endothelial and inflammatory cells was occasionally observed (Figure 4.3B). 
Incubations using isotype matched control ab’s were negative for healthy and septic 
lung tissues (Figure 4.3C). In the healthy liver, MD-2 positive cells were sporadically 
detected (Figure 4.3D). During sepsis, MD-2 protein was predominantly located in 
endothelial cells lining hepatic sinusoids, Kupffer cells and inflammatory cells (Figure 
4.3E). In addition, the distribution of MD-2 in the kidney, spleen and lymph nodes was 
assessed (data not shown). In line with the constitutive pulmonary and hepatic MD-2 
expression, multiple inflammatory cells appeared to be weakly positive for MD-2 in 
these organs. In kidneys, moderate epithelial staining was detected. During sepsis, 
MD-2 staining was not increased in the lymph nodes. In the septic spleen, some MD-2 
positive endothelial cells were detected. Although during sepsis, a moderate increase 
of the renal and splenic MD-2 expression (mainly renal epithelial cells and some 
inflammatory cells) was detected, by far the strongest increase was observed in the 
liver and lung. 
Since the immunohistochemical analysis revealed that MD-2 in vivo is predominantly 
expressed by different subsets of inflammatory cells and the endothelium, we further 
analyzed the protein distribution by flow cytometry. Expression was found on 
monocytes, B-lymphocytes, granulocytes, immature and mature dendritic cells and 
endothelial cells whereas no MD-2 expression by T-lymphocytes was detected (Figure 
4.4). The increase in mean fluoresence intensity (MFI) for MD2 vs Isotype are: 
iDCs: 6.9x (mean = 267.4 vs. 38.7), mDCs: 4.3x (mean = 168.3 vs. 39.1), monocytes: 
2.7x (mean = 17.8 vs. 6.6), granulocytes: 2.3x (mean = 7.9 vs. 3.4), B cells: 1.7x (8 vs. 
4.7), endothelial cells: 6.1 (mean = 72.5 vs. 11.8) and T cells: no increase (4 vs. 4).  
Next, reduced western blotting was used to demonstrate the presence of sMD-2 in 
culture supernatants from the cells described above. The data showed that basal 
sMD-2 secretion was restricted to endothelial cells and dendritic cells (Figure 4.5A+B). 
The latter finding confirms and extends a report from Visintin who suggested the 
release of sMD-2 by human monocyte-derived immature DCs (iDCs)6. Next, we 
investigated the release of sMD-2 by cells present in circulating blood and endothelial 
cells in response to LPS in order to further define the cellular source responsible for 
the enhanced sMD-2 release as seen during endotoxemia and sepsis. Cultures of 
whole blood, isolated peripheral blood mononuclear cells (PBMC’s) and endothelial 
cells incubated for 0, 2, 6 and 24h with or without 100 ng/ml LPS were analyzed for 
sMD-2 release. Small amounts of sMD-2 were measured in supernatants from 
unstimulated endothelial cells while exposure to LPS resulted in increased sMD-2 
release, in a time-dependent-fashion up to 24h (Figure 4.5C). We subsequently 
investigated the sMD-2 production by endothelial cells after treatment with the LPS 
response related cytokines TNF-α and IL-1ß26. Stimulation of endothelial cells with 
TNF-α raised sMD-2 levels over time, in a pattern similar to that observed upon LPS 
activation (Figure 4.5D). In a similar fashion, IL-1ß was observed to induce the release 
of sMD-2 by endothelial cells (Figure 4.5E). Without stimulation, sMD-2 did not 
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accumulate over time (data not shown). IL-8 release was monitored as positive 
control for endothelial cell activation (Figure 4.5F).  
 
 
 
Figure 4.3 In vivo MD-2 expression in lung and liver. Paraffin sections of autopsy lung and liver tissue 
from patients that died of bronchopneumonia related sepsis (n=4) were immunostained 
with anti MD-2. A) In septic lungs MD-2 was clearly detected in endothelial cells (indicated 
by arrows) and pericytes (arrow heads). Asterix denote MD-2 positive inflammatory cells. 
B) In healthy lung (n=4), some endothelial (arrows) and inflammatory cells (arrow heads) 
stained weakly positive for MD-2. C) No AEC reaction product in septic lung tissue was 
detected using a mouse isotype control. D) In the healthy liver (n=4), MD-2 positive cells 
were hardly detected. E) MD-2 positive staining in the septic liver is represented by 
endothelial cells (arrow), Kuppfer cells (arrow head) and inflammatory cells (inset) (original 
magnification 200x). See page 161 for colour figure. 
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In contrast to endothelial cells, isolated PBMC’s cultured for up to 24 hours in the 
presence and absence of LPS, did not release detectable amounts of sMD-2 (Figure 
4.5G). In line, sMD-2 levels did not increase in whole blood cultures with LPS (Figure 
4.5H).  
The apparent capacity of endothelial cells to release enhanced levels of sMD-2 upon 
LPS stimulation prompted us to determine the MD-2 surface expression of LPS treated 
endothelial cells by Flow cytometric analysis. The extracellular MD-2 expression of 
unstimulated cells (mean = 72.5 vs. 11.0) (Figure 4.6A) remained unaltered after 2h of 
LPS stimulation (mean = 73.1 vs. 11.3) (Figure 4.6B). In contrast, after 4 hours of 
exposure to LPS (Figure 4.6C), 30% decrease of the MD-2 surface expression was 
observed (mean = 49.5 vs 11.3). Although 22h post LPS treatment the MD-2 
expression remained reduced when compared with untreated cells, the expression 
levels tended to recover (mean = 57.2 vs. 12.1) (Figure 4.6D). Thus, at timepoints 
when sMD-2 levels increase in the endothelial cell supernatant (between 2 and 6 
hours post LPS treatment), MD-2 surface expression starts to decrease. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 4.4 MD-2 expression by hematopoietic cells. Flow cytometric analysis of MD-2 expression on 
peripheral blood cells, cultured monocyte derived dendritic cells and endothelial cells 
(n=4). The histograms show MD-2 expression stained with anti-MD-2 antibody (HM33) 
(black lines). Gray lines denote isotype control staining.  
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Figure 4.5 Activation of endothelial cells by LPS and TNF-α leads to sMD-2 release. sMD-2 in 
supernatants (n=4) of cultured endothelial cells (A) and iDCs (B) was detected by reduced 
western blot analysis. Enhanced release in a time dependent fashion of sMD-2 in 
supernatants of LPS (C) or TNF-α (D) activated HUVEC’s was shown by reduced western 
blotting (n=4). E) A smaller sMD-2 increase in cell supernatant of IL-1ß activated 
endothelial cells was observed, at 24 hours after stimulation. F) Activation of endothelial 
cells was ascertained by measuring the interleukin-8 release. Statistical significance was 
reached from 6 hours for all stimuli. G) PBMC’s (n=4) cultured for up to 24 hours in the 
absence and presence of LPS, did not release detectable amounts of sMD-2. H) Stimulation 
of whole blood cultures (n=4) with LPS for up to 24 hours, did not lead to enhanced release 
of sMD-2, compared with non-stimulated cultures.  
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Figure 4.6 Reduction of MD-2 surface expression on endothelial cells after LPS stimulation. 
Endothelial surface MD-2 expression after exposure to LPS for 0 hours (A), 2 hours (B), 
4 hours (C) and 22 hours (D) is shown. Dotted line: isotype control; solid line anti MD-2 
antibody 18H10. Numbers shown on top right represent the mean fluorescence intensity of 
MD-2 and isotype respectively. Representative data of four independent experiments are 
shown. 
Discussion  
Since the discovery of MD-2, evidence has been accumulating that MD-2 is an 
indispensable protein for LPS recognition and signaling by TLR4. To answer unresolved 
questions concerning the function of MD-2, unique monoclonal antibodies were 
developed. We discovered that under reducing circumstances, circulating sMD-2 is 
mainly present as a doublet of ~20 and 25 kDa, representing differentially glycosylated 
forms. The smallest observed and weakest expressed unit was approximately 17 kDa, 
consistent with the calculated molecular mass of the non glycosylated peptide. 
Interestingly, conflicting reports have been published about the functionality of such 
unglycosylated MD-2. Earlier studies report that lack of glycosylation impaired MD-2 
function in a LPS reporter system27,28. In contrast, a recent study shows that 
glycosylation is not important for membrane MD-2 function, while it rather plays a 
role in the function of soluble MD-2 in LPS stimulation of TLR4 positive HEK cells16.  
Non-reduced analysis shows primarily large sMD-2 multimers in control and septic 
plasma. These high molecular weight sMD-2 isoforms correspond probably to inactive 
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disulfide-linked MD-2 multimers. Although we cannot exclude the possibility that 
sMD-2 multimers contain MD-2 ligands, the complexes appear not to activate the 
TLR4 positive cells. Interestingly, monomeric sMD-2, representing the active form, was 
only detected in septic plasma. In line with this observation, septic but not normal 
plasma was found to support LPS activation of TLR4 positive epithelial cells. Direct 
evidence that sMD-2 in septic plasma is functionally involved in LPS responses was 
demonstrated by immunodepletion of sMD-2. These combined findings confirm and 
extend earlier observations which suggested that functional sMD-2 is present in the 
circulation during sepsis10. 
The absence of monomeric MD-2 in control plasma could be due to either the rapid 
formation of polymers, or the effective clearance from the circulation in combination 
with a lower production of monomeric sMD-2. This remains to be elucidated.  
Assessment of sMD-2 concentrations in plasma of control and septic individuals 
resulted in average sMD-2 concentrations in the low ng/ml range which is in 
agreement with a recent report9. In addition, in septic plasma we estimated 
concentrations of the active monomeric form to be in the pg/ml range. In 
concordance, very low concentrations of sMD-2 were reported to exhibit a 
remarkable capacity for restoring LPS responsiveness to TLR4 expressing reporter 
cells6. Moreover, recent studies describe the generation of defined LPS:MD-2 
complexes at very low concentrations (pM) of endotoxin and soluble MD-2 and 
demonstrate that these complexes, at pM concentrations, activate cells in a TLR4-
dependent fashion13,29.  
The fact that circulating sMD-2 is predominantly polymeric raises questions regarding 
the function of sMD-2 multimers. Aggregation into large polymers might protect 
sMD-2 from renal clearance, resulting in the formation of a reservoir that when 
necessary, could be activated by cleavage. Of interest, a recent study suggests that 
the molecular structure and the concomitant function of sMD-2 are influenced by an 
intestinal serine protease30. Whether a comparable system is present in the 
circulatory system or in local tissues during inflammation remains to be determined. 
sMD-2 multimers have also been suggested to function as LPS decoy, facilitating LPS 
clearance form the circulation, as demonstrated for the other LPS-binding proteins 
CD14 and LBP14. This suggestion is in agreement with an earlier report, showing that 
high amounts of sMD-2 inhibit cellular responses of cells expressing the TLR4 MD-2 
complex to LPS11. This decoy function could be explained by a report showing that 
besides very efficient binding of LPS by sMD-2 monomers, also low affinity 
interactions between polymeric sMD-2 and LPS can occur16. Increased concentrations 
of sMD-2 polymers can thus compete for LPS. However, others have reported that 
sMD-2 multimers do not bind LPS17. The role of circulating MD-2 multimers remains 
therefore to be elucidated. 
In order to determine the kinetics of (monomeric) sMD-2 release in vivo as observed 
during sepsis, we made use of a standardised human endotoxemia model. LPS 
administration to healthy volunteers induces a well defined temporal release of 
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overlapping pro- and anti-inflammatory signals26. In these subjects, an increase of 
circulating monomeric and total sMD-2 was observed, starting 6 hours after LPS 
administration. Plasma sMD-2 levels remained elevated up to 23 hours post LPS 
infusion. Consistently, this enhancement of sMD-2 monomers was largely paralleled 
by an increase of TLR4 costimulatory activity. Remarkably, elevated release and LPS 
supporting activity of sMD-2 occurs when manifestations of systemic inflammation 
generally abate. The time-related change in plasma concentrations of sMD-2 upon LPS 
infusion, mirrors the expression pattern of typical acute phase reactants such as CRP 
and SAA in this endotoxemia model31. Therefore, and also based on the increased 
levels of sMD-2 in septic patients as discussed above, one may argue that sMD-2 is an 
acute-phase protein. 
The potential cellular sources of circulating sMD-2 were studied. The 
immunohistochemical demonstration of MD-2 expression by endothelial and 
inflammatory cells in liver and lung of septic patients led us to analyze the MD-2 
releasing capacity of leukocytes and endothelial cells. These experiments revealed 
that MD-2 was mainly expressed by endothelial cells and dendritic cells and to a lesser 
extend by monocytes, granulocytes and B-lymphocytes. In line, TLR4 expression and 
LPS reactivity by myeloid cells, B cells and endothelial cells have been extensively 
reported32-34. In addition, for the first time we demonstrate that sMD-2 release of the 
MD-2 expressing cells studied in this work was restricted to dendritic and endothelial 
cells. LPS exposure of in vitro cultured endothelial cells led to a strong induced release 
of sMD-2, whereas LPS treatment of hematopoietic cells did not result in sMD-2 
release. Besides LPS, also TNF-α appeared to be a potent inducer of the sMD-2 release 
by endothelial cells, suggesting that MD-2 protein expression by endothelial cells can 
be regulated at sites of acute inflammation. This is supported by previous studies 
demonstrating upregulation of MD-2 mRNA by endothelial and epithelial cells in 
multiple organs by cytokines, including TNF-α35-38. Although this study does not 
exclude the possibility that other sources such as epithelial cells are capable of 
producing sMD-2 in vivo, our findings combined with the fact that numerous 
endothelial cells cover the immense network of blood vessels suggest that endothelial 
cells are a source of the enhanced circulating MD-2 levels during acute systemic 
inflammatory diseases such as endotoxemia and sepsis. 
Recent studies may help to understand the functional importance of sMD-2 in vivo. In 
particular, previous reports strongly suggest that sMD-2 can complement cells that 
express TLR4 but lack mMD-2 such as pulmonary epithelial cells38. This suggestion is 
extended by Ohnishi et al. showing that LPS can induce the formation of CD14-TLR4 
complexes on the cell surface in the absence of mMD-2 while subsequent binding of 
sMD-2 is essential for activation of these cells39.   
Here, we show for the first time a strongly enhanced expression of MD-2 by 
pulmonary endothelial cells during sepsis. This increased MD-2 expression could be 
responsible for enhanced sensitivity to LPS, resulting in the production of chemokines 
and adhesion molecules and could explain the extreme susceptibility of lung tissue 
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during endotoxemia and sepsis10. This is supported by a murine endotoxemia study, 
showing that the pulmonary endothelium is the dominant regulator of neutrophil 
accumulation and concomitant pulmonary failure40. Interestingly, we also observed in 
the septic lung enhanced MD-2 expression by pericytes. These cells have been 
reported to be capable to respond to LPS by enhanced TLR4 expression and cytokine 
release in the rat41. 
In the liver of septic patients a significant MD-2 expression was predominantly 
localized in endothelial cells covering hepatic sinusoids and Kupffer cells while MD-2 
was undetectable in healthy control liver. These human data closely resemble the 
hepatic distribution and regulation of TLR2 in control and endotoxemic mice42, 
suggesting that during inflammation, hepatic TLR’s and MD-2 are strategically located 
to respond to gut-derived bacteria and bacterial toxins.  
In conclusion, in this report we show that during sepsis total sMD-2 plasma levels are 
elevated. In these patients but not in controls, the presence of monomeric sMD-2, 
representing the active form, was detected. In endotoxemic volunteers, a time related 
increase of the total sMD-2 content and sMD-2 monomers occurred.  
Release of sMD-2 was found to be restricted to dendritic cells and endothelial cells, 
while both LPS and TNF-α were potent inducers for MD-2 release by endothelial cells. 
Our study suggests a novel role of the endothelium in mediating the host response 
during inflammation.  
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Abstract  
Microbiota in the intestinal lumen provide an abundant source of potentially 
detrimental antigens, including lipopolysaccharide (LPS), a potent immunostimulatory 
product of Gram-negative bacteria recognized by the host via TLR-4 and MD-2. An 
aberrant immune response to LPS or other bacterial antigens has been linked to 
inflammatory bowel disease (IBD) and necrotizing enterocolitis (NEC).  
We investigated which cells express MD-2 in the normal and inflamed ileum from 
neonates and adults by immunohistochemistry. Moreover, MD-2 and TLR4 mRNA 
expression in normal adult ileum was studied by RT-PCR on cells isolated by laser 
capture microdissection.  
Premature infants did not show MD-2 expression neither in epithelial cells nor in the 
lamina propria. Similarly, MD-2 was absent in epithelial cells and lamina propria 
inflammatory cells in preterm infants with NEC. MD-2 protein in the healthy term 
neonatal and adult ileum was predominantly expressed by Paneth cells and some 
resident inflammatory cells in the lamina propria. MD-2 and TLR-4 mRNA expression 
was restricted to crypt cells. Also in IBD, Paneth cells were still the sole MD-2 
expressing epithelial cells whereas inflammatory cells (mainly plasma cells) were 
responsible for the vast majority of the MD-2 expression.  
In conclusion, the absence of MD-2 in the immature neonatal gut suggests impaired 
LPS sensing, which could predispose neonates to NEC upon microbial colonization of 
the immature intestine. The apparent expression of MD-2 by Paneth cells supports 
the critical concept that these cells respond to luminal bacterial products in order to 
maintain homeostasis with the intestinal microbiota in vivo. 
 Intestinal TLR4/MD-2 expression⏐93 
Introduction 
Microbiota are abundantly present in the intestinal lumen and provide a continuous 
source of antigens and toxins capable of activating the host immune system. A 
dysregulated immune response to bacterial derived molecules can result in excessive 
mucosal inflammation. Such an inappropriate intestinal inflammatory response is 
considered to underlie intestinal disorders such as ulcerative colitis, Crohn’s disease 
and necrotizing enterocolitis (NEC)1,2, the latter predominantly affecting premature 
infants. NEC is assumed to be caused by an immature immune response to 
commensal organisms that initially colonize the gut after birth1,3,4. In contrast, the 
inflammatory bowel diseases ulcerative colitis and Crohn’s disease are considered to 
be the consequence, in part, of an excessive response of the intestinal immune 
system to the host microbiota2,5. 
The healthy intestine is populated with various cells capable of responding to 
microbiota and their immunostimulatory products. First, antigen presenting cells as 
dendritic cells in the lamina propria monitor the luminal contents and coordinate an 
appropriate immune response6,7. Second, enterocytes are considered to actively 
participate as innate immune sensors of microbial pathogens and commensal 
organisms8. Finally, Paneth cells release their antimicrobial peptides in the crypt 
lumen in response to the entry of bacteria9-12. 
Host recognition of microbial components is achieved by so-called pattern recognition 
receptors (PRRs), such as the NOD-like (NLRs) and Toll-like receptors (TLRs). Muramyl 
dipeptide (MDP), derived from peptidoglycan, is present in the cell wall of virtually all 
bacteria and recognized by NOD2, a PRR expressed in intestinal epithelial cells8 
including Paneth cells13. The activity of another PRR, TLR9 was implicated by the 
degranulation observed in response to its ligand bacterial CpG DNA14. In addition, 
functional studies suggest that human lamina propria dendritic cells in the intestine 
respond to TLR ligands15.  
Several experimental studies in rodent and porcine models suggest a role for Gram-
negative organisms in the development of intestinal inflammatory pathology16-18. The 
capacity to induce proinflammatory responses by sensing conserved bacterial 
structures via TLRs, might therefore be important for aberrant immune reactions in 
the intestinal mucosa. This prompted us to investigate the expression of TLR4 and 
MD-2, two molecules responsible for the pattern recognition and signaling of Gram-
negative derived LPS, in the healthy and inflamed gut of preterms, term infants and 
adults. The distribution of MD-2 in the healthy and inflamed intestine of premature 
neonates and adults was determined by immunohistochemistry (IHC). In addition, 
MD-2 and TLR4 mRNA expression was assessed in the healthy adult intestine in villus 
and crypt epithelial cells that were isolated by laser capture microdissection. 
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Materials and methods 
Patients 
Some of the intestinal samples were obtained from the Maastricht Pathology Tissue 
Collection (MPTC). Collection, storage and use of tissue and patient data were 
performed in agreement with the “Code for Proper Secondary Use of Human Tissue in 
the Netherlands”. In addition, fresh tissue samples were collected during routine 
gastrointestinal surgery (such as closure of stoma) after appropriate informed consent 
of the patients and/or their parents or caretakers. The study was approved by the 
medical ethics committee of the Maastricht University Medical Centre.  
Immunohistochemistry 
Staining for MD-2 was performed using the anti-MD-2 mab HM31 which was earlier 
characterized as MD-2 specific19. To ascertain the suitability of HM31 for 
immunohistochemistry on paraffin sections, staining was performed on MD-2 and 
TLR4 transfected CHO cells that were fixed in 4% formaldehyde, embedded in 2% 
agarose and subsequently in paraffin according to the AgarCyto cell block procedure20. 
Sections of paraffin-embedded tissue or transiently transfected CHO cells were 
dewaxed and rehydrated through xylene and a decreasing ethanol gradient, followed 
by blocking the endogenous peroxidase with 0.3% H2O2 in methanol. After blocking 
with 5% bovine serum albumin, sections were incubated for 1 hour with the anti-
MD-2 antibody HM31 followed by incubation with a goat anti mouse biotinylated 
secondary antibody (Dako, Glostrup, Denmark). Binding of the primary antibody was 
demonstrated by the streptavidin-biotin system (Dako) and visualized by applying 
3-amino-9-ethylcarbazole (AEC; Sigma, St. Louis, Mo). Nuclei were counterstained 
with haematoxylin. The slides were photographed by a Nikon eclipse E800 microscope 
with a Nikon digital camera DXM1200F and were analysed by the computer program, 
Lucia G/F color image analysis. 
To identify cell types that expressed MD-2, an immunohistochemical procedure for 
sequential double-antigen localization was applied. Paraffin sections were pretreated 
as described above. Antibodies directed against human defensin-5 (antibody 8C8)21, 
human lysozyme (Dako) or human CD138 (Dako) were used to perform IHC in 
combination with anti MD-2. In this procedure, sections were incubated for 1 hour 
with the anti-MD-2 antibody HM31 followed by incubation with a goat antimouse 
biotinylated secondary antibody. MD-2-positive cells were demonstrated by the 
streptABComplex/HRP detection system (Dako) and visualized by 3,3-
diaminobenzidine (DAB) Dako).  
Before incubation with the second primary antibody for detection of the cellular 
marker of interest, slides were blocked again with 5% bovine serum albumin for 30 
minutes. Cells that stained positive for human defensin-5, lysozyme or CD138 were 
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counterstained by HistoGreen (Linaris, Wertheim, Germany). Control experiments 
were performed with isotype control IgG.  
Laser microdissection and pressure catapulting  
Fresh ileum mucosa samples were cut into 18 μm thick sections using a cryostat (Leica 
CM1850, Leica Microsystems, Wetzlar, Germany) and processed as follows: the 
sections were mounted on membrane slides (PEN-membrane, 1 mm glass, Carl Zeiss 
MicroImaging, Bernried, Germany) and incubated for 10 min at -20°C in RNAlater-ICE 
(Ambion, Austin, TX). For further preservation, samples were fixed in ethanol and 
stained in cresyl violet acetate (1% (w/v) in ACS-grade ethanol (Sigma) for 15 sec. 
Subsequently, the slides were washed in ethanol and incubated for 5 min in xylene. 
After air-drying the slides were mounted on the stage of an inverse microscope that is 
a component of a Microbeam LMPC System (Carl Zeiss MicroImaging). We employed 
the RoboLPC method to microdissect and capture the appropriate tissue fragments 
(approx. 8 mm2 crypt epithelium and epithelium lining the tips of the villi each, 
~ 100,000 – 250,000 cells). For sample collection we applied 0.5 ml AdhesiveCaps 
opaque (Carl Zeiss MicroImaging).  
RNA Isolation of microdissected samples  
Total RNA was isolated from each sample using the Chomczynski/Sacchi method22 
according to the manufacturer’s instructions (peqGOLD TriFast kit, PeqLab 
Biotechnology, Erlangen Germany). For precipitation, 2 μl of Pellet Paint Co-
Precipitant (Novagen, San Diego, CA) per sample was used. Subsequently, isolated 
RNA was purified using an Absolutely RNA Nanoprep Kit (Stratagene, La Jolla, CA), 
using an elution volume of 12 µl. Quality of the RNA was assessed on RNA 6000 Nano 
microfluidics chips (Agilent Technologies, Waldbronn, Germany) on an Agilent 2100 
BioAnalyzer according to the manufacturer's instructions.  
Evaluation of mRNA levels by RT-PCR  
RNA samples (10 µl of purified mRNA) were reverse-transcribed into cDNA using 
VersoTM Reverse Transcriptase and a blend of random hexamers and anchored oligo-
dT 3/1 (v/v) as primer (VersoTM cDNA Kit; Thermo Fisher Scientific, ABgene House, UK) 
according to the manufacturer's protocol (Abgene). PCR reactions were performed in 
a total volume of 25 µl with specific primers for cytokeratin-18, TLR4, MD-2, alpha-
defensin-5, lysozyme or CD45 using 1 µl of 5x diluted cDNA. Next, a nested PCR was 
conducted using 2.5µl of the first reaction as a template. Amplified products were 
visualized on ethidiumbromide stained 1.2% agarose gels and photographed with a 
CCD camera (Pharmacia, Uppsala, Sweden). Primers for cytokeratin-18 were: 5’- GAG 
ACT GGA GCC ATT ACT TCA AG-3’ (sense primer), 5’-GCC TTT TAC TTC CTC TTC CTG-3’ 
(antisense primer), 5’-GAT CTT CGC AAA TAC TGT GGA C-3’ (nested sense primer) and 
5’-CTT GGC GAG GTC CTG AGA TT-3’ (nested antisense primer). Primers for TLR4 were: 
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5’-TGC ATG GAG CTG AAT TTC TAC-3’ (sense primer), 5’-TGA GCC ACA TTA AGT TCT 
TTC-3’ (antisense primer), 5’-ACC TGG ACC TGA GCT TTA ATC-3’ (nested sense primer) 
and 5’-CCA ATG GGG AAG TTC TCT AG-3’ (nested antisense primer). Primers used for 
the amplification of MD-2 were: 5’-CCT GTT TTC TTC CAT ATT TAC TG-3’ (sense 
primer), 5’-CTT GAA GGA GAA TGA TAT TGT TG-3’ (antisense primer), 5’-TGG GTC TGC 
AAC TCA TCC G-3’ (nested sense primer) and 5’-AAT AAC TTC TTT GCG CTT TGG-3' 
(nested antisense primer). Primers designed for amplification of alpha-defensin-5 
mRNA were: 5’-TCG CCA TCC TTG CTG CCA-3’ (sense primer), 5’-GTA GAG GCG GCC 
ACT GAT TTC-3’ (antisense primer), 5’-ATT CTC CTG GTG GCC CTG-3’ (nested sense 
primer) and 5’-TCA CAC ACC CCG GAG AGG-3’ (nested antisense primer). Primers 
designed for amplification of lysozyme were: 5’-CCC TCC TTT CTG TTA CGG TCC-3’ 
(sense primer), 5’-CTA ACG CCT TGT GGA TCA CGG 3’ (antisense primer), 5’-TGT TAC 
GGT CCA GGG CAA G-3’ (nested sense primer) and 5’-AAG CAC TGC AGG ATA AAT GAC 
A-3’ (nested antisense primer). Primers for CD45 were 5’-CCT CAG CCT TGC ACA CCA 
CAG-3’ (sense primer), 5’-CTT TTC AAC CCC TGG TGG CAC-3’ (antisense primer), 5’-
GCC TTA CCT GCA CGC ACC-3’ (nested sense primer) and 5’-ATG AGA TAT GGA AAC 
AGA CGC A-3’ (nested antisense primer). All primers were synthesized by Eurogentec, 
Seraing, Belgium. 
Results 
Expression of MD-2 in the healthy intestine of preterm and term infants 
To investigate the suitability of the anti-MD-2 mab for immunohistochemistry, 
MD-2-TLR4 transfected CHO cells were fixed, embedded in paraffin and stained for 
MD-2. These experiments showed positive staining in MD-2 expressing (Figure 5.1A), 
but not in mock transfected CHO cells (Figure 5.1B). Using this earlier characterized 
anti-MD-2 antibody19, intestinal tissue of preterm and term infants was investigated 
by immunohistochemical analysis. In the healthy ileum of term infants (n=10), the 
majority of the MD-2 expression was located at the base of the crypts of Lieberkühn 
(Figure 5.2B1, Table 5.1). The crypt position and cellular morphology of the MD-2 
positive cells corresponded with Paneth cells. Consistent with this presumption, 
sequential double-antigen localization clearly showed colocalisation of MD-2 with the 
typical Paneth cell markers alpha-defensin-5 (Figure 5.3B, Table 5.1) and lysozyme 
(data not shown). No MD-2 staining was detectable in other epithelial cells in the 
healthy ileum of term infants (n=10) (Figure 5.2B1). In addition, some resident 
inflammatory cells in the lamina propria of the ileum stained positive for MD-2 (Figure 
5.2B1, Table 5.1). No staining was observed after replacement of the primary Ab with 
the corresponding isotype control (Figure 5.2E1). 
In line with the healthy ileum of term infants, Paneth cells of preterms (<39 weeks) 
(n=10) stained also positive for alpha-defensin-5 (Figure 5.3A) and lysozyme (data not 
shown). However, MD-2 was not detected immunohistochemically in the Paneth cells 
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or inflammatory cells of the healthy ileum of these premature infants (Figure 
5.2A1+5.3A, Table 5.1). 
 
 
 
 
 
 
 
 
 
 
Figure 5.1 Characterization of monoclonal antibodies to human MD-2. Paraffin sections of MD-2 
transfected CHO cells, stained for the presence of human MD-2, using AEC as a substrate (red) 
showed that MD-2 positive staining was observed in transfected cells, being 50% of the cells 
(A). No positive cells were detectable in mock-transfected cells (B). 
 
 
See page 162 for colour  figure. 
Expression of MD-2 in the healthy mature intestine 
Similar to the staining pattern observed in term infants, virtually all MD-2 positive 
cells in the adult ileum (n=10) were located at the base of the crypts of Lieberkühn 
(Figure 5.2C1) and these MD-2 expressing epithelial cells colocalized with the Paneth 
cells markers alpha-defensin-5 (Figure 5.3C, Table 5.1) and lysozyme (data not shown). 
MD-2 staining was not detectable in other epithelial cells in the healthy ileum or colon 
(n=10) (Figure 5.2C1+5.2D1). In addition, some resident inflammatory cells in the 
lamina propria of the ileum and colon stained positive for MD-2 (Figure 5.2C1+5.2D1, 
Table 5.1). The negative control with the replacement of the primary antibody with an 
isotype-matched control antibody showed no staining (data not shown).  
Next, TLR4 and MD-2 mRNA expression was analyzed by RT-PCR in the healthy adult 
ileum, in either crypt or villus epithelial cell populations that were isolated by laser 
capture microdissection (LCM) (n=7). In concordance with our findings on protein 
level, MD-2 mRNA expression was detected exclusively in epithelial cells lining the 
bottom of the crypts (Figure 5.4). Interestingly, TLR4 mRNA was also restricted to 
epithelial cells located in the crypts (Figure 5.4). As a control, RT-PCR for cytokeratin-
18 expression confirmed the epithelial identity of isolated cells in both villus and crypt 
samples. Isolation of epithelial cells from the crypt was confirmed by the presence of 
mRNA for lysozyme and alpha- defensin-5 (Figure 5.4). In addition, CD45 mRNA was 
undetectable in microdissected cells confirming that the detected MD-2 and TLR4 
RT-PCR signals in the crypt epithelium could not be attributed to contaminant 
leukocytes (data not shown). 
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Figure 5.2 MD-2 expression in the healthy and inflamed intestine of preterm and term infants and 
adults.  
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MD-2 positive cells, visualized with AEC (red), were not detected in paraffin sections of the 
immature intestine (n=10) (A1). In the healthy ileum of term infants and adults (n=10), MD-2 
expression is mainly located at the base of the crypts of Lieberkühn (B1+C1). Sporadically, 
MD-2 positive inflammatory cells were detected in the lamina propria (indicated by arrows) 
(B1+C1). No MD-2 staining was detected in epithelial cells in paraffin sections of the mature 
healthy colon (n=10) (D1). Occasionally, MD-2 expressing inflammatory cells were observed in 
the lamina propria (indicated by arrows) (D1). No staining could be observed when an isotype-
matched primary control antibody was used (E1). MD-2 expressing cells were not detected in 
paraffin sections of the immature intestine of NEC patients (n=10) (A2). During intestinal 
inflammation of the mature ileum, expression of MD-2 is observed in Paneth cells, but most is 
expressed by a subset of characteristic inflammatory cells in the lamina propria (C2). In the 
inflamed mature colon (n=20), large numbers of MD-2 positive cells were detectable in the 
lamina propria whereas epithelial staining for MD-2 was absent (D2). A representative section 
is shown for the outcome of three separate immunohistochemical experiments on the 
indicated samples. See page 163 for colour figure. 
 
 
Table 5.1 Patient characteristics and main findings. 
Subgroup Collected tissue Surgical indication Gender MD-2 distribution 
Healthy ileum of 
premature infants 
MPTC (*) n=5 
Fresh tissue n=5 
Volvulus, malrotation, 
closure of stoma 
    5 men 
    5 women 
Absent 
Healthy  ileum of term 
infants 
MPTC n=5 
Fresh tissue n=5 
Volvulus, malrotation, 
closure of stoma 
    4 men 
    6 women  
Primarily Paneth cells, 
some inflammatory cells 
Healthy mature ileum MPTC n=0 
Fresh tissue n=10 
closure of stoma     4 men 
    6 women 
Primarily Paneth cells 
some inflammatory cells 
Inflamed ileum of 
premature infants 
MPTC n=9 
Fresh tissue n=1 
NEC (#)  n=10     6 men 
    4 women 
Absent 
Inflamed adult colon MPTC n=10 
Fresh tissue n=10 
Crohn’s disease n=10, 
ulcerative colitis n=10 
    8 men 
  12 women 
Multiple inflammatory 
cells 
Inflamed adult ileum MPTC n=4 
Fresh tissue n=6 
Crohn’s disease n=10     5 men 
    5 women 
Multiple inflammatory 
cells, Paneth cells 
* MPTC = Maastricht Pathology Tissue Collection; # NEC = Necrotizing enterocolitis. 
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Figure 5.3 Sequential double-antigen localization of MD-2 and alpha-defensin-5. 
 For antigen colocalisation, MD-2 positive cells were visualized with DAB (brown) and a 
classical Paneth cell marker alpha-defensin-5 with HistoGreen (green). Immunoreactivity for 
alpha-defensin-5 but not for MD-2 was seen in the ileum of preterm infants (A). In the ileum 
of term infants and adults (B+C), Alpha-defensin-5 colocalized with all MD-2 positive epithelial 
cells (n=10). Representative examples of the immunohistochemical staining patterns are 
shown. See page 165 for colour figure. 
Lack of MD-2 expression in the inflamed gut of preterms 
Specimens obtained from the ileum of NEC patients (n=10), showed an increased 
influx of inflammatory cells at the site of mucosal injury. However, these inflammatory 
cells lacked the MD-2 protein (Figure 5.2A2, Table 5.1) In line with the expression 
pattern in healthy preterms, MD-2 staining of intestinal epithelial cells was not 
observed during inflammation in these infants (Figure 5.2A2, Table 5.1). 
Expression of MD-2 in the inflamed adult intestine 
In inflamed mature ileal tissue (n=10), MD-2 was expressed by the Paneth cell (Figure 
5.2C2, Table 5.1). However, inflammatory cells in the lamina propria were responsible 
for the majority of the MD-2 expression in these sections. In the inflamed colon of 
patients with Crohn’s disease (n=10) or ulcerative colitis (n=10), MD-2 was not 
detected in epithelial cell populations, whereas multiple inflammatory cells in the 
Mature ileum
Term ileumPreterm ileum
A B
C
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lamina propria stained positive for MD-2 (Figure 5.2D2, Table 5.1). Many of the MD-2 
positive inflammatory cells in both inflamed ileal and colon were identified as CD138 
positive plasma cells (Figure 5.5). 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 5.4 Basal TLR4 and MD-2 mRNA expression in microdissected epithelial cells lining the villi or the 
crypts of the adult ileum.  
 Cytokeratin-18 mRNA expression was detected using cDNA from both villus and crypt samples 
obtained by LCM. Constitutive ileal TLR4 and MD-2 mRNA expression was confined to crypt 
epithelial cells. Crypt epithelial cells expressed mRNAs for antimicrobial peptides lysozyme 
and alpha-defensin-5 characteristic for Paneth cells. 
 
 
 
 
 
 
 
 
 
 
 
Figure 5.5 Identification of cells expressing MD-2 in the inflamed mucosa of the adult gut.  
 Many inflammatory cells, positive for MD-2 (brown), co-express the marker for plasma cells, 
CD138 (green). See page 165 for colour figure. 
Villus        Crypt
Cytokeratin-18
MD-2
TLR4
Lysozyme
Alpha-defensin-5
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Discussion  
This study shows that MD-2 is absent in the premature gut, indicating that the 
premature intestine lacks crucial molecules required for detection and sensing of LPS. 
Such a deficient innate immune defense might predispose preterm born infants to 
bacterial overgrowth once the gut becomes colonized. Several reports concerning 
maturation of TLR4 during fetal development in other organs support our findings 
that preterm infants have a reduced capacity to sense LPS. In particular, for mice and 
baboons, evidence was provided that TLR4 mRNA levels in the immature fetal lung are 
decreased in comparison to mature newborns23,24. In addition, human premature 
infants express considerably lower levels of TLR4 on their monocytes then term born 
infants, and concomitantly, the cytokine production by monocytes upon LPS 
stimulation is increased in a gestational age–dependent manner25.  
In term infants as in healthy adults, ileal MD-2 was predominantly expressed by 
Paneth cells and some resident inflammatory cells. In addition, TLR4 and MD-2 mRNA 
was detected in small intestinal crypts isolated by laser capture microdissection. The 
TLR4 and MD-2 positive epithelial cell populations were also positive for lysozyme and 
alpha-defensin-5 mRNA, two Paneth cell markers. Together, these data strongly 
suggest that Paneth cells are the predominant, if not sole epithelial cells that express 
the molecules of the LPS recognition complex in the healthy ileum. We were not able 
to assess the distribution of the TLR4 protein since appropriate high affinity antibodies 
for immunohistochemistry are till now not available26. 
The present finding that Paneth cells harbor molecules required for the detection and 
sensing of LPS, extends previous studies showing that Paneth cells express PRRs, 
including TLR9 and NOD-227. In addition, our data might explain work from Ayabe et 
al. who showed that Paneth cells secrete their antimicrobial peptides following 
exposure to microbial components, such as LPS9. Moreover, our data are in 
agreement with a recent publication which showed that penetration of luminal 
commensal and pathogenic bacteria is controlled by Paneth cell intrinsic MyD88-
signaling28. Collectively, these data suggest that Paneth cells actively sense luminal 
bacterial products, potentially via microbial detector molecules such as TLR4/MD-2, 
resulting in the release of their antimicrobial peptides. On their turn, Paneth cells 
derived antimicrobial peptides are considered to play an essential role in maintaining 
host-microbial homeostasis at the mucosal interface28. 
The presence of MD-2 in the cytoplasm of Paneth cells might imply that Paneth cells 
secrete soluble MD-2 (sMD-2), which has recently been shown to exist in vivo19,29 in 
addition to TLR4-bound MD-2. Of interest, two recent reports demonstrated that 
sMD-2 binds tightly to the surface of live Gram-negative bacteria, enhancing cellular 
activation, bacterial internalization and intracellular killing, in a TLR4 dependent 
manner30,31. Such a possible role of Paneth cell derived sMD-2 would be in line with 
the antibacterial defense function of these cells.  
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In contrast to the MD-2 expression pattern in the healthy adult intestine, our data in 
IBD patients reveal that many MD-2 positive inflammatory cells were present in the 
lamina propria. In line with these data, abundant expression of MD-2 by inflammatory 
cells located in the lamina propria was reported in the inflamed colon of IBD 
patients32. However, despite the presence of multiple inflammatory cells, minimal 
MD-2 expression was detected in the terminal ileum of patients with active IBD32. 
Consistent with our findings, previous studies show enhanced numbers of TLR4 
positive inflammatory cells in the lamina propria during active IBD in man33,34. In 
addition, we found that the lamina propria infiltrating plasma cells strongly stained for 
MD-2, indicating enhanced responsiveness to LPS in such tissue.   
Of interest, data presented here show that during active IBD, Paneth cells were still 
the only MD-2 expressing epithelial cells in the gut. Although the debate regarding 
TLR4 and MD-2 expression by epithelial cells during active IBD is still open32-34, our 
data are consistent with those of Hausmann et al. that suggest that absorptive 
epithelial cells are not directly involved in the response to LPS.  
In line with the absence of MD-2 expression in healthy preterms, MD-2 was not 
present in epithelial cells of preterm infants suffering NEC. Moreover, in NEC patients, 
MD-2 staining was also absent in the abundantly recruited inflammatory cells. A lack 
of MD-2 expression suggests reduced inflammatory signaling which could predispose 
these preterm infants to bacterial overgrowth after intestinal colonization and might 
therefore be a possible mechanism for the pathophysiology of the disease1.  
Paradoxically, C3H/HeJ mice that carry a malfunctioning TLR4, were reported to be 
protected to the development of NEC in a model of formula feeding and hypoxia35. 
The authors suggest that TLR4 is involved in the pathogenesis of NEC, by disturbance 
of the balance between mucosal injury and repair in the small intestine. In addition, 
using neonatal rats and TLR4 mutant C3H/HeJ mice, Jilling and colleagues provided 
evidence that bacterial-derived products activate TLR4 on intestinal epithelial cells 
that are abnormally up-regulated following neonatal stress, resulting in downstream 
inflammatory gene expression and NEC16. The differences between experimental and 
clinical NEC needs further investigation.  
Taken together, this study shows that the in vivo distribution of MD-2 is gestation and 
inflammation-dependent. The absence of MD-2 in the healthy and inflamed 
premature gut supports the hypothesis that an immature immune system underlies 
the pathophysiology of NEC1,3,36. In contrast, the abundant increase of MD-2 positive 
inflammatory cells during IBD suggest an increased capacity to react to Gram negative 
derived LPS and this might be involved in the excessive response of the adult 
intestinal immune system. 
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Abstract  
Chorioamnionitis is the most significant source of prenatal inflammation and preterm 
delivery. Prematurity and prenatal inflammation are associated with compromised 
postnatal developmental outcomes, of the intestinal immune defence, gut barrier 
function and the vascular system. We developed a sheep model to study how the 
antenatal development of the gut was affected by gestation and/or by endotoxin 
induced chorioamnionitis. 
Chorioamnionitis was induced at different gestational ages (GA). Animals were 
sacrificed at low GA after 2d or 14d exposure to chorioamnionitis. Long term effects of 
30d exposure to chorioamnionitis were studied in near term animals after induction 
of chorioamnionitis. The cellular distribution of tight junction protein ZO-1 was shown 
to be underdeveloped at low GA whereas endotoxin induced chorioamnionitis 
prevented the maturation of tight junctions during later gestation. Endotoxin induced 
chorioamnionitis did not induce an early (2d) inflammatory response in the gut in 
preterm animals. However, 14d after endotoxin administration preterm animals had 
increased numbers of T-lymphocytes, myeloperoxidase-positive cells and gammadelta 
T-cells which lasted till 30d after induction of chorioamnionitis in then near term 
animals. At early GA, low intestinal TLR-4 and MD-2 mRNA levels were detected which 
were further down regulated during endotoxin-induced chorioamnionitis. 
Predisposition to organ injury by ischemia was assessed by the vascular function of 
third-generation mesenteric arteries. Endotoxin-exposed animals of low GA had 
increased contractile response to the thromboxane A2 mimetic U46619 and reduced 
endothelium-dependent relaxation in responses to acetylcholine. The administration 
of a nitric oxide (NO) donor completely restored endothelial dysfunction suggesting 
reduced NO bioavailability which was not due to low expression of endothelial nitric 
oxide synthase. 
Our results indicate that the distribution of the tight junctional protein ZO-1, the 
immune defence and vascular function are immature at low GA and are further 
compromised by endotoxin-induced chorioamnionitis. This study suggests that both 
prematurity and inflammation in utero disturb fetal gut development, potentially 
predisposing to postnatal intestinal pathology. 
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Introduction 
Chorioamnionitis is a bacterial infection of the amniotic fluid, placenta and 
membranes that is very frequently diagnosed after preterm birth1. The disorder is 
usually clinically silent which makes estimates about the onset of infection during 
gestation difficult2. Chorioamnionitis results from the fetal exposure to bacteria and 
bacterial toxins in the contaminated amniotic fluid. Animal studies showed that fetal 
aspiration of contaminated amniotic fluid induces lung inflammation, resulting in 
profound changes of the pulmonary homeostasis as indicated by increases in 
surfactant lipids and transient injury to the microvasculature and alveolar septa3-6. 
These alterations in lung development are associated with increased risk of 
bronchopulmonary dysplasia7. 
Swallowing of the bacterial contaminated amniotic fluid is likely to result in antenatal 
exposure of the premature intestine to bacteria and their toxins in utero. Whether 
this exposure results in inflammatory and or developmentary changes of the gut of 
preterm babies is subject of the current study. We hypothesized that prematurity and 
inflammation, either alone or combined, disturb maturation of the gut barrier, the 
innate immune defense and vascular function thereby potentially increasing the risk 
to postnatal intestinal pathologic conditions. To test our hypothesis, chorioamnionitis 
was induced by intraamniotic endotoxin injection at low gestational age (GA) and 
animals were delivered either preterm or near term. In this model, the distribution of 
the tight junctional protein zonula occludens protein 1 (ZO-1) was determined since 
no data exists on its expression during gestation. Besides the TLR4 and MD-2 mRNA 
expression, also the distribution of either myeloperoxidase (MPO) expressing cells 
(polymorphonuclear leukocytes (PMN) as marker for early inflammation) or 
T-lymphocytes and gammadelta T-cells (cells known to be crucial in monitoring and 
maintaining integrity of epithelial tissues; late inflammation) were assessed. Finally, 
the contraction or relaxation of third-generation mesenteric arteries was studied. 
Relaxation was studied in the absence and presence of a NO donor and concomitantly 
the expression of endothelial nitric oxide synthase (eNOS) was assessed. 
In this study, we show that a low gestational age and endotoxin induced 
chorioamnionitis both prevent maturation of the intestinal barrier function, the innate 
immune defense and vascular function. 
Materials and methods 
Animals 
This study was performed according to the guidelines of the Animal Care Committee 
of the University of Maastricht, which approved the protocol. The study was 
conducted after approval and in compliance with the guidelines of the ethical 
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committee. Time-mated Texel ewes with singleton fetuses were randomly assigned to 
groups of four or five animals, to receive a single dose of 10 mg endotoxin (Escherichia 
coli 055:B5; Sigma Chemical, St. Louis, MO) resuspended in saline or the equivalent 
volume of saline for control animals by ultrasound guided intraamniotic injections 
(Figure 6.1). Chorioamnionitis was induced at 110–111d GA and at 123d GA. Animals 
were sacrificed at low GA of 125d GA after 2d or 14d exposure to chorioamnionitis. 
The low GA of 125d GA is comparable with a human GA of approximately 27 weeks. 
Long term effects of 30d exposure to endotoxin were studied in near term animals at 
140d GA (term gestation being 147d GA) after induction of chorioamnionitis at 
110-111d (Figure 6.1). All animals were delivered by caesarean section. Lambs 
received a lethal i.v. injection of phenobarbiturate. The stomach content was 
collected for analysis. Samples of the small intestine were collected for snap freezing 
and fixation. Third generation mesenteric arteries of the small intestine were 
prepared for analysis of vascular reactivity. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 6.1 Experimental design. Gestational development and effects of chorioamnionitis were 
studied at two different gestational ages. At 125d GA, fetuses were comparable to 27 
weeks of human gestation. Lambs were almost near term at 140d GA since term gestation 
is 147d. Chorioamnionitis was induced by a single injection of endotoxin under ultrasound 
guidance at 111d GA and at 123d GA. Animals were delivered at 125d GA and animals of 
the control group underwent the same procedure with an injection of saline. Animals of 
140d GA had a separate control group to assess gestational changes. 
Antibodies and reagents 
Intestinal tissue was analysed with the following antibodies: monoclonal antibody 
against endothelial nitric oxide synthase (eNOS) (BD Transduction laboratories, San 
Jose, CA); rabbit antibodies against human MPO and CD3 Dakocytomation (Glostrup, 
Denmark) or Zonula Occludens protein 1 (ZO-1) (Invitrogen, San Francisco, CA); 
monoclonal antibody IL-A29 for the detection of gammadelta T-cells (VMRD, Pullman, 
Intra-amniotic saline (control)
Intra-amniotic endotoxin
Preterm delivery
Preterm delivery
Near term delivery
0 d GA                                                 123 d GA 125 d GA
0 d GA                111 d GA                                  125 d GA
0 d GA               111 d GA                                   140 d GA
2 d
14 d
30 d
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WA). Secondary antibodies, biotin conjugated rabbit anti-mouse and Texas red 
conjugated goat anti-rabbit were purchased from Dakocytomation and peroxidase 
conjugated goat anti-rabbit from Jackson (West Grove, PA). 
Immunohistochemistry 
Small intestinal biopsies, fixed overnight in 4% formaldehyde, were embedded in 
paraffin and sectioned at 3 µm. For staining of CD-3 and eNOS expressing cells, slides 
were heated in 10 mM Na-citrate (pH 6.0) for 20 min. Endogenous peroxidase activity 
was blocked with 0.3% H2O2 in methanol and subsequently, slides were blocked with 
either normal goat serum (eNOS and MPO) or bovine serum albumin (CD-3) for 30 min 
at room temperature. Slides were incubated with the primary antibody of interest for 
one hour at RT (CD-3 and MPO) or overnight at 4°C (eNOS). After washing, sections 
were incubated with the appropriate secondary conjugated antibody. Binding of the 
eNOS antibody was demonstrated by the streptavidin-biotin system (Dakocytomation) 
and binding of antibodies against CD-3 and MPO was detected using a peroxidase 
conjugated secondary antibody. Positive staining was visualized by applying 3-amino-
9-ethylcarbazole (AEC, Sigma); nuclei were counterstained with haematoxylin. The 
number of cells exhibiting immunostaining for MPO and CD-3 were counted per high 
power field (200x). Figures were expressed as number of MPO or CD-3 expressing cells 
per high power field. 
Frozen tissue sections were first fixed in filtered, ice-cold acetone and next in 4% 
paraformaldehyde. Endogenous peroxidase was blocked with 0.3% H2O2 in methanol. 
After blocking with 10% normal goat serum, sections were incubated for two hours 
with a mab against gamma delta T-cells. After washing, an appropriate biotin 
conjugated secondary antibody was used. Binding of the primary antibody was 
demonstrated by the streptavidin-biotin system (Dakocytomation) and visualized by 
AEC. Nuclei were counterstained with haematoxylin. All slides were photographed by 
a Nikon eclipse E800 microscope with a Nikon digital camera DXM1200F and were 
analysed by the computer program, Lucia G color image analysis.  
Immunofluoresence 
Tight junction distribution was examined by immunofluorescent staining of frozen 
sections (3 µm) with an antibody to Zonula Occludens protein 1 (ZO-1). Ileum sections 
were fixed with 4% paraformaldehyde. After blockage of non-specific binding sites 
with 10% goat serum, slides were incubated with anti-ZO-1 for one hour. Thereafter, 
the sections were incubated 45 min with Texas red conjugated goat anti-rabbit 
antibody, followed by 2 min incubation with 4′,6-diamino-2-phenyl indole (DAPI), 
dehydrated in ascending ethanol series and mounted in Fluorescence Mounting 
Solution (Dakocytomation). The distribution of ZO-1 was recorded at a magnification 
of 200x using the Metasystems Image Pro System (black and white charge-couple 
device camera; Metasystems, Sandhausen, Germany) mounted on a Leica DM-RE 
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fluorescence microscope (Leica, Wetzler, Germany). All images were taken at equal 
time-exposures after being normalized to negative control sections without primary 
antibody, to exclude non-specific binding of the secondary antibody or 
autofluorescence. At least 25 microscopic fields for each tissue section were studied. 
Evaluation of mRNA levels by RT-PCR 
For RT-PCR total RNA was extracted from ileal tissues using the SV Total RNA isolation 
system (Promega, Madison, WI). Next, isolated total RNA was treated with RQ1 
RNase-Free DNase (Promega) and reverse transcribed using oligo (dT) primer and 
Moloney murine leukemia virus reverse transcriptase (Life technologies, Paisley, 
United Kingdom) according to the supplier's recommendations. cDNA samples were 
standardized based on the content of GAPDH cDNA as housekeeping gene. GAPDH 
cDNA was evaluated by performance of a GAPDH PCR on multiple dilutions of each 
cDNA sample. The amount of amplified product was estimated by densitometry of 
ethidiumbromide stained 1.2% agarose gels using a CCD camera and Imagemaster 
VDS software (Amersham, Uppsala, Sweden). Primer sequences for GAPDH were:5′-
CGT CTT CAC CAC CAT GGA GA-3′ (sense primer) and 5′-CGG CCA TCA CGC CAC AGT 
TT–3′ (antisense primer); primers used for the amplification of TLR4 mRNA: 5′- CCT 
CTC CAC CTT GAT ACT GAC G -3′ (sense primer) and 5′- GGT ACC TGG TTC AAT AAA 
GCC T-3′ (antisense primer) and primers designed for amplification of MD-2 mRNA: 5′- 
CCT GTT TTC TTC CAT ATT TAC TG (sense primer) and 5′- AAT AAC TTC TTT GCG CTT 
TGG–3′. PCR reactions with GAPDH, TLR4 or MD-2 specific primers were performed 
using appropriate dilutions of the cDNA. PCR reactions were performed in a total 
volume of 25 µl in PCR buffer (Perkin Elmer/Cetus, Emeryville, CA) in the presence of 
0.2 mM dNTP (Amersham), 1.0 µM of each primer, 0.3 mM MgCl2 and 0.5 U Taq 
polymerase (Perkin Elmer). PCR conditions for each primer couple were as follows: 
GAPDH: 95°C for 30 sec, 55°C for 30 sec and 72°C for 30 sec during 21 cycles; TLR4: 
95°C for 30 sec, 54°C for 30 sec and 72°C for 30 sec during 40 cycles; MD-2: 95°C for 
30 sec, 52°C for 30 sec and 72°C for 30 sec during 33 cycles. Levels of TLR4 and MD-2 
RNA expression were evaluated by densitometric image analysis as described above. 
Relative TLR4 and MD-2 mRNA levels were calculated by comparison of band 
intensities of the RT-PCR products to standard curves prepared by PCR amplifications 
on dilution series of a highly concentrated ileal ovine cDNA. 
Arterial reactivity 
Since ischemia as a consequence of vascular compromise is one of the frequently 
proposed risk factors for impaired intestinal homeostasis, responsiveness to 
contractile and endothelium-dependent and -independent relaxant agonists was 
assessed in isolated third-generation mesenteric arteries. Artery rings were mounted 
in a wire myograph, bathed in Krebs solution (gassed with 95% air/5% CO2, pH 7.4), 
and normalized to a resting pretension corresponding to an intraluminal pressure of 
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40 mm Hg (125d GA) or 50 mm Hg (140d GA). The contractions induced by KCl 
(62.5 mM), the thromboxane A2 mimetic U46619 (10-10-10-7M) and the adrenergic 
receptor agonist norepinephrine (NE; 10-10-10-4M) was assessed. In addition, the 
endothelium-dependent relaxation (evoked by acetylcholine, Ach;10-9-10-4M)8 and 
endothelium–independent relaxation evoked by the NO donor sodium nitroprusside 
(SNP; 10-9-10-4M) were analyzed. For the study of the relaxant responses, vessels were 
pre-contracted with U46619 (10-7M) as previously described9. 
Statistical analysis 
The number of cells exhibiting immunostaining for MPO and CD-3 were counted per 
high power field. A Mann-Whitney U-test was used for between-group comparisons. 
Vascular contractile and relaxation responses are represented as mean±SEM and the 
2-way unpaired t-test was used to test for significant differences between saline and 
endotoxin treated groups. TLR4 and MD-2 mRNA levels were represented as 
mean±SEM and differences between preterm and term lambs or saline and endotoxin 
injected animals were compared using an unpaired t-test. Statistical calculations were 
made using SPSS 15.0 for Windows (SPSS, Chicago, IL) and differences were 
considered statistically significant at P<0.05. 
Results 
Tight junctions 
Tight junctions have an important role in maintaining the barrier integrity by 
connecting enterocytes10,11. In order to analyse the maturation and the influence of 
endotoxin in the fetal gut on this essential component of the gut barrier, the 
distribution of the zonula occludens protein 1 (ZO-1) was determined. ZO-1 staining 
was fragmented in premature saline treated control animals of 125d GA (Figure 6.2A). 
Interestingly, endotoxin exposure for 2d did not change the pattern (Figure 6.2B). 
Fetuses exposed to endotoxin for 14d showed further fragmented tight junctional 
distribution at 125d GA (Figure 6.2C). In contrast, in near term saline injected animals 
of 140d GA, ZO-1 proteins formed a continuous ring, which is indicative for a normal 
tight junctional distribution (Figure 6.2D). Interestingly, in these near term lambs of 
140d GA, exposure to endotoxin for 30d resulted in partial loss of the ZO-1 protein in 
comparison to the age-matched control animals with saline injection (Figure 6.2E). 
114⏐Chapter 6 
A B
C D
E
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 6.2 Immunolocalisation of ZO-1 (red) in the fetal intestine. At 125d GA, a fragmented staining 
pattern for ZO-1 was seen in control animals (A) or lambs exposed to endotoxin for 2 (B) or 
14d (C). At 140d GA, a normal ZO-1 distribution was detected in control animals (D) that 
became disrupted upon endotoxin exposure for 30d (E). Magnification 200x. For inset, 
1000x magnification was used. See page 166 for colour figure. 
Inflammatory parameters  
In preterm control animals of 125d GA, hardly any MPO expressing cells were 
detected (data not shown). At this GA, endotoxin exposure for 2d did not result in a 
significant increase of infiltrating intestinal MPO positive cells (data not shown). 
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Interestingly, at 14 days post endotoxin treatment, large numbers of MPO positive 
cells were present in the lamina propria of the immature intestine (Figure 6.3A). 
Remarkably, 30d post endotoxin treatment, the number of MPO expressing cells 
reactivity was still significantly enhanced in the near term fetus (Figure 6.3B) when 
compared to saline treated control animals of this GA (Figure 6.3C). For each 
individual animal, the number of infiltrating MPO expressing cells was counted per 
high-powerfield and displayed in a scatter plot (Figure 6.3D). 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 6.3 At 14 and 30d after intraamniotic endotoxin injection, massive influx of PMNs was detected 
(A+B). At 140d GA, some MPO positive cells were detected in control sections (C). For each 
experimental group mean cell counts of MPO positive cells are depicted per high-power field 
(D). See page 167 for colour figure. 
 
 
The recruitment of CD-3 positive T-cells into the fetal gut paralleled that of PMN: in 
preterm lambs exposed to endotoxin for 2d, no significant increase of CD-3 expressing 
T-cells in the lamina propria was observed when compared with time matched control 
tissues of 125d GA (data not shown). In contrast, increased numbers of CD-3 
expressing cells were seen at 14d and 30d post endotoxin exposure in both preterm 
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and near term animals of 125 and 140d GA respectively, with the highest density in 
the 14d group (Figure 6.4A+B). For each individual section, the number of CD-3 
positive cells was quantified per high-powerfield and data are depicted in a scatter 
plot (Figure 6.4C). 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 6.4 Intraamniotic endotoxin results in increased ileal T-cell density. Significant increase of CD-3 
immunoreactivity was seen at 14 and 30d after endotoxin exposure (A+B). For each 
experimental group mean cell counts of CD-3 positive cells are depicted per high-power 
field (C). See page 168 for colour figure. 
 
 
Next, the distribution of gammadelta T-cells was evaluated, cells known to be crucial 
in monitoring and maintaining integrity of epithelial tissues12. In saline treated 
preterm animals of 125d GA, hardly any gammadelta T-cells were present in the 
lamina propria or lower mucosa (data not shown). Accordingly, in these preterm 
lambs, migration of gammadelta T-cells from the lower to the upper mucosa occurred 
sporadically after 2 or 14d post endotoxin treatment (Figure 6.5A+B). In saline 
injected animals of 140d GA, gammadelta T-cells were also undetectable in the lamina 
propria (Figure 6.5C). However, in these near term lambs, the lymphoid follicles in the 
lower mucosa became populated with gammadelta T-cells (Figure 6.5D). Interestingly, 
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30d of intraamniotic endotoxin exposure in near term animals resulted in migration of 
gammadelta T-cells from the lower to the upper mucosa in close proximity to areas of 
damaged intestinal epithelial cells (Figure 6.5E). 
TLR4 and MD-2 expression 
The molecular complex responsible for the recognition and signaling of endotoxin is 
formed by TLR4 and its indispensable cofactor MD-213,14. In preterm lambs of 125d, 
weak constitutive TLR4 and MD-2 mRNA expression was detected and this expression 
even decreased within 2d following intraamniotic endotoxin treatment (Figure 6.6). 
Also intraamniotic exposure to endotoxin for 14d in preterms resulted in a 
downregulation of the TLR4 and MD-2 mRNA levels (Figure 6.6). In saline treated near 
term sheep of 140d GA, TLR4 and MD-2 expression was significantly increased when 
compared with preterm controls of 125d GA. However, intraamniotic endotoxin 
exposure for 30d also resulted in a strong reduction of the TLR4 and MD-2 expression 
in near term lambs (Figure 6.6). 
Vascular contraction and relaxation responses 
Contractions of third-generation mesenteric arteries, evoked by the thromboxane 
receptor agonist U46619 increased with gestational age (Figure 6.7A). After 
endotoxin-induced chorioamnionitis, the potency and the contractile efficacy of 
U46619 was significantly increased at early (125d) but not at late GA (140d) (Figure 
6.7A). In contrast, the contractions induced by KCl (data not shown) and NE (Figure 
6.7B) were not statistically different, both in control animals at different gestational 
ages and in lambs exposed to chorioamnionitis. 
Either ACh (Figure 6.7C) or SNP (Figure 6.7D) relaxed U46619-contracted fetal 
mesenteric arteries in a concentration-dependent manner and these relaxations did 
not change with gestational age. Interestingly, ACh-evoked relaxation was almost 
abolished in the 125d fetuses exposed to endotoxin (Figure 6.7C). However this effect 
of endotoxin on ACh-induced relaxation was not further observed at 140d GA (Figure 
6.7C). 
Interestingly, the presence of SNP completely reversed the impaired relaxation of 
premature animals exposed to endotoxin (Figure 6.7D). These findings suggest a 
vascular impairment during chorioamnionitis at low GA on account of reduced release 
of NO by endothelial cells. 
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Figure 6.5 Endotoxin induced chorioamnionitis results in migration of gammadelta T-cells to sites of 
mucosal damage at late GA. After 2d or 14d of endotoxin exposure, hardly any gammadelta 
T-cells were detected in the upper mucosa of the preterm intestine (A+B). At 140d GA, 
gammadelta T-cells were not detected in the lamina propria whereas lymphoid follicles in 
the basal mucosa became populated with gamma delta T-cells (C+D). 30d after endotoxin 
injection, increased numbers of gammadelta T-cells were found within areas of mucosal 
damage (E). See page 169 for colour figure. 
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Figure 6.6 Ileal TLR4 and MD-2 mRNA was evaluated by ovine specific RT-PCR amplification of cDNA 
samples from healthy control lambs and lambs subjected to endotoxin induced 
chorioamnionitis. Representative DNA fragments are shown for each group (n=4). cDNAs 
were standardized for GAPDH content. Quantitative data were obtained by densitometric 
evaluation of RT-PCR products which were compared to a standard curve obtained by 
amplification of a serial dilution of highly concentrated cDNA. At 125d GA, TLR4 and MD-2 
mRNA levels were significantly (*) lower compared to animals at 140d GA. TLR4 and MD-2 
mRNA expression was significantly reduced following intraamniotic endotoxin injection for 
2 , 14 and 30d. 
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Figure 6.7 Thromboxane A2 mimic U46619 induced contractions of jejunal arteries increased with 
gestational age and were significantly (*) (P<0.05) augmented after intra-amniotic 
endotoxin injection in the 125d (P<0.05) but not in the 140d GA animals (A). 
Concentration-dependent contractile effects of norepinephrine tend to increase (P>0.05) 
during gestation but remained unaltered during chorioamnionitis (B). Concentration-
dependent relaxation of mesenteric arteries induced by acetylcholine was unaltered during 
gestation and was significantly (*) inhibited at 14d but not after 30d of endotoxin exposure 
(C). The relaxation response curve for sodium nitroprusside remained identical during 
gestation or chorioamnionitis (D).  
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eNOS expression 
Since the findings described above point at endothelial dysfunction due to impaired 
synthesis of NO, the distribution of endothelial nitric oxide synthase (eNOS) was 
studied in mesenteric arteries. Constitutive eNOS expression was absent in preterm 
and near term control tissues of 125 and 140d GA respectively (data not shown). 
However, two days after intraamniotic endotoxin injection in preterm animals, eNOS 
was weakly expressed by submucosal vascular endothelia (Figure 6.8A). At this GA, 
endothelial staining further enhanced at 14 days after endotoxin exposure (Figure 
6.8B). eNOS immunoreactivity was also present in the vascular endothelium of the 
submucosa in near term animals that were exposed to endotoxin for 30d (Figure 
6.8C). 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 6.8 Intraamniotic endotoxin induces eNOS expression. Weak eNOS staining was seen at 2d 
post endotoxin treatment (A) while expression increased in animals exposed to endotoxin 
for 14 or days 30d (B-C). See page 170 for colour figure. 
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Discussion  
This study shows for the first time the effects of gestation either alone or combined 
with antenatal exposure to bacterial toxins on the development of the fetal gut. A 
sheep model was used that closely resembles the human situation of preterm babies 
that are in utero exposed to chorioamnionitis by bacterial toxins resulting in adverse 
outcomes15. Administration of endotoxin to the amniotic fluid resulted in increased 
concentrations of endotoxin activity in the stomach fluid of animals exposed for 2d to 
endotoxin (data not shown), indicating passage of endotoxin to the fetal gut. This 
experimental set up allowed us to investigate whether prematurity and inflammation, 
either alone or combined, influence the development of the intestine in utero. 
To our knowledge, this is the first report showing that the cellular distribution of tight 
junction protein ZO-1 was underdeveloped at 125d GA in sheep. Although ZO-1 is not 
the only tight junction protein responsible for paracellular barrier sealing, it plays a 
central role in maintenance of paracellular intestinal barrier integrity by connection of 
the intercellular tight junction proteins (claudins and occludin) with the cell 
cytoskeleton. 
The presence of fragmented tight junctions in the gut of preterms (125d GA) is 
inherent to immaturity and correlates with diminished gut barrier function in preterm 
infants, as assessed by sugar absorption tests16. In near term control tissue of 140d 
GA, staining of ZO-1 formed a continuous band lining the mucosal epithelium, 
indicating maturation of the gut barrier during gestation. 
This study shows that bacterial toxins impair maturation of tight junctions during 
gestation, an effect which lasted as long as 30d post endotoxin administration. These 
data are in line with earlier in vitro and in vivo findings showing that the permeability 
of the intestinal epithelium is impaired after exposure to LPS17-19. An imperfect tight 
junctional distribution, either due to immaturity or inflammation suggests an easy 
access of microbial toxins to the mucosa and the inner layers of the gut, both in utero 
and after birth. This led us to investigate the mRNA levels of the molecules 
representing the endotoxin recognition complex during gestation and after 
intraamniotic endotoxin injection. A gestational dependent increase of intestinal TLR4 
and MD-2 mRNA was detected. In line, recent findings from our group showed that 
the human MD-2 protein is expressed in term but absent in preterm infants20. 
Combined, these findings suggest that the capacity to recognize and sense Gram-
negative derived endotoxin by the fetal intestine is immature at low GA. Interestingly, 
within 48 hours after intraamniotic endotoxin, TLR4 mRNA became undetectable and 
concomitantly, also MD-2 expression levels were reduced. The nature of this rapid 
downregulation needs further investigation21,22, but it might explain the here 
observed hyporesponsiveness of the fetal gut to endotoxin at low GA. In particular, an 
impaired recruitment of MPO-positive cells or T-lymphocytes was detected in the 
intestine at 2d after intraamniotic injection of endotoxin at 125d GA, likely due to 
absence of endotoxin recognition. This is consistent with earlier studies in this 
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chorioamnionitis model showing that proinflammatory cytokine mRNAs were 
unaltered in the fetal intestine, from five hours to 25d after intraamniotic injection of 
endotoxin23. In contrast to the intestinal TLR4 and MD-2 mRNA expression data 
presented here, previous studies with this animal model showed that intraamniotic 
endotoxin induced pulmonary TLR4 mRNA expression within 2d24. In line, endotoxin 
induced chorioamnionitis provoked a rapid inflammatory reaction in the respiratory 
system within 24 hours5,6,25,26.  
Interestingly, at 14 and even 30d after intraamniotic endotoxin injection, a strong 
intestinal inflammatory response was present with a massive influx of MPO positive 
cells and T-lymphocytes. Paradoxically, at 14 and 30d post endotoxin exposure, TLR4 
mRNA was still undetectable while MD-2 expression levels remained reduced. 
Whether this sustained inflammatory process is the result of a broken or absent 
tolerance to endotoxin remains to be elucidated22,27. In addition, activation via TLR4-
MD-2 independent intestinal innate immune receptors cannot be excluded with these 
experiments. Alternatively, the delayed inflammatory response in the fetal gut might 
be the consequence of a systemic rather than a local response of the fetal intestine. 
Esophageal occlusion experiments need to be performed to define the site of 
stimulation of the massive influx of PMNs and T-cells in the fetal gut. 
At 30d post endotoxin exposure, inflammatory parameters were decreased compared 
to the 14d group, and this was paralleled by migration of gammadelta T-cells from the 
lower mucosa towards compromised epithelial surfaces. These findings are supported 
by a report from Chen et al. who showed that gammadelta T-cells preserve the 
integrity of stressed or injured intestinal mucosa12. Moreover, our study showed that 
the lymphoid follicles of the healthy fetal intestine became populated with 
gammadelta T-lymphocytes between 125 days and 140 days of gestational age. In 
addition to the fragmented tight junctional distribution as seen in preterms or 
following endotoxin treatment, the absence of gamma delta T-cells in the mucosa at 
125d GA suggests a reduced capacity to preserve the already compromised 
epithelium. 
This study shows that intrauterine exposure to endotoxin induced a transient increase 
in the mesenteric vascular responsiveness to the thromboxane receptor agonist 
U46619. In addition a profound suppression of ACh-induced endothelium-dependent 
relaxation in mesenterial arteries was found during chorioamnionitis at low GA a 
process that was completely reversed by administration of the NO donor SNP. Our 
results strongly suggest the presence of an endotoxin-evoked transient endothelial 
damage and it could be speculated that a similar mechanism of endothelial 
dysfunction and diminished NO production might be partially responsible for the 
vascular vulnerability of the intestine in preterm infants28. 
The decreased NO availability could have several explanations. First, clinical reports 
showed that the intestinal synthesis of the important NO precursor arginine is 
strongly reduced in premature infants29-32. Second, a mechanism for the reduced NO 
biosynthesis would be a decreased expression of eNOS. Paradoxically, our data 
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showed an enhanced expression of eNOS in the chorioamnionitis exposed animals. 
Such an increase in eNOS expression indicates the presence of a compensatory 
mechanism, which would attempt to maintain normal NO level by upregulating 
eNOS33,34. 
In summary, in this study evidence is provided that both prematurity and 
chorioamnionitis are associated with impaired development of the intestinal innate 
immune defence, the tight junctional distribution and vascular function in utero. 
Although at present, we can only speculate about the postnatal consequences of 
these developmental disorders, immaturity of the parameters investigated in this 
study are all associated with neonatal intestinal pathology and NEC in particular35-38. 
The immature gut of preterm babies is a risk factor on its own which is further 
aggravated by the presence of antenatal inflammation. In addition, reduced 
expression of innate immune receptors as seen in the intestine of preterm lambs 
suggests that the capacity to recognize and sense Gram-negative derived endotoxin 
by the fetal intestine is immature at low GA. Such a lack of endotoxin sensing in the 
preterm intestine, against the background of a disrupted tight junctional distribution, 
supports the theory that an inadequate immune response contributes to the 
pathogenesis of NEC, potentially by allowing bacterial invasion and subsequent 
overgrowth in premature infants. Further research is needed to assess the importance 
of preterm delivery and the consequences of inflammation in utero on the 
development of neonatal intestinal pathologies such as NEC. 
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Summary and discussion 
The innate immune system is the first line of defense against infection and injury. 
Infectious microorganisms are predominantly detected by TLR, a family of PRR which 
recognize and sense conserved molecular structures shared by a broad range of 
microbes. In addition, evidence is accumulating that TLR are  involved in the response 
against endogenous damage-associated molecular patterns (DAMPs) which are 
released following cellular injury. The inflammatory response mediated by TLR 
activation is elicited to combat infecting microbes, to remove cellular remnants and to 
initiate tissue regeneration. However, the intensity and duration of TLR responses 
must be tightly controlled since prolonged and excessive activation of these TLR can 
contribute to abundant inflammation, tissue damage, multiple organ dysfunction and 
eventually death. Such inappropriate immune activation is seen after trauma, 
following major surgery including vascular, cardiac and transplant surgery and in 
diseases related to surgery including sepsis, IBD and NEC.  
The purpose of this thesis is to increase the understanding of TLR biology in surgical 
patients. Characterization of the molecular pathways involved in TLR mediated 
immune activation is crucial to develop therapeutic strategies to blunt, but not 
abrogate, cellular responses to TLR ligands. 
Sterile injury following renal ischemia reperfusion 
Ischemia reperfusion (I/R) induces an inflammatory reaction, illustrated by cytokine 
production and neutrophil influx in reperfused tissue. I/R injury is a major cause of 
acute renal failure after hemorrhagic shock or major cardiovascular surgery. In the 
context of renal transplant surgery, I/R-induced inflammatory injury is associated with 
delayed graft function that may affect long-term transplant outcome. The signals 
activating the innate immune system which underlie the inflammatory response 
following renal I/R include altered or injured cellular structures, molecules released by 
injured cells, or substances actively synthesized and secreted by cells upon I/R. 
Hypothesizing that TLR mediate innate immune activation in the course of I/R, the 
distribution of TLR expressed in the kidney was analyzed (Chapter 2). In addition, the 
role of cytokines in the regulation of TLR expression following I/R was studied. To this 
end, a renal I/R model was used that causes transient tissue damage associated with 
inflammation developing rapidly after I/R. This model enabled us to study modulation 
of TLR2 and TLR4 mRNA expression by cytokines in vivo during inflammation.  
TLR2 and TLR4 mRNA in the murine kidney was constitutively expressed by renal 
tubular epithelial cells (TECs) and epithelial cells in the Bowman capsule. During renal 
inflammation, TLR2 and TLR4 mRNA synthesis was enhanced by action of TNF-α and 
IFN-γ. This increased expression was mainly localized in TEC, the thin limb of the loops 
of Henle, and collecting ducts. Interestingly, endogenous TLR2 and TLR4 ligands 
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including high mobility group box 1, hyaluronan, biglycan and heat shock protein 70 
that are claimed to activate TLR2 and TLR4, are known to be abundantly present upon 
I/R injury in TLR expressing renal epithelial cells1,2. These combined data provide 
circumstantial evidence that activation of TLR by ligands released during I/R injury 
could be an important link between an inflammatory immune response and damage 
in the organ. Functional evidence that TLR play a central role in early tubular injury 
and the onset of inflammation following renal I/R, has been found in mice engineered 
to lack either TLR2 or TLR43-5. Concordingly, human data showed that the 
pathogenesis of I/R injury following kidney transplantation involves signaling through 
TLR4 expressed in donor kidney cells6. Loss of function TLR4 mutations attenuated 
intragraft proinflammatory gene expression and these mutations were associated 
with improved early graft function6.  
In conclusion, evidence was provided that TLR contribute to the inflammatory 
response occurring after renal I/R. Additional studies are required to reveal the 
mechanisms underlying TLR mediated immune activation following I/R. Defining such 
pathways might lead to the development of novel pharmacotherapies for I/R injury in 
the kidney and other organs. 
 
Earlier work from our laboratory showed that the sterile inflammatory process 
following renal I/R could be prevented with specific inhibitors of apoptosis, suggesting 
that this form of cell death is causally involved in I/R-induced inflammation and 
subsequent tissue injury. Moreover, more apoptotic cells were detected in 
transplanted kidneys with early graft dysfunction when compared with grafts that 
function immediately7,8. Understanding the apoptotic pathways activated in the 
course of renal cell death induced by I/R may provide a basis for therapeutic targeting 
of apoptosis in the course of acute or chronic renal injury. Therefore, initiation of the 
apoptotic cascade was studied in a human ex vivo model for warm ischemic injury 
(Chapter 3). In this model, consecutive biopsies were taken from kidneys 
nephrectomized because of renal cell carcinoma.  
Warm ischemia resulted in upregulation of pro-apoptotic Bax and suppression of the 
anti-apoptotic proteins Bcl-2 and cFLIP in a time-dependent fashion. During ischemia, 
activated caspase-9 increased with ischemia time, whereas caspase-8 and caspase-3 
were not activated.  
These data indicate that during normothermic ischemia, conditions are created that 
facilitate execution of apoptosis upon reperfusion. The decrease of anti-apoptotic 
proteins Bcl-2 and cFLIP and activation of pro-apoptotic proteins Bax and caspase-9 
during ischemia point to these proteins as therapeutic targets for the prevention of 
renal I/R injury. Interestingly, a caspase inhibitor IDN-6556 was shown to ameliorate 
early hepatic injury in an ex vivo rat model of warm and cold ischemia9. In addition, 
the applicability of this caspase inhibitor in the clinical setting was demonstrated10. In 
particular, administration of IDN-6556 in cold storage and flush solutions during liver 
transplantation offered local therapeutic protection against I/R-mediated apoptosis 
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and injury10. Although the potential of therapeutics that modulate activity of 
apoptotic proteins such as caspases seems evident, it is questionable whether 
apoptosis can be selectively modulated in one organ or cell type without adverse 
effects (e.g. carcinogenesis) on other vital functions.  
Infectious inflammation 
Microorganisms residing on mucosal surfaces are the most important source of 
infectious inflammation. Of the mucosal tissues, the gastrointestinal tract contains the 
highest number of microorganisms with a remarkable diversity. It is important to 
sequester microbiota in the gut lumen, since the immune system may be excessively 
activated following translocation of microorganisms across the intestinal epithelial 
barrier into the lamina propria, mesenteric lymph nodes and circulation.  In patients 
undergoing major surgery, reduced splanchnic blood flow is considered to result in 
translocation of luminal gut microbiota across an impaired intestinal epithelial barrier 
into the circulation11-13. These translocated bacteria are predominantly Gram-negative 
aerobic genera including Escherichia, Proteus and Klebsiella that can act as a source of 
sepsis14.  
LPS, the principal inducer of inflammatory responses to Gram-negative bacteria is 
sensed by TLR4 and MD-215-17. To gain more insight into the biology of MD-2 during 
systemic inflammation, the biochemical and functional properties of this molecule 
were studied during sepsis and experimental human endotoxemia (Chapter 4). In this 
study, strong suggestive evidence was provided that endothelial cells are an 
important source for release of soluble MD-2 (sMD-2) in vivo. It was shown that 
human sMD-2 circulate constitutively in the low ng/ml range as large inactive 
multimers. During endotoxemia and sepsis, the total amount of sMD-2 in plasma was 
strongly elevated and contained next to polymeric also a small amount of monomeric 
sMD-2. In line with this observation, in Chapter 4 and in previous publications, it was 
shown that septic but not normal plasma supported LPS activation of TLR4 positive 
MD-2 deficient epithelial cells. Based on these findings, it is tempting to speculate that 
active sMD-2 in septic plasma is a source for TLR4 expressing MD-2 negative cells in 
vivo, thereby acting as a mediator of organ damage during severe systemic 
inflammation. Consistent with this hypothesis, different studies suggest that sMD-2 
can modulate LPS signaling during Gram-negative infections by supplementing cells 
that express TLR4 but lack mMD-2 such as pulmonary and intestinal epithelial 
cells18,19. This is further extended by Ohnishi et al. who showed that LPS can induce 
the formation of CD14-TLR4 complexes on the cell surface in the absence of mMD-2 
while subsequent binding of sMD-2 is essential for activation of these cells19. 
Furthermore, there is growing evidence that the presence of active sMD-2 such as 
seen during endotoxemia and sepsis plays an important role in the anti-bacterial 
defense. In particular, recent studies elegantly demonstrated that opsonization of 
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Gram-negative bacteria by sMD-2 accelerates bacterial internalization and enhances 
intracellular killing, predominantly by neutrophils20.  
The apparent immuno-modulating and anti-bacterial role of sMD-2 identifies the 
TLR4/MD-2 complex as an attractive pharmacological target for antisepsis therapy. 
Different investigators have aimed to dampen excessive immune activation in animal 
models of sepsis through targeting TLR4/MD-2. First, an antagonistic antibody 
directed against TLR4/MD-2 was shown to protect mice from an otherwise lethal dose 
of LPS21. In addition, administration of a single dose of this antibody protected mice 
against mortality in a peritonitis model of polymicrobial sepsis21. Second, an analog of 
the non-toxic lipid A from Rhodobacter sphaeroides, Eritoran, competes with LPS for 
binding to MD-2, and has been shown to be an effective inhibitor of the toxic effects 
of LPS in animal models of endotoxemia22,23. Finally, TAK-242, which selectively 
suppresses TLR4-signaling by binding to its intracellular domain, protects mice from 
endotoxin-induced mortality24,25.  
Whether targeting of one particular factor such as LPS is sufficient during clinical acute 
infectious inflammatory disorders such as sepsis remains to be established. Since 
bacteria possess ligands for multiple TLR and other PRR, it is likely that individual PRR 
ligands have to be included in combination therapies to treat acute inflammatory 
disorders. Alternatively, interventions can be developed which inhibit the action of 
proteins involved in signal transduction such as MyD88, TRIF and MAL, in order to 
prevent the stimulatory effects of multiple PRR agonists. Multiplex approaches such 
as DNA chips and protein arrays are ideal tools to identify such (combined) 
pharmacological targets. 
Gut microbiota are also suspected to play an important role in mucosal inflammation 
as seen in ulcerative colitis, Crohn’s disease and NEC. Although the etiologies of these 
diseases remain largely unknown, an inappropriate intestinal inflammatory response 
directed against normal resident intestinal bacteria or their products is considered to 
play a crucial role in the pathophysiology of these disorders.  
Hypothesizing that inappropriate recognition and sensing of microbiota derived 
products by TLR plays a role in the pathogenesis of IBD and NEC, the distribution of 
the LPS recognition complex was analyzed in the healthy and inflamed premature and 
adult gut (Chapter 5). In the healthy ileum of term born infants and adults, evidence 
was provided that Paneth cells are the predominant, if not sole epithelial cells that 
express the molecules of the LPS recognition complex. These findings that Paneth cells 
are equipped with molecules essential for detection and sensing of LPS, are consistent 
with work from Ayabe et al. who showed that Paneth cells secrete their antimicrobial 
peptides following exposure to microbial components, such as LPS29. Finally, data 
described in Chapter 5 are in agreement with a recent report which showed that 
penetration of luminal commensal and pathogenic bacteria is controlled by Paneth 
cell intrinsic MyD88-signaling30. Collectively, Paneth cells actively sense luminal 
bacterial products, potentially via microbial detector molecules such as TLR4/MD-2, 
resulting in the release of their antimicrobial peptides. On their turn, Paneth cells 
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derived antimicrobial peptides are considered to play an essential role in maintaining 
host-microbial homeostasis at the mucosal interface30. 
The strong staining for MD-2 in the cytoplasm of Paneth cells suggests that Paneth 
cells might have an “opsonophagocytic” function mediated by secretion of sMD-2. 
Such a role of Paneth cell derived sMD-2 would be in line with the antibacterial 
defence function of these cells.  
Immunohistochemical analysis revealed that in IBD patients many MD-2-positive 
inflammatory cells were present in the lamina propria (Chapter 5). These data are 
partially supported by a report from Cario et al. In this study they showed abundant 
expression of MD-2 by lamina propria located inflammatory cells in the inflamed colon 
of IBD patients whereas a few MD-2 expressing cells were detected in the terminal 
ileum of patients with active IBD31.  
Studies which investigated the distribution of TLR4 in the lamina propria in the 
healthy and inflamed gut are paralled by the MD-2 data provided in Chapter 5: 
enhanced numbers of TLR4 positive inflammatory cells in the lamina propria during 
active IBD in man were detected when compared with healthy tissue32,33.  
Of interest, during active IBD, Paneth cells were still the only MD-2 expressing 
epithelial cells in the gut (Chapter 5). Although the debate regarding TLR4 and MD-2 
expression by epithelial cells during active IBD is still open31-33, data shown in this 
Chapter indicate that in the healthy and inflamed mature gut, apical epithelial cells 
facing the gut lumen are not directly involved in the response to LPS. Generation of 
inducible TLR-deficient mice with the Cre-LoxP system would be an important tool to 
further evaluate the cell-type-specific responses of intestinal TLR during health and 
disease.  
In the healthy and even in the inflamed gut of premature infants, MD-2 expression is 
absent (Chapter 5), indicating that the premature intestine lacks crucial molecules 
required for detection and sensing of LPS. To explore the functional consequences of 
luminal endotoxin exposure of the premature and mature gut, endotoxin was 
administered intra-amniotically to fetal sheep (Chapter 6). As in man, TLR4 and MD-2 
mRNA expression levels were reduced in the intestine of preterm lambs when 
compared to mRNA levels for both genes in the mature gut (Chapter 6). Consistent 
with the reduced or absent expression of TLR4 and MD-2, endotoxin exposure for two 
days did not induce an inflammatory response in the gut in preterm animals. 
Remarkably, despite the absence of an initial inflammatory response in these preterm 
animals, the already low intestinal TLR-4 and MD-2 mRNA levels were further down 
regulated within two days after induction of endotoxin-induced chorioamnionitis. The 
inhibition of intestinal TLR in the absence of local inflammation might be the 
consequence of a systemic rather than a local response of the fetal intestine. 
Additional studies such as esophageal occlusion experiments are warranted to further 
investigate this issue.  
The data discussed in Chapter 5 and 6 suggest that besides prematurity, also 
inflammation in utero leads to a reduced capacity to sense bacterial components such 
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as LPS. Once such immuno-compromised neonates are born, an intact gut barrier is 
crucial in order to avoid bacterial translocation and subsequent overgrowth in the 
underlying intestinal layers.  
Therefore, it was studied whether gestation in the presence or absence of 
intraamniotic endotoxin affects the distribution of ZO-1, a protein that plays a central 
role in the maintenance of the paracellular intestinal barrier (Chapter 6). The 
distribution of ZO-1 was shown to be disturbed at low GA whereas endotoxin induced 
chorioamnionitis prevented maturation of tight junctions during later gestation.  
These data suggest that the immature gut cannot cope with the transition from the 
normally sterile intra-uterine situation into the foreign antigen-rich environment 
which is created upon colonization of the intestinal tract by microorganisms, thereby 
predisposing to postnatal intestinal pathologies such as NEC. Future therapeutic 
strategies are needed to accelerate maturation of the intestinal immune system and 
the gut barrier function in the premature neonate to prevent intestinal disorders. 
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Micro-organismen worden voornamelijk herkend door speciale receptoren, de 
zogenaamde Pattern Recognition Receptors (PRR). Toll-like receptoren (TLR) vormen 
een belangrijke familie binnen deze PRR. TLR activeren ons aangeboren immuun-
systeem na herkenning van geconserveerde microbiële structuren. Daarnaast is er 
toenemend bewijs dat lichaamseigen moleculen, die vrijkomen bij weefselschade als 
ligand voor TLR kunnen dienen. Deze endogene moleculen kunnen om die reden ook 
zorgen voor het activeren van ontstekingsreacties.  
Een ontstekingsreactie, geactiveerd door TLR is belangrijk voor bestrijding van 
infectieuze micro-organismen, het opruimen van celresten en de initiatie van weefsel-
regeneratie. Het is echter van cruciaal belang dat deze TLR gemedieerde 
ontstekingsreactie nauwkeurig gereguleerd wordt. Een te hevige reactie op bacteriële 
componenten of lichaamseigen moleculen kan namelijk leiden tot excessieve 
ontsteking met ernstige weefselschade, multi-orgaan falen en zelfs de dood tot 
gevolg. Onvoldoende gecontroleerde activatie van de aangeboren afweer wordt 
onder andere waargenomen na trauma, grote chirurgie zoals vaat-, hart- en 
transplantatiechirurgie, en bij ziekten zoals sepsis, ‘inflammatory bowel disease’ (IBD) 
en necrotizerende enterocolitis (NEC). 
In dit proefschrift is de distributie en regulatie van TLR bestudeerd in de gezonde 
situatie, tijdens de foetale ontwikkeling en gedurende ontsteking. Een beter inzicht in 
de cellulaire lokalisatie en regulatie van TLR moleculen tijdens immuunactivatie is van 
belang voor de ontwikkeling van therapeutische interventies, die erop gericht zijn 
buitensporige activatie van het immuunsysteem te voorkomen. 
Weefselschade na renale ischemie reperfusie 
Bij niertransplantaties is weefselschade, veroorzaakt door I/R-geïnduceerde 
ontsteking geassocieerd met vertraagd functioneren van de getransplanteerde nier. 
Acute weefselschade ten gevolge van I/R kan de nierfunctie ook op lange termijn 
nadelig beïnvloeden. De signalen die de aangeboren afweer aanzetten tot de 
schadelijke ontstekingsreactie na I/R zijn afkomstig van beschadigde cellen. Moleculen 
die vrijkomen na celschade en producten die door beschadigde cellen actief gemaakt 
en uitgescheiden worden, activeren de afweerreactie. Verondersteld wordt dat deze 
lichaamseigen moleculen vrijgekomen na I/R, een belangrijke rol vervullen bij de 
activatie van de afweer via binding aan TLR. 
In hoofdstuk 2 werd de cellulaire lokalisatie en regulatie van TLR onderzocht in een 
muizenmodel voor renale I/R schade. In gezonde nieren bleek de expressie van TLR2 
en TLR4 mRNA voornamelijk in tubulair epitheel en in epitheliale cellen van het kapsel 
van Bowman gelokaliseerd te zijn. I/R resulteerde in een sterke toename van de TLR2 
en TLR4 mRNA expressie in het distale tubulaire epitheel, het dunne segment van de 
lis van Henle en de verzamelbuisjes. Deze toename was volledig afhankelijk van de 
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cytokines TNF-α en IFN-γ. Samen met recente bevindingen van anderen laten deze 
bevindingen zien dat TLR een belangrijke rol spelen bij het schadelijke 
ontstekingsproces na I/R. Aanvullende studies zijn vereist om te onderzoeken via 
welke mechanismen TLR ons aangeboren immuun systeem activeren tijdens I/R. Het 
ontrafelen van deze activatieroutes is van belang voor de ontwikkeling van nieuwe 
therapieën ter reductie van I/R geïnduceerde schade in de nier en andere organen. 
 
Eerdere studies uitgevoerd in ons laboratorium hebben aangetoond dat het  
ontstekingsproces dat optreedt na I/R, voorkomen kan worden met specifieke 
apoptose remmers, hetgeen suggereert dat er een causaal verband bestaat tussen 
deze vorm van celdood en I/R-geïnduceerde ontsteking. Bovendien werden in niet 
functionerende getransplanteerde nieren meer apoptotische cellen aangetoond dan 
in nieren met intacte functie. Meer inzicht in de apoptotische routes die geactiveerd 
worden na I/R, kan een mogelijke  basis vormen voor anti-apoptotische therapie bij 
acute of chronische nierschade. In hoofdstuk 3 werd daarom het optreden van 
apoptotische celdood ten gevolge van warme ischemie onderzocht. Humane nieren, 
verwijderd vanwege een niercelcarcinoom, werden ex vivo bij 37°C bewaard. Tijdens 
de ischemische incubatie werden in de tijd opeenvolgende biopten genomen om 
apoptotische processen in kaart te brengen. 
Warme ischemie resulteerde in een toename van het pro-apoptotische eiwit Bax en 
een tijdsafhankelijke afname van de anti-apoptotische eiwitten Bcl-2 en cFLIP. In 
overeenstemming hiermee werd gedurende warme ischemie een toename van de 
hoeveelheid actief caspase-9 aangetoond. Echter, activatie van caspase-8 en 
caspase-3 werd niet waargenomen tijdens warme ischemie. Deze gegevens laten zien 
dat tijdens ischemie de omstandigheden gecreëerd worden, die een snelle voltooiing 
van het apoptotisch proces ten tijde van reperfusie mogelijk maken. De afname van 
de anti-apoptotische eiwitten Bcl-2 en cFlip en de activatie van het pro-apoptische Bax 
en caspase-9 tijdens ischemie maken deze eiwitten interessante therapeutische 
targets ter voorkoming van I/R schade. 
Infectieuze ontsteking 
Micro-organismen aanwezig op slijmvliezen zijn de belangrijkste bron van infectieuze 
ontsteking. Het maag-darmstelsel bevat van alle mucosale weefsels het grootste 
aantal micro-organismen. Het is van belang dat deze microbiota in het darmlumen 
afgeschermd worden van de omringende weefsels door een intacte darmbarrière. 
Translocatie van microbiota naar de lamina propria, de mesenteriale lymfeknopen of 
de circulatie kan namelijk leiden tot hevige stimulatie van het aangeboren immuun-
systeem door microbiële componenten. Verondersteld wordt dat tijdens grote 
operaties een verminderde doorbloeding van het splanchnicus gebied resulteert in 
darmschade en barrière verlies. Verstoring van de darmbarrière kan leiden tot 
translocatie van luminale darmmicrobiota naar de mucosa en de circulatie. Deze 
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getransloceerde bacteriën, die voornamelijk bestaan uit Gram-negatieve aerobe 
species zoals Escherichia, Proteus en Klebsiella, kunnen vervolgens leiden tot sepsis. 
Lipopolysaccharide (LPS) dat aanwezig is in de celwand van Gram-negatieve bacteriën, 
activeert het aangeboren immuunsysteem na binding aan TLR4 en de cruciale cofactor 
MD-2. Om meer inzicht te krijgen in de werking van MD-2 tijdens systemische 
ontsteking werden de biochemische en functionele eigenschapen van MD-2 
bestudeerd in een experimenteel humaan endotoxine model en tijdens sepsis 
(hoofdstuk 4). In deze studie is indirect bewijs geleverd dat endotheel cellen een 
belangrijke bron zijn voor circulerend oplosbaar MD-2 (sMD-2) in vivo. De hoeveelheid 
sMD-2 in de circulatie van gezonde personen bedroeg enkele ng/ml. Dit circulerend 
sMD-2 bestond uitsluitend uit inactieve complexen (multimeren). Tijdens 
endotoxemie en sepsis bleek de totale hoeveelheid circulerend sMD-2 sterk verhoogd 
en werd naast inactieve multimeren ook een geringe hoeveelheid functioneel actief 
monomeer sMD-2 aangetoond. De aanwezigheid van dit actieve sMD-2 tijdens 
endotoxemie en sepsis is in overeenstemming met functionele in vitro MD-2 proeven. 
Deze functionele experimenten lieten zien dat septisch plasma, TLR4 positieve MD-2 
negatieve cellen in staat stelde op endotoxine te reageren, dit in tegenstelling tot 
plasma van gezonde individuen. sMD-2 in septisch plasma zou dus een bron kunnen 
zijn voor cellen in vivo die wel TLR4, maar geen MD-2 tot expressie brengen. 
Naast de beschreven rol in sepsis, worden darmmicrobiota ook in verband gebracht 
met de buitensporige ontsteking die bij IBD en NEC wordt gezien. Hoewel de etiologie 
van deze ziekten nog grotendeels onbekend is, wordt verondersteld dat een te hevige 
respons van de aangeboren afweer op producten van de normale darmflora, een 
cruciale rol speelt in de pathofysiologie van deze aandoeningen.  
Zoals vermeld is LPS een belangrijke bacteriële component die in staat is ons 
aangeboren immuunsysteem te activeren. In deze context werd de distributie van het 
LPS herkenningscomplex bestudeerd in de gezonde en ontstoken darm van 
prematuren en volwassenen (hoofdstuk 5). In het gezonde ileum van aterm geboren 
kinderen en volwassen werd aangetoond dat de Paneth-cel de voornaamste, zo niet 
de enige epitheelcel is, die de moleculen van het LPS herkenningscomplex tot 
expressie brengt.  
Immunohistochemische analyse van darmweefsel van IBD-patiënten liet zien dat er 
veel MD-2 positieve ontstekingscellen aanwezig zijn in de lamina propria. Net zoals in 
de gezonde situatie bleek de Paneth cel in de ontstoken darm van volwassenen de 
enige MD-2 positieve epitheelcel te zijn.   
In de gezonde en ontstoken darm van te vroeg geborenen kon daarentegen geen 
MD-2 worden aangetoond. Deze bevinding werd nader bestudeerd in een LPS-
geïnduceerd chorioamnionitis model. Dit model stelde ons in staat de in vivo reactie 
van de premature darm op LPS te onderzoeken. Twee dagen na LPS blootstelling werd 
in de premature darm geen ontstekingsreactie gevonden, hetgeen in 
overeenstemming is met de geringe TLR4/MD-2 expressie in deze dieren. Ondanks de 
afwezigheid van een ontstekingsreactie in de darm, twee dagen na endotoxine 
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geïnduceerde chorioamnionitis, werd een vermindering van de toch al lage expressie 
van TLR4 en MD-2 in dit orgaan gevonden. Deze vermindering van de TLR4/MD-2 
expressie in de darm wordt mogelijk veroorzaakt door een systemische 
ontstekingsreactie in de foetus.  
De data in hoofdstuk 5 en 6 suggereren dat naast prematuriteit, ontsteking in utero 
verantwoordelijk kan zijn voor een beperkte capaciteit van de darm om op bacteriële 
componenten zoals LPS te reageren. Voor deze immuno-gecompromiteerde 
prematuren is het essentieel dat bij geboorte, de darmbarrière intact is om bacteriële 
translocatie te voorkomen. Deze darmbarrière wordt gevormd door epitheelcellen die 
verbonden zijn door tight-junctions. In hoofdstuk 6 werd tijdens de ontwikkeling in 
utero de histologische distributie van het tight-junction eiwit ZO-1 in de darm 
bestudeerd in de aan- of afwezigheid van LPS. De ZO-1 distributie in de darm van 
premature dieren bleek verstoord te zijn.  
Verder werd gevonden dat LPS geïnduceerde chorioamnionitis maturatie van tight 
junctions tijdens ontwikkeling in utero verhinderde. Deze bevindingen suggereren dat 
de immature darm niet klaar is voor de overgang van de steriele intra-uterine situatie 
naar het antigeenrijke milieu dat gecreëerd wordt na kolonisatie van de darm door 
micro-organismen. De massale bacteriële invasie van de darm die na geboorte 
plaatsvindt, zou bij prematuren met een verstoorde darmbarrière en een immatuur 
immuunsysteem kunnen resulteren in intestinale aandoeningen waaronder de ziekte 
NEC. Toekomstige therapeutische strategieën moeten er op gericht zijn de 
ontwikkeling van het intestinale immuunsysteem en de darmbarrière functie te 
versnellen om intestinale aandoeningen in de premature neonaat te voorkomen.   
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Figure 2.2 Localization of constitutive and inflammation induced renal TLR2 mRNA by in situ 
hybridization. Renal TLR2 localization is shown in medulla (A) and cortex (B) of healthy 
kidneys, and in mice subjected to renal ischemia followed by 1 day (C,D) and 5 days (E,F) of 
reperfusion respectively. Constitutive expression for TLR2 was moderate and diffuse in cortex 
(B) and relatively low in the medulla (A). One day post-ischemia staining for TLR2 mRNA was 
reduced (C,D). Five days post-ischemia TLR2 expression is strongly enhanced (E,F) and 
predominantly located in collecting ducts, distal tubular epithelium and Henle’s loop. The 
arrow indicates a macrophage like cell. 
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Figure 2.3 Localization of constitutive and inflammation induced renal TLR4 mRNA by in situ hybridization. 
TLR4 localization is shown by incubation with the anti-sense riboprobe in medulla (A) and 
cortex (B) in healthy kidneys, and in mice subjected to renal ischemia followed by 1 day (C,D) 
and 5 days (E,F) of reperfusion respectively. Control incubations using TLR4 sense riboprobe 
were negative (G). Constitutive expression for TLR4 was moderate and diffuse in cortex, mainly 
by the tubular epithelial cells (B), and relatively low in the medulla (A). One day after ischemia 
TLR4 expression was primarily observed in collecting ducts, distal tubules and the thin limb of 
Henle’s loop (C,D). Five days after ischemia TLR4 mRNA staining was strongly enhanced in 
collecting ducts, the distal tubules and the thin limb of the loops of Henle (E,F). A small number 
of macrophage like cells was observed, which stained all positive. Arrows indicate macrophage 
like cells. Distal tubules were identified by Tamm Horsfall protein staining (H). 
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Figure 3.2 Activated Bax protein is predominantly expressed by distal tubular epithelial cells. While 
hardly detectable in control kidneys (A), Bax protein was increasingly expressed (red) in distal 
tubules in kidneys exposed to 30 min (B) or 80 min (C) of ischemia. In the ischemic sections 
also some focal staining of proximal tubules was observed (B,C). Proximal tubules were 
identified by FITC Lotus Lectin staining (green). Red staining, active Bax protein (Texas Red); 
blue staining, nuclei (4,6-diamidino(2)phenylindole). Magnification: x200. 
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Figure 3.4 Immunofluorescence staining of Bcl-2 during renal normothermic ischemia. Renal Bcl-2 
staining was most abundant (red) in proximal tubules of control tissue (A) and in kidneys 
rendered ischemic for 35 min (B) and 80 min respectively (C). Less staining was detected in 
distal tubules in both control and ischemic tissue. Proximal tubules were identified by FITC 
Lotus Lectin staining (green). Red staining, Bcl-2 protein (Texas Red); green staining, Lotus 
Lectin (fluorescein isothiocyanate); blue staining, nuclei (4,6-diamidino(2)phenylindole). 
Magnification: x200 
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Figure 4.3 In vivo MD-2 expression in lung and liver. Paraffin sections of autopsy lung and liver tissue 
from patients that died of bronchopneumonia related sepsis (n=4) were immunostained 
with anti MD-2. A) In septic lungs MD-2 was clearly detected in endothelial cells (indicated 
by arrows) and pericytes (arrow heads). Asterix denote MD-2 positive inflammatory cells. 
B) In healthy lung (n=4), some endothelial (arrows) and inflammatory cells (arrow heads) 
stained weakly positive for MD-2. C) No AEC reaction product in septic lung tissue was 
detected using a mouse isotype control. D) In the healthy liver (n=4), MD-2 positive cells 
were hardly detected. E) MD-2 positive staining in the septic liver is represented by 
endothelial cells (arrow), Kuppfer cells (arrow head) and inflammatory cells (inset) (original 
magnification 200x). 
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Figure 5.1 Characterization of monoclonal antibodies to human MD-2. Paraffin sections of MD-2 
transfected CHO cells, stained for the presence of human MD-2, using AEC as a substrate (red) 
showed that MD-2 positive staining was observed in transfected cells, being 50% of the cells 
(A). No positive cells were detectable in mock-transfected cells (B). 
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Figure 5.2 MD-2 expression in the healthy and inflamed intestine of preterm and term infants and 
adults.  
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MD-2 positive cells, visualized with AEC (red), were not detected in paraffin sections of the 
immature intestine (n=10) (A1). In the healthy ileum of term infants and adults (n=10), MD-2 
expression is mainly located at the base of the crypts of Lieberkühn (B1+C1). Sporadically, 
MD-2 positive inflammatory cells were detected in the lamina propria (indicated by arrows) 
(B1+C1). No MD-2 staining was detected in epithelial cells in paraffin sections of the mature 
healthy colon (n=10) (D1). Occasionally, MD-2 expressing inflammatory cells were observed in 
the lamina propria (indicated by arrows) (D1). No staining could be observed when an isotype-
matched primary control antibody was used (E1). MD-2 expressing cells were not detected in 
paraffin sections of the immature intestine of NEC patients (n=10) (A2). During intestinal 
inflammation of the mature ileum, expression of MD-2 is observed in Paneth cells, but most is 
expressed by a subset of characteristic inflammatory cells in the lamina propria (C2). In the 
inflamed mature colon (n=20), large numbers of MD-2 positive cells were detectable in the 
lamina propria whereas epithelial staining for MD-2 was absent (D2). A representative section 
is shown for the outcome of three separate immunohistochemical experiments on the 
indicated samples. 
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Figure 5.3 Sequential double-antigen localization of MD-2 and alpha-defensin-5. 
 For antigen colocalisation, MD-2 positive cells were visualized with DAB (brown) and a 
classical Paneth cell marker alpha-defensin-5 with HistoGreen (green). Immunoreactivity for 
alpha-defensin-5 but not for MD-2 was seen in the ileum of preterm infants (A). In the ileum 
of term infants and adults (B+C), Alpha-defensin-5 colocalized with all MD-2 positive epithelial 
cells (n=10). Representative examples of the immunohistochemical staining patterns are 
shown.  
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 5.5 Identification of cells expressing MD-2 in the inflamed mucosa of the adult gut.  
 Many inflammatory cells, positive for MD-2 (brown), co-express the marker for plasma cells, 
CD138 (green). 
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Figure 6.2 Immunolocalisation of ZO-1 (red) in the fetal intestine. At 125d GA, a fragmented staining 
pattern for ZO-1 was seen in control animals (A) or lambs exposed to endotoxin for 2 (B) or 
14d (C). At 140d GA, a normal ZO-1 distribution was detected in control animals (D) that 
became disrupted upon endotoxin exposure for 30d (E). Magnification 200x. For inset, 
1000x magnification was used. 
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Figure 6.3 At 14 and 30d after intraamniotic endotoxin injection, massive influx of PMNs was 
detected (A+B). At 140d GA, some MPO positive cells were detected in control sections (C). 
For each experimental group mean cell counts of MPO positive cells are depicted per high-
power field (D).  
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Figure 6.4 Intraamniotic endotoxin results in increased ileal T-cell density. Significant increase of CD-3 
immunoreactivity was seen at 14 and 30d after endotoxin exposure (A+B). For each 
experimental group mean cell counts of CD-3 positive cells are depicted per high-power 
field (C).  
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Figure 6.5 Endotoxin induced chorioamnionitis results in migration of gammadelta T-cells to sites of 
mucosal damage at late GA. After 2d or 14d of endotoxin exposure, hardly any gammadelta 
T-cells were detected in the upper mucosa of the preterm intestine (A+B). At 140d GA, 
gammadelta T-cells were not detected in the lamina propria whereas lymphoid follicles in 
the basal mucosa became populated with gamma delta T-cells (C+D). 30d after endotoxin 
injection, increased numbers of gammadelta T-cells were found within areas of mucosal 
damage (E).  
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Figure 6.8 Intraamniotic endotoxin induces eNOS expression. Weak eNOS staining was seen at 2d 
post endotoxin treatment (A) while expression increased in animals exposed to endotoxin 
for 14 or days 30d (B-C). 
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